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ABSTRACT 
 
Obesity, an epidemic problem in the world, is associated with higher mortality and increase 
in the risk of diabetes, cardiovascular diseases, and certain forms of cancer. Calorie 
restriction (CR) with adequate nutrition is the most effective method to induce weight loss, 
though compliance with low-caloric diets is often poor among obese individuals. Compounds 
capable of mimicking the effects of CR therefore hold great promise as novel anti-obesity 
drugs. The main aim of the present study was to investigate the molecular and signaling 
pathways mediating the effects of CR with special emphasis on the sirtuin, AMPK and mTOR 
pathways.  As data from recent clinical and experimental studies suggest, milk-derived whey 
proteins could enhance the anti-obesity effects of CR by yet unknown mechanisms, the 
study also aimed to clarify the anti-obesity effects of whey proteins and their mechanisms of 
action. 
High-fat diet induced C57Bl/6J mice were used as a model of experimental obesity. The 
metabolic effects of dietary regimens were examined by daily recording of food and energy 
intake, body weight monitoring three times weekly, in vivo calorimetry, and analysis of body 
fat percentage and lean body mass by dual-energy X-ray. The cellular effects were 
investigated by immunohistochemistry, Western blot and qRT-PCR analyses, as well as by 
protein arrays and microarray genechips.   
CR (energy intake 70% of ad libitum intake) protected against obesity and fatty liver, 
induced physical activity and ameliorated adipose tissue inflammation. These effects were 
associated with an increased SIRT1 expression in the liver and skeletal muscle as well as the 
SIRT3 expression in the liver, skeletal muscle and adipose tissue. CR also increased the SIRT4 
expression in the skeletal muscle. In contrast, the SIRT1 activating compound resveratrol did 
not prevent obesity although it partially prevented fatty liver and modestly increased 
skeletal muscle SIRT1 and SIRT4 expressions. CR exerted distinct effects on adipose tissue 
cytokine and angiogenesis profiles in obese and lean mice. Obesity induced cytokine and 
angiogenesis-related protein expressions, and these changes were largely ameliorated by 
CR, while in lean mice, CR increased the expression of several cytokines and angiogenesis-
related proteins. 
High-calcium whey protein (WPI) and α-lactalbumin diets enhanced the anti-obesity 
effects of CR. These diets produced marked alteration in the skeletal muscle gene expression 
profile compared to the casein diet, with the Wnt signaling being the most highly altered 
pathway. Unlike casein, WPI and α-lactalbumin diets induced SIRT3 protein expressions in 
muscle and decreased the Aldh1a7, Fasn, leptin, Nr4a3 and Scd1 mRNA expressions, 
indicating alterations in lipid and fatty acid metabolism. A novel WPI rich in lactoperoxidase, 
lactoferrin, growth factors and immunoglobulins dose-dependently enhanced weight loss 
during CR, prevented weight re-gain and protected against fatty liver formation during the 
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ad libitum phase. WPI increased hepatic SIRT3 expressions more than casein and decreased 
hepatic S6 ribosomal protein phosphorylation, suggesting inhibition of the mTOR pathway. 
In conclusion, the present study showed that CR increases the expression of sirtuins, in 
particular SIRT3, in metabolically important tissues suggesting their central role as mediators 
of the metabolic and cellular effects of CR. The present study also provides evidence that CR 
ameliorates obesity-induced cytokine and angiogenesis protein overexpression in adipose 
tissue. Finally, the present study underlined that whey protein-based diets enhance the anti-
obesity effects of CR via mechanisms linked to sirtuins and altered skeletal muscle gene 
expression profile. 
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1. Introduction 
 
Obesity has become a major worldwide health problem that is associated with several 
metabolic abnormalities contributing to the risk of chronic diseases, such as type 2 diabetes, 
cardiovascular diseases, and certain types of cancer (Mitchell et al. 2011). Development of 
obesity is associated with adipose tissue remodeling, which leads to adipocyte dysfunction, 
abnormal cytokine secretion and chronic low-grade inflammation (Guilherme et al. 2008, 
Hajer et al. 2008). Obesity also contributes fat deposition to non-adipose tissues as an 
ectopic fat, and it is a major risk factor for nonalcoholic fatty liver disease (NAFLD) (Parekh 
and Anania 2007, Dowman et al. 2010). Fatty liver is insulin resistant and it overproduces 
glucose, very-low density lipoprotein, C-reactive protein and coagulation factors (Kotronen 
and Yki-Järvinen 2008). Both chronic low-grade inflammation and NAFLD are important 
mediators in development of obesity-linked metabolic diseases.  
Weight loss is the primary treatment for obesity and its consequences. Calorie restriction 
(CR) with adequate nutrition effectively induces weight loss and ameliorates obesity-induced 
metabolic disturbances. In lower organisms, reducing the caloric intake below the usual 
levels decreases the incidence of aging-related diseases and is associated with longevity 
(Fontana et al. 2010). Although the results are still insufficient to show the longevity impact 
of CR in humans, CR has been shown to reduce the risk of type 2 diabetes and cardiovascular 
diseases and induce similar adaptive responses as in lower organisms (for review see 
Holloszy and Fontana 2007). However, the mechanism underlying the beneficial effects of CR 
is not well understood. Accumulating evidence indicates an important role for highly 
conserved nutrient sensing pathways; sirtuin, AMPK and mTOR pathways in mediating the 
effects of CR on health and lifespan (for review see Guarente 2005, Fontana et al. 2010, 
Canto and Auwerx 2011).  
Compliance to a CR lifestyle is low and therefore there has been great interest in finding 
compounds capable of regulating the activity of nutrient sensing pathways and to mimic the 
effects of CR. Several sirtuin activating compounds (STACS) have been developed (Howitz et 
al. 2003, Milne et al. 2007). The polyphenolic compound resveratrol (3,5,4`-
trihydroxystillbene) is one of the STACS that has been shown to extend lifespan in yeast in a 
Sir2-dependent manner (Howitz et al. 2003). The beneficial effects of resveratrol are also 
demonstrated in mammalian cells (for review see Baur and Sinclair 2006). In vivo studies 
with diet-induced obese mice have shown that resveratrol improves health and prevents 
premature mortality associated with obesity (Baur et al. 2006, Lagouge et al. 2006). The 
effects of resveratrol are generally believed to happen through mammalian SIRT1, which is 
the closest homologue of the yeast Sir2 protein.    
 Nutrition also has a crucial role in the prevention and treatment of obesity. 
Epidemiological studies have shown that a diet high in dairy products is inversely associated 
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with body mass index (BMI) (Mirmiran et al. 2005, Marques-Vidal et al. 2006, Varenna et al. 
2007, Azadbakht and Esmailzadeh 2008), and the intake of dairy products is related to a 
lower risk of type 2 diabetes and metabolic syndrome (Crichton et al. 2011). In addition, 
clinical trials have shown that high dairy intake facilitates weight and fat loss during CR 
(Abargouei et al. 2012).  Dairy calcium has been suggested to account for part of the anti-
obesity effects of dairy products via increased fat excretion (Christensen et al. 2009) and 
1,25-dihydroxy-vitamin D3 (1,25(OH)2D3) –mediated changes in adipocyte lipid metabolism 
(Zemel 2003). In addition, dairy proteins, especially whey proteins, have been shown to 
prevent weight gain and enhance weight loss during CR via as yet unknown mechanisms 
(Pilvi et al. 2007, Frestedt et al. 2008, Royle et al. 2008, Pilvi et al. 2009).    
The better understanding of the mechanism of how CR mediates its effects could reveal 
new targets for anti-obesity drug development. Therefore, the present study aimed to 
investigate the molecular and signaling pathways mediating the effects of CR with special 
emphasis on the sirtuin, AMPK and mTOR pathways.  As milk-derived whey proteins have 
been shown to augment weight loss effects of CR via as yet unknown mechanisms, the study 
also aimed to clarify the anti-obesity effects of whey proteins and their mechanisms of 
action. 
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2. Review of literature 
2.1 Obesity 
 
Obesity is defined as abnormal or excessive fat accumulation in adipose tissue to the extent 
that health may be impaired (WHO 2012a). The fundamental cause of obesity is a positive 
imbalance between energy intake and energy expenditure. However, the etiology of obesity 
is multifactorial, and it involves the interaction between genetic, environmental, 
psychosocial, physiological and metabolic factors (Mitchell et al. 2011). Body mass index 
(BMI) is the most useful population-level measure of obesity to classify underweight, 
overweight and obesity in adults (WHO 2000). BMI is defined as the weight in kilograms 
divided by the square of the height in meters (kg/m2).  Overweight and obesity in adults is 
based on various BMI cutoffs that are associated with the risk of co-morbidities (Table 1).  
Both overweight and obese persons with excess fat are associated with many risks of 
medical conditions that can lead to further morbidity and mortality. Numerous 
epidemiological studies have shown that the main health consequences of being overweight 
and obese are type 2 diabetes, cardiovascular diseases, certain types of cancer and 
musculoskeletal disorders (Guh et al. 2009). In addition, excess weight is an important factor 
in the development of other illnesses and metabolic disorders, including respiratory 
diseases, chronic kidney diseases, gastrointestinal and hepatic disorders, lower physical 
performance and psychological problems (Tsigos et al. 2008). Obesity is estimated to 
decrease life expectancy by 7 years at the age of 40 years (Peeters et al. 2003). Being 
overweight or obese is estimated to be the fifth leading risk factor for global deaths (WHO 
2012a).  
The prevalence of obesity has increased dramatically worldwide, and the rate of obesity 
has more than doubled since 1980 (WHO 2012a). According to the WHO, more than 1.4 
billion adults were overweight in the year 2008, and of those, over 200 million men and 
nearly 300 million women were obese (WHO 2012a). In Europe, obesity has increased 10-
40% in the past 10 years, and 10-25% of men and 10-30% of women are obese depending on 
 
Table 1. Definition of obesity and risk of co-morbities according to WHO (2000). 
Classification BMI (kg/m2) Risk of co-morbities 
Underweight ˂18.5 Low (but risk for other clinical 
problems increased) 
Normal weight 18.5-24.9 Average 
Overweight: 
Preobese 
Obese Class I 
Obese Class II 
Obese Class III 
≥25.0 
25.0-29.9 
30.0-34.9 
35.0-39.9 
≥40.0 
 
Increased 
Moderate 
Severe 
Very severe 
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the European country (Tsigos et al. 2008). The cost to society from obesity is enormous, and 
up to 8% of the total health-care costs in Europe are due to obesity in adults (WHO 2013). Of 
alarming concern is the increase in the prevalence of obesity in childhood which is 
associated with a higher chance of obesity, premature death and disability in adulthood 
(WHO 2012a).  
The increased intake of energy-dense foods which are high in fat, salt and sugars, 
together with reduced physical activity at work and during leisure time are considered to be 
the main reason for the dramatic growth in obesity (WHO 2012a). Both the European (Tsigos 
et al. 2008) and Finnish (Aikuisten lihavuus, Käypä hoito –suositus, 2011) evidence-based 
guidelines for management and treatment of adult obesity aim to improve health and 
prevent and alleviate obesity associated co-morbidities which can be achieved by 5-10% 
permanent weight loss. Guidelines involve lifestyle counseling on eating and physical activity 
behavior as well as on thoughts and attitudes that guide eating and physical activity habits. 
The guidelines emphasize that weight management should be lifelong and in addition to 
weight loss, it involves weight maintenance and prevention of weight re-gain. In some cases 
weight reduction can be supported by a very-low-calorie diet, drug therapy and obesity 
surgery. 
According to Finnish and European guidelines, drug therapy is recommended for patients 
with a BMI ≥30 kg/m2 or a BMI ≥27 kg/m2 with obesity-related diseases (Tsigos et al. 2008, 
Aikuisten lihavuus, Käypä hoito-suositus, 2011). At present, orlistat is the only anti-obesity 
drug on the market in Europe. The appetite suppressants sibutramine and phentermine are 
no longer licensed in Europe due to adverse cardiac effects. Orlistat, a pancreatic lipase 
inhibitor, reduces intestinal digestion and absorption of approximately 30% of dietary fat 
(Bray and Ryan 2007). A one year orlistat treatment has shown to induce an additional 2.9 kg 
weight loss compared to a placebo (Rucker et al. 2007). Several combination therapies 
targeting hypothalamic pathways that regulate appetite and body weight are under 
investigation for development of novel pharmacologic treatments for obesity (Vetter et al. 
2010). The most promising of those is phentermine/topiramate (sympatomimetic 
amine/anti-epileptic agent) combination which is currently approved in the US as an obesity 
treatment.       
Obesity surgery is considered for severely obese patients aged 18-60 years with a BMI 
≥40 kg/m2 or a BMI >35 kg/m2 with a obesity-related co-morbidities which can be expected 
to be alleviated by the surgery (Tsigos et al. 2008, Aikuisten lihavuus, Käypä hoito-suositus, 
2011). Bariatric surgery has been shown to decrease body weight an average of 40 kg, and at 
the moment, it is the most effective treatment against obesity in severely obese patients 
(Aikuisten lihavuus, Käypä hoito-suositus, 2011). 
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2.1.1 Adipose tissue metabolism and obesity 
 
The main physiological function of white adipose tissue (WAT) is to store excess energy as 
triglycerides and release them as fatty acids when energy expenditure exceeds energy intake 
to ensure a sufficient energy status (Rosen and Spiegelman 2006). In addition, WAT is a 
highly active endocrine organ that secretes large number of hormones, cytokines and other 
proteins involved in specific biological function such as glucose and lipid metabolism, 
inflammation, coagulation, and blood pressure and food intake control (Rosen and 
Spiegelman 2006, Hajer et al. 2008). Due to the major role of WAT in the whole-body energy 
homeostasis, WAT metabolism has a central role in the development of obesity-associated 
metabolic disorders.  
Obesity is associated with visceral adipose tissue accumulation and the expansion of adipose 
tissue is characterized by adipocyte hypertrophy (an increase in adipocyte volume) and 
hyperplasia (an increase in adipocyte cell number) (for review see Bays et al. 2008). 
However, it is believed that the number of adipocytes is largely set by early adulthood and 
adipocyte hypertrophy is the dominant feature of obese adipose (Spalding et al. 2008). 
Adipose tissue is also a highly vascularized organ and therefore, new blood vessel formation, 
angiogenesis is a necessity for adipose tissue growth (Christiaens and Lijnen 2010, Daquinag 
et al. 2011, Sun et al. 2011). Adipocyte hypertrophy is known to cause hypoxia in cells which 
induces expressions of angiogenic factors (Hosogai et al. 2007). Overall, adipocyte 
hypertrophy leads to dysfunctional adipocytes that metabolic and secretory activities are 
changed (Figure 1). Dysfunctional adipocytes are known to produce chemoattractant 
peptides (e.g. MCP-1) that enhance macrophage infiltration into adipose tissue (Weisberg et 
al. 2003, Xu et al. 2003). Macrophages are responsible for most of the pro-inflammatory 
cytokine (e.g. IL-6, TNF-α) production in obese adipose tissue contributing to the progression 
of chronic low-grade inflammation (Guilherme et al. 2008, Ouchi et al. 2011). This is 
accompanied by the diminished insulin action in adipocytes which results in increased 
lipolysis and fatty acids release (Guilherme et al. 2008). High levels of circulating free fatty 
acids (FFAs) increase depositions in non-adipose tissues, primarily in the liver and skeletal 
muscle (Guilherme et al. 2008). Both inflammation and ectopic fat accumulation is 
associated with reduced skeletal muscle and liver insulin sensitivity, and the development of 
type 2 diabetes and cardiovascular diseases (Hajer et al. 2008).  
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Figure 1. Obesity induced adipocyte dysfunction and development of insulin resistance. Adipocyte 
hypertrophy (increased adipocytes size) increases cytokine and free fatty acid secretion leading to 
inflammation and ectopic fat accumulation which contributes to the development of insulin resistance, type 2 
diabetes and cardiovascular diseases. IL-6; interleukin 6, MCP-1; monocyte chemoattractant protein-1, TNF-α; 
tumor necrosis factor-alpha (Adapted from Galic et al. 2010). 
 
 
2.1.2 Skeletal muscle metabolism and obesity 
 
Skeletal muscle is responsible for the major part of insulin-stimulated whole body glucose 
disposal, and hence plays an important role in the pathogenesis of insulin resistance and 
development of type 2 diabetes. Much evidence suggests that FFAs, which circulating levels 
are markedly increased in obesity (see section 2.1.1), play a crucial role in the development 
of skeletal muscle insulin resistance (for review see Phielix and Mensink 2008). It has been 
shown that prolonged exposure of skeletal muscle and myocytes to high levels of fatty acids, 
especially to saturated fatty acids, leads to severe insulin resistance (Griffin et al. 1999, Yu et 
al. 2002, Hirabara et al. 2010). 
Several mechanisms have been shown to explain the insulin resistance induced by fatty 
acids (for review see Martins et al. 2012). The first mechanistic explanation for the fatty acid-
induced insulin resistance was proposed by Randle et al. (1963), who assumed that there is 
an inverse relationship between fatty acid availability and glucose utilization. According to 
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that glucose fatty-acid cycle theory, elevated fatty acids supply and oxidation lead to 
reduced glucose uptake and metabolism. Later, it was been found that FFAs primarily inhibit 
glucose transport, but glucose metabolism remains unchanged (Dresner et al 1999, Griffin et 
al. 1999). In addition, the increased accumulation of FFAs within skeletal muscle 
(intramyocellular lipids) is strongly associated with insulin resistance (for review see Moro et 
al. 2008). However, intramyocellular lipid per se does not cause muscle insulin resistance, 
but rather the accumulation of fatty acid-derived metabolites, such as diacylglycerol and 
ceramides (Schmitz-Peiffer et al. 1999, Yu et al. 2002). Evidence has shown that reduced 
muscle oxidative capacity in obese subjects, which is assumed be due to mitochondrial 
dysfunction, results in muscle lipid accumulation (for review see Martins et al. 2012). 
Chronic elevation of FFA levels has been shown to reduce the expression of genes involved 
in mitochondrial biogenesis and oxidative capacity (Schmid et al. 2004, Sparks et al. 2005), 
and the production of reactive oxidative species (ROS) is increased by FFAs (Bonnard et al. 
2008). As a result, mitochondrial biogenesis and function are impaired, which reduce 
mitochondrial mass and impair mitochondrial oxidative capacity leading to an accumulation 
of lipid metabolites and further increased ROS production (for review see Martins et al. 
2012). Both lipid metabolites and ROS activate several kinases (e.g. JNK (c-Jun N-terminal 
kinase), NF-кB (nuclear factor-кB), PKC (protein kinase c)). That activation impairs the insulin 
signaling pathway by inducing serine/threonine phosphorylation of the insulin receptor 
substrate 1 (IRS-1) and thus decreases glucose uptake and metabolism in response to insulin 
(for review Martins et al. 2012).  
 
2.1.3 Non-alcoholic fatty liver disease and obesity 
 
Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological condition characterized by 
lipid accumulation in the liver causing liver damage similar to alcohol, but it occurs in 
individuals without a history of chronic alcohol consumption (Angulo and Lindor 2002). 
NAFLD represents a wide spectrum of liver diseases ranging from pure steatosis to 
steatohepatitis (NASH), and fibrosis to irreversible cirrhosis (Machado and Cortez-Pinto 
2005, Parekh and Anania 2007). Pure steatosis is defined histological as >5% hepatic lipid 
accumulation (Neuschwander-Tetri and Caldwell 2003) that rarely progresses to advanced 
liver diseases, whereas NASH constitutes an inflammation and hepatocellular damage having 
a strong potential to progress into cirrhosis, end stage liver failure, and hepatocellular 
carcinoma (Rafiq et al. 2009) .   
Concomitant with obesity, NAFLD is an increasingly recognized condition and up to 30% 
of adults in Western countries have NAFLD (Browning et al. 2004, Zelber-Sagi et al. 2006). 
Obesity and insulin resistant are the key pathogenic abnormalities associated with NAFDL, 
and it is a common condition among patients with type 2 diabetes (for review see Smith and 
Adams 2011). A fatty liver is insulin resistant and it overproduces glucose and very-low 
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density lipoprotein, and also other factors, such as C-reactive protein and coagulation 
factors, which lead to hyperglycemia, hyperinsulinemia and lipid disorders (for review see 
Kotronen and Yki-Järvinen 2008). Due to those metabolic consequences, NAFLD is closely 
linked to metabolic syndrome and the risk of developing type 2 diabetes and cardiovascular 
diseases. However, not all obese persons deposit fat in the liver and liver fat content is 
recognized to be independent of age, gender and BMI (Kotronen et al. 2007). The deviation 
in liver fat accumulation between individuals is thought to explain, at least in part, why some 
obese and even lean individuals develop metabolic syndrome and insulin resistance whereas 
other equally obese do not (for review see Kotronen and Yki-Järvinen 2008).  
Although the accumulation of triglycerides within the hepatocytes is evident in the 
pathogenesis of NAFLD, the precise mechanism leading to hepatic lipid accumulation is 
poorly understood.  It has been suggested that it is based on a `2-hit hypothesis` (Day and 
James 1998). The `first hit` is characterized by hepatic triglyceride accumulation and 
progression of hepatic steatosis, and the `second hit` involves the emergence and 
progression of inflammation and development of NASH. Insulin resistance and excess 
adiposity are associated with increased lipid influx into the liver, increased de novo hepatic 
lipogenesis by up-regulating hepatic lipogenic transcription factors (e.g. SREBP1c, ChREBP), 
and decreased hepatic mitochondrial lipid oxidation, promoting the `first hit` in the 
hypothesis (for review see Browning and Horton 2004, Dowman et al. 2010). In addition, 
insulin resistance and especially visceral adiposity are associated with increased levels of 
toxic FFAs, pro-inflammatory cytokines, mitochondrial oxidative stress and endoplasmic 
reticulum stress which leads to inflammation, cell death and fibrosis, and contribute to the 
`second hit` of hypothesis (for review see Browning and Horton 2004, Dowman et al. 2010).  
 
2.1.4 Type 2 diabetes and obesity 
 
Type 2 diabetes is a complex metabolic and endocrine disease that is characterized by insulin 
resistance and pancreatic β-cell dysfunction. The early phenomenon of progression of type 2 
diabetes is insulin resistance when the biological effects of insulin are less effective, and 
both glucose disposal in skeletal muscle and suppression of endogenous glucose production 
primarily in the liver are disturbed. When the pancreatic β-cells are no longer able to 
produce adequate insulin to overcome insulin resistance, impaired glucose tolerance 
progresses to type 2 diabetes. (For review see Stumvoll et al. 2005).  
Type 2 diabetes is a highly heterogeneous disease that etiology is multifactorial with 
genetic and environmental factors playing an important role in the pathogenesis (for review 
see Nolan et al. 2011). As mentioned above (see sections 2.1.1-2.1.3), obesity and 
subsequent chronic low grade inflammations and ectopic fat accumulation to skeletal 
muscle and liver (NAFLD) are the major risk factors for type 2 diabetes. Toxic FFAs and 
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cytokines (e.g. TNF-α and IL-6) can detrimentally affect both insulin signaling and pancreatic 
β-cells function (for review see Kahn et al. 2006, Hajer et al. 2008). Considering the high 
prevalence of obesity, it is not surprising that type 2 diabetes is now a pandemic. The 
estimated worldwide prevalence of diabetes among adults was 285 million (6.4%) in 2010 
and the value is predicted to rise to around 439 million (7.7%) by 2030 (Shaw et al. 2010). 
Type 2 diabetes causes both macrovascular and microvascular complications and it is a 
major global cause of premature mortality. It has been estimated that the global excess 
mortality in 2000 attributable to diabetes in adults was 2.9 million (5.2% of deaths) (Roglic et 
al. 2005). Diabetes strongly increases the risk of heart disease and stroke and approximately 
50% of people with type 2 diabetes die of cardiovascular diseases (Morrish et al. 2001). 
Diabetes is also a leading cause of kidney failure which explains 10-20% of deaths among 
people with diabetes (Van Dieren et al. 2010). In addition, diabetes is the most common 
cause of blindness among adults aged 30-69 years (Klein 2007), as well as non-traumatic 
lower-limb amputations (Van Dieren et al. 2010). Overall, the risk of dying among people 
with diabetes is at least double compared to their non-diabetic peers (WHO 2012b).   
       
 
Taken together, obesity is associated with visceral fat accumulation 
and the expansion of adipose tissue, cause adipocyte hypertrophy, 
which leads to adipocyte dysfunction. In dysfunctional adipocytes, 
cytokine and free fatty acid secretion are increased resulting in 
chronic low-grade inflammation and ectopic fat accumulation in 
skeletal muscle and the liver (NAFLD). Both inflammation and ectopic 
fat impairs skeletal muscle and liver insulin sensitivity and contribute 
to the development of cardiovascular diseases and type 2 diabetes.       
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2.2 Calorie restriction  
 
While excessive calorie intake and subsequent obesity are associated with the increased risk 
of several chronic diseases and premature mortality, calorie restriction (CR) with adequate 
nutrition improves multiple parameters of health and extends lifespan. CR is defined as a 
dietary intervention where calorie intake is reduced below the usual ad libitum intake while 
adequate intake of proteins and micronutrients are maintained at sufficient levels to avoid 
malnutrition. The effects of CR on disease risk and life expectancy is widely studied in model 
organisms and humans.  
 
2.2.1 Calorie restriction in model organisms 
 
CR in lower organisms 
The first evidence that CR can extend the mean and maximum lifespan of rats was published 
in 1935 by McCay et al. (1935). Subsequent data have shown that CR slows aging and 
increases maximum lifespan in different species, including yeast, fruit flies, worms, spiders, 
fish, mice and dogs (Weindruch and Walford 1988, Masoro 2005). However, the only 
mammals in which CR has clearly shown to slow aging and extend maximum lifespan are rats 
and mice (Fontana et al. 2010). The magnitude of lifespan extension is shown to be 
dependent on the age when CR is started, the severity of restriction and strain or genetic 
background of animals (Cheney et al. 1983, Merry 2002, Liao et al. 2010). In rodents, 
initiating a 25-60% reduction in calorie intake below ad libitum food intake, started early in 
life (from shortly after weaning to age 6 months), increases maximum lifespan up to 50% 
(Koubova and Guarente 2003). When a 44% reduction in calorie intake is started in 
adulthood (age 12 months), the lifespan is extended by 10-20% (Weindruch and Walford 
1982).  
Data from studies conducted in laboratory rodent models have shown that CR induces 
several health benefits such as reduced adiposity and inflammation (Muzumbar et al. 2008, 
Fontana 2009), decreased oxidative damage and serum IGF-1 levels (Breese et al. 1991, 
Sohal and Weindruch 1996), and improvements in vascular function, glucose and lipid 
metabolism (Fontana and Klein 2007, Fontana 2008) (Figure 2). Collectively those 
physiological changes increase longevity by preventing or delaying the occurrence of chronic 
diseases, including diabetes, autoimmune and respiratory diseases, cardiovascular diseases 
(Weindruch and Walford 1988, Guo et al. 2002, Masoro 2005, Fontana 2008), kidney 
diseases (Lee et al. 2004, Chen et al. 2007), and cancer (Hursting et al. 2003, Longo and 
Fontana 2010). In addition, CR in mice decreases neurodegeneration, β-amyloid deposition 
in the brain and enhances neurogenesis in animal models of Alzheimer disease, Parkinson 
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disease, Huntington disease and stroke (Mattson 2005, Martin et al. 2006). However, 
approximately one third of these experimental rodents die without any evidence of 
apparent organ pathology (Shimokawa et al. 1993) suggesting that reduction of chronic 
diseases does not completely explain the increased lifespan of calorie restricted rodents. 
 
                     
Figure 2. Some of the physiological changes associated with calorie restriction in mammals. 
 
CR in non-human primates 
There are two active randomized, non-human primate studies testing the benefits of long-
term CR on longevity and disease prevention in rhesus monkeys, one at the University of 
Wisconsin at Madison (Kemnitz et al. 1993, Ramsey et al. 2000) and the other at the 
National Institute of Aging in Baltimore (Lane et al. 2001, Mattison et al. 2003). The 20 year 
data from a group at the University of Wisconsin revealed that moderate CR significantly 
reduced incidence of aging-related death in rhesus monkeys, even though the overall 
mortality was unaffected by CR (Colman et al. 2009). Taking only the aging-related death 
into account, 50% of control monkeys survived compared with 80% survival of CR animals. 
The group at the University of Maryland found similar beneficial effects of CR on lifespan, 
though results did not reach statistical significance (Bodkin et al. 2003). 
Similar to rodents, CR in rhesus monkeys resulted in lower body weight and adiposity 
(Bodkin et al. 2003, Mattison et al. 2003, Cefalu et al. 2004, Colman et al. 2009), decreased 
body temperature and resting energy expenditure (Lane et al. 1996, Blanc et al. 2003), 
reduced triiodothyronine (T3) concentration (Roth et al. 2002), inflammatory markers and 
oxidative stress (Kim et al. 1997, Zainal et al. 2000) and delayed immune senescence 
(Messaoudi et al. 2006). In addition, CR improved cardiometabolic health by decreasing 
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blood pressure, serum glucose and insulin concentrations, and improving insulin sensitivity 
and serum lipid profile (Kemnitz et al. 1994, Lane et al. 1995, Verdery et al. 1997, Mattison 
et al. 2003). The physiological changes in non-human primates are associated with the 
reduced risk of several chronic diseases, including incidence of diabetes, cancer, 
cardiovascular diseases and brain atrophy (Colman et al. 2009). 
 
2.2.2 Calorie restriction in humans 
 
The promising evidence from research in monkeys suggests that CR might have beneficial 
effects in humans as well. There are several studies in the literature evaluating CR in 
humans, but the evidence is still insufficient to show the longevity impact of CR in humans 
(for review see Holloszy and Fontana 2007). The Okinawan centenarians are shown as 
evidence that CR improves human health. People from the Japanese island of Okinawa have 
a lower caloric intake and higher prevalence of centenarians than the mainland Japanese 
population and Americans (Wilcox et al. 2007, 2008). 
The role of CR in human health is also evaluated by three different epidemiological 
studies. One of these studies is Biosphere 2, which included 4 women and 4 men consuming 
a low-calorie, nutrient dense diet (1750-2100 kcal/day) inside a sealed environment for 2 
years (Walford et al. 2002). CALERIE (Comprehensive Assessment of Long-Term Effects of 
Reducing Calorie Intake) consists of phase 1 studies evaluating the effects of 20-25% CR in 
humans for 6 or 12 months (for review see Holloszy and Fontana 2007), and a phase 2 study, 
which is a 2 year multicenter trial of 225 subjects randomized to a 25% CR diet or a weight 
maintenance diet (Rochon et al. 2011). In addition, data from a series of studies conducted 
by 18 members of the Calorie Restriction Society (CRS) group that practices self-imposed CR 
(~30% less calories than age- and sex-matched volunteers consuming a typical Western diet) 
for an average 6.5 years are published (Fontana et al. 2004, Fontana et al. 2006, Meyer et al. 
2006).  
Information obtained from the above mentioned studies show that CR improves 
cardiovascular and glucoregulatory health. Specifically, CR may reduce the risk of 
cardiovascular disease by lowering cholesterol, triglycerides, blood pressure, and carotid 
intima-media thickness (Verdery and Walford 1998, Walford et al. 2002, Fontana et al. 2004, 
Meyer et al. 2006, Fontana et al. 2007, Lefevre et al. 2009). CR improves glucoregulatory 
health by decreasing circulating insulin and glucose (Walford et al. 2002, Fontana et al. 2004, 
Heilbronn et al. 2006) and by increasing insulin sensitivity (Weiss et al. 2006, Fontana et al. 
2007).  
Even though CR reduces the risk of cardiovascular diseases and diabetes in humans and 
induces similar adaptive responses that occur in laboratory animals, the major concern in 
human studies is the ability to maintain long-term CR. In the Biosphere 2 study, participants 
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were followed for several months after the 2 year study and their body weight and other 
variables returned to their pre-study levels after the study, indicating the difficulty of 
maintaining a CR lifestyle (Walford et al. 2002). In addition, in CALERIE study, subjects were 
assigned to a 20% CR diet for 1 year, but participants managed to maintain only 10% CR over 
the study period (Racetta et al. 2006).   
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2.2.3 Molecular mechanisms of calorie restriction 
 
Although the beneficial effects of CR are well established, the exact mechanism whereby CR 
exerts its health- and lifespan-extending effects is still quite unclear. Considering the 
beneficial effects of CR in aging and many chronic diseases, the understanding of how CR 
exerts these effects could reveal targets for drugs and therapies for broad-spectrum 
diseases. Recent studies in model systems have revealed that highly conserved nutrient 
sensing pathways; sirtuin, AMPK and mTOR pathways are connected to CR and longevity 
regulation (for review see Guarente 2005, Fontana et al. 2010, Canto and Auwerx 2011). 
Noteworthy is that the nutrient sensing pathways strongly overlap with each other (Figure 
3). In addition, it is well-established that down-regulation of insulin and insulin/IGF-1 
signaling system are associated with longevity (for review see Berryman et al. 2008). 
Impaired autophagy is linked to several metabolic- and aging-related diseases (for review 
see Levine and Kroemer 2008), and all nutrient sensing pathways regulate autophagy.  
 
        
                        
Figure 3. Schematic representation of nutrient sensing signaling pathways in calorie restriction. CR is 
suggested to activate the SIRT1 (sensitive to high NAD+ levels) and AMPK (sensitive to high ADP/ATP and 
AMP/ATP ratios) pathways and suppress insulin/IGF-1/mTOR signaling pathway. Sirtuins and AMPK pathways 
positively regulate each other through increasing NAD
+ 
levels and deacetylating LKB1 (upstream kinase of 
AMPK). AMPK negatively regulates the mTOR pathway through phosphorylating TSC2 (upstream regulator of 
mTOR) and Raptor (mTOR component). All nutrient sensing pathways regulate autophagy through UNC-51-like 
kinase (ULK1) and autophagy genes (Atg).        
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2.2.3.1 Sirtuin pathway 
 
The sirtuin protein family 
Sirtuins are the class III histone deacetylase protein family that use oxidized nicotinamide 
adenine dinucleotide (NAD+) as a cofactor. The first member of the sirtuin family of proteins 
to be identified was histone deacetylase Sir2 (silent information regulator 2) in yeast 
(Saccharomyces cerevisiae). Sir2 was originally identified as a gene which has importance in 
the maintenance of the silent chromatin at the mating-type loci, telomeras and rRNA-
encoding DNA repeats (Guarente 2000). Later on, Sir2 was recognized as regulating the yeast 
replicative lifespan as the overexpression of the Sir2 extends lifespan up to 30% and the 
deletion or mutation of Sir2 gene shortens lifespan by 50% (Kaeberlein et al. 1999). Yeast 
lifespan can also be increased by CR; reducing the amount of sugar in the growth medium, 
and the effect has been shown to be dependent on the Sir2 gene (Lin et al. 2000). In addition 
to yeast, Sir2 orthologous genes found in worms and flies also function to increase lifespan 
and are required for CR-induced longevity (Tissenbaum and Guarente 2001, Rogina and 
Helfand 2004, Wang and Tissenbaum 2006).  
Sirtuins are highly conserved from prokaryotes to mammals. The first sirtuin identified 
from mammals was SIRT1 (silent mating type information regulation-2 homolog 1), which is 
the closest homologue of yeast Sir2 protein. In addition to SIRT1, the mammalian sirtuin 
family comprises seven proteins (SIRT1 to SIRT7), which can be divided into four classes 
according to sequence homology to yeast Sir2 protein. SIRT1 - SIRT3 belong to class I, SIRT4 
to class II, SIRT5 to class III and SIRT6 and SIRT7 to class IV (Frye 2000) (Table 2).  
 
Sirtuins subcellular localization and enzymatic activity 
Mammalian sirtuins are localized in numerous compartments within the cell (Table 2). SIRT1 
and SIRT6 predominantly localizes in the nucleus, while SIRT7 presents in the nucleolus and 
SIRT2 predominantly localizes in the cytosol (Haigis and Sinclair 2010, Houtkooper et al. 
2012). SIRT3, SIRT4 and SIRT5 localize in the mitochondria (for review see He et al. 2012, 
Huang et al. 2012). However, subcellular localization of these proteins has been shown to be 
dependent on the cell type, cellular stress status and molecular interaction. For instance, 
mainly nuclear SIRT1 can also present in the cytosol, and mainly cytosolic SIRT2 can also 
present in nucleus (Haigis and Sinclair 2010, Houtkooper et al. 2012). Although the 
physiological relevance of SIRT1 shuttling is still unclear, SIRT1 has been shown to shuttle to 
the cytosol upon inhibition of insulin signaling (Tanno et al. 2007).  
Sirtuins were originally identified as NAD+-dependent class III histone deacetylase 
enzymes. However, sirtuins do not just deacetylate histones, but also a wide range of 
proteins in different subcellular compartments (Table 2). In addition to deacetylase activity, 
SIRT4 and SIRT6 can function as ADP-ribosyltransferases, although SIRT6 also has 
deacetylase activity (Haigis and Sinclair 2010, Houtkooper et al. 2012). Moreover, SIRT5 was  
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Table 2. Summary of the mammalian sirtuins. 
Sirtuin Class Localization Activity Targets Functions Null phenotype References 
SIRT1 I Nucleus, 
Cytosol 
Deacetylation CRTC2, FOXO1, FOXO3, 
FXR, LXR, NF-кB, p53, 
PGC-1α, PPAR-γ, SREBP-
1c, STAT3, UCP-2 and 
more 
Energy 
metabolism, 
stress response 
Developmental defects, 
lethal in some 
backgrounds 
Luo et al. 2001, Vaziri et al. 2001, 
McBurney et al. 2003, Yeung et al. 
2004, Haigis and Sinclair 2010, 
Houtkooper et al. 2012 
SIRT2 I Cytosol Deacetylation FOXO1, FOXO3a, H4K16, 
PEPCK, PAR3, Tubulin 
Cell cycle Developmentally normal North et al. 2003, Vaquero et al. 
2006, Jing et al. 2007, Wang et al. 
2007, Beirowski et al. 2011, Jiang et 
al.  2011 
SIRT3 I Mitochondria Deacetylation Oxidative 
phosphorylation 
complex I, II, III, IV and V, 
AceCS2, LCAD, HMGCS2, 
IDH2, MnSOD, SOD2 
ATP production, 
anti-oxidative 
stress, 
thermogenesis 
Developmentally normal Huang et al. 2010,  
Giralt and Villarroya 2012, 
He et al. 2012 
SIRT4 II Mitochondria ADP-
ribosylation 
GHD Insulin secretion, 
fatty acid 
oxidation 
Developmentally normal Haigis et al. 2006 
SIRT5 III Mitochondria Deacetylation, 
demalonylation, 
desuccinylation 
CPS1 Urea cycle Developmentally normal Nakagawa et al. 2009,  
Du et al. 2011, Peng et al. 2011 
SIRT6 IV Nucleus Deacetylation, 
ADP-
ribosylation 
H3K9, H3K56 DNA repair, 
metabolism, 
inflammation 
Premature aging Mostovslavsky et al. 2006, 
Michishita et al. 2008, Michishita et 
al. 2009, Yang et al. 2009, Schwer 
et al. 2010 
SIRT7 IV Nucleolus Unknown Unknown rDNA 
transcription 
Smaller size, short 
lifespan, heart defects 
Ford et al. 2006,  
Vakhrusheva et al. 2008 
AceCS2; acetyl-CoA synthase 2, CPS1; carbamoyl phosphate synthase 1, CRTC2; CREB regulated  transcription coactivator 2, FOXO1; fordkhead box O1, FOXO3a; fordkhead 
box O1 3a, FXR; farnesoid X receptor, GDH; glutamate dehydrogenase, H3K9; Histone 3 lysine 9, H3K56; histone 3 lysine 56, H4K16; histone 4 lysine 16, HMGCS2; 3-hydroxy-
3-methylglutaryl-CoA synthase 2, IDH2; isocitrate dehydrogenase 2, LCAD; long-chain acyl-CoA dehydrogenase, LXR;  liver X receptor α, MnSOD; manganese superoxide 
dismutase, NF-кB; nuclear factor-кB, PAR3; partitioning defective 3 homologue, PEPCK;  phosphoenolpuryvate carboxykinase PGC-1α; peroxisome proliferator-activated 
receptor-γ coactivator 1α, PPAR-γ; peroxisome proliferator-activated receptor-γ, SOD2; superoxide dismutase 2, SREBP-1c; sterol response element binding protein-1c, 
STAT3; signal transducer and activator of transcription 3, UCP-2; uncoupling protein 2     
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recently shown to primarily demalonylate and desuccinylate proteins (Du et al. 2011, Peng et al. 
2011). One common feature of all enzymatic reactions of sirtuins is that the enzymatic activities 
are based on NAD+, which is an indicator of cellular energy and nutrient status (for reviews see 
Canto and Auwerx 2012, Houtkooper et al. 2012). In the enzymatic reaction, sirtuins convert NAD+ 
to nicotinamide (NAM) and O-acetyl-ADP-ribose (O-AADPR) (for review see Haigis and Sinclair 
2010, Guarente 2012) 
 
Sirtuins function 
SIRT1 is the best-characterized mammalian sirtuin. SIRT1 has been shown be important for 
embryogenesis and reproduction as SIRT1 null mice are small in size, sterile, they have 
developmental defects, and most die during the early postnatal period (McBurney et al. 2003). 
SIRT1 deacetylates several transcriptional factors and proteins important for energy metabolism 
and stress resistance (Table 2) (see in below). However, SIRT1 also has several targets beyond 
energy metabolism. For instance, SIRT1 has a marked anti-inflammatory effect in diverse tissues 
and cell models (Pfluger et al. 2008, Purushotham et al. 2009) which is thought to happen through 
negative regulation of the nuclear factor-кB (NF-кB) (Yeung et al. 2004). In addition, SIRT1 
activation was initially linked to increased tumor formation after the finding that SIRT1 
deacetylates and inactivates tumour suppressor protein p53 and inhibits p53-dependent apoptosis 
(Luo et al. 2001, Vaziri et al. 2001). However, contrary to this, in vivo studies have indicated that 
SIRT1 is in fact a tumour suppressor (for review see Herranz and Serrano 2010). 
Of the mitochondrial sirtuins (SIRT3-SIRT5), SIRT3 is the major mitochondrial deacetylase and 
several targets involved in energy homeostasis have been identified (Table 2) (see below). 
Although mitochondria are important in energy production and mitochondrial dysfunction is 
linked to many metabolic and aging-related diseases (for review see Nunnari and Suomalainen 
2012), mice lacking mitochondrial sirtuin (SIRT3-/-, SIRT4-/- and SIRT5-/- mice) develop normally, but 
they have several metabolic disturbances and reduced resistance to nutrient stress (for review see 
Huang et al. 2010, Giralt and Villarroya 2012, He et al. 2012) (see more in detail below).  
Compared to SIRT1 and SIRT3, less is known about the physiology of other sirtuins. SIRT2 is 
known to deacetylate tubulin, but the relevance of it is unknown (North et al. 2003). More 
importantly, SIRT2 regulates cell cycle by deacetylating histone 4 lysine 16 (H4K16) (Vaquero et al. 
2006) and increases cell survival by deacetylating fordkhead box O1 3a (FOXO3a) (Wang et al. 
2007). SIRT2 also deacetylates partitioning defective 3 homologue (PAR3) leading to decreased 
activity of the cell polarity control protein atypical protein kinase C (aPKC), and thereby changes 
the myelin formation of Schwann cells (Beirowski et al. 2011). In addition, SIRT2 regulates 
gluconeogenesis through deacetylating phosphoenolpuryvate carboxykinase (PEPCK) (Jiang et al. 
2011) and adipogenesis through FOXO1 (Jing et al. 2007).  
SIRT6 is the highly specific histone 3 deacetylase that targets H3K9 and H3K56, playing an 
important role in DNA repair, telomerase function, genomic stability, and cellular senescence 
(Michishita et al. 2008, Michishita et al. 2009, Yang et al. 2009). SIRT6 deficiency causes the most 
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striking phenotype. SIRT6 null mice suffer from several metabolic imbalances, postnatal growth 
retardation and premature death at age one month (Mostoslavsky et al. 2006). SIRT6-/- mice are 
severely hypoglycaemic which is possibly mediated by hypoxia-inducible factor 1α (HIF1α)-
dependent activation of glycolysis (Zhong et al. 2010). Interestingly, neural SIRT6-deleted mice are 
small at birth which is due to low growth hormone and IGF-1 levels and they reach normal size at 
age 1 year and develop obesity later in life (Schwer et al. 2010).  
SIRT7 is one of the most unknown sirtuins. SIRT7 is reported to activate RNA polymerase I 
transcription, but the protein substrate is still unknown (Ford et al. 2006). However, SIRT7 null 
mice have a shorter lifespan, they are smaller, and they develop heart hypertrophy and 
inflammatory cardiomyopathy, which is linked to p53 hyperacetylation (Vakhrusheva et al. 2008).   
 
Regulation of sirtuin activity 
Regulation of sirtuin activity occurs at four different levels, and as the best-characterized sirtuin, 
SIRT1 regulation is also the best-described (Figure 4). In general, SIRT1 mRNA expression is higher 
during low energy status (Nemoto et al. 2004), while high-fat diet (HFD) feeding reduces it (Coste 
et al. 2008). Various transcription factors are suggested to regulate sirtuin mRNA expression in 
response to these stimuli (Figure 4a). FOXO1, peroxisome proliferator-activated receptor-α (PPAR-
α), PPAR-β and cAMP response element-binding (CREB) induce SIRT1 expression (Hayashida et al. 
2010, Okazaki et al. 2010, Noriega et al. 2011, Xiong et al. 2011), whereas PPAR-γ, carbohydrate 
response element-binding protein (ChREBP), poly(ADP-ribose) polymerase 2 (PARP2) and 
hypermetylated in cancer 1 (HIC1) repress SIRT1 expression (Chen et al. 2005b, Han et al. 2010, Bai 
et al. 2011a, Noriega et al. 2011). The HIC1-mediated repression is dependent on the carboxy-
terminal binding protein (CTBP) and it is enhanced by NADH (Chen et al. 2005b). MicroRNAs 
(miRNAs) are post-transcriptional regulators that modulate mRNA levels through the degradation 
of the primary mRNA transcript or by inhibition of translation. Two miRNAs, miR-34a and miR-
199a repress SIRT1 expression (Yamakuchi et al. 2008, Rane et al. 2009), and miR-34a levels are 
increased during diet-induced obesity (Lee et al. 2010a).  
SIRT1 activity is also regulated by post-translational modification (Figure 4b). SIRT1 is 
phosphorylated by the cyclin-dependent kinase 1 (cyclin B-CDK1), which results in enhanced cell 
proliferation (Sakaki et al. 2008). JUN N-terminal kinase (JNK) also phosphorylates SIRT1 in 
response to oxidative stress, which leads to deacetylation of histone H3, but not p53 indicating 
that phosphorylation directs SIRT1 to specific targets (Nasrin et al. 2009). In addition, dual 
specificity Tyr-phosphorylated and regulated kinase 1 (DYRK1) and DYRK3 phosphorylate and 
activate SIRT1 leading to increased cell survival through inhibition of p53-dependent apoptosis 
(Guo et al. 2010). Genotoxic stress (e.g. UV light and hydrogen peroxide) inactivates SIRT1 by 
desumoylationing through sentrin-specific protease (SENP) (Yang et al. 2007), whereas 
sumoylation activates SIRT1 (Yang et al. 2007).  
Sirtuins are also regulated by complex formation (Figure 4c). AROS is the only identified positive 
regulator protein of SIRT1 which binding to SIRT1 leads to inhibition of p53-dependent apoptosis  
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Figure 4. Regulation of sirtuin expression and activity. Regulation of sirtuins expression and activity occurs at four 
different levels; modulation of transcription (a), post-translational modifications (b), complex formation (c) and 
substrate level (d). Cd68i; CD68 inhibitor, ChREBP; carbohydrate response element-binding protein, CTP; carboxy-
terminal binding protein, cyclin B-CDK1; cyclin B-dependent kinase 1, DBC1; deleted in breast cancer 1, DYRK; Tyr-
phosphorylated and regulated kinase, H3K4; histone lysine 4, H4K16/26; histone lysine 16/26, HIC1; hypermetylated in 
cancer 1, CREB; cAMP response element-binding, FOXO1; fordkhead box O1, JNK; JUN N-terminal kinase, LSD1; lys-
specific demethylase 1, miRNA; microRNA, NA; nicotinic acid, NAAD; NA adenine dinucleotide, NAD; nicotinamide 
adenine dinucleotide, NADS; NAD synthase, NAM; nicotinamide, NAMN; NA mononucleotide, NAMPT; nicotinamide 
phosphoribosyltransferase, NAPT; NA phosphoribosyltransferase, NCoR1; nuclear receptor co-repressor 1, NMN; NAM 
mononucleotide, NMNAT;  NMN adenylyltransferase, NR: NAM riboside, NRK; NR kinase, PARP2; poly(ADP-ribose) 
polymerase 2, PARPi; PARP inhibitor, PPAR-α/-β,-γ; peroxisome proliferator-activated receptor-α/-β/-γ, SENP; sentrin-
specific protease, SMRT; silencing mediator of retinoic acid and thyroid hormone receptor. (Adapted from Houtkooper 
et al. 2012).   
 
(Kim et al. 2007b). However, several negative regulators of SIRT1 have been identified. Nuclear 
receptor co-repressor 1 (NCoR1) and silencing mediator of retinoid and thyroid hormone 
receptors (SMRT) form complex with SIRT1 and PPAR-γ, and thus repress the PPAR-γ-mediated 
adipogenesis during fasting (Picard et al. 2004). Deleted in breast cancer 1 (DBC1) also inhibits 
SIRT1 activity in vitro during genotoxic stress (Kim et al. 2008c, Zhao et al. 2008). The DBC1-SIRT1 
complex formation is dependent on the cellular energy status; fasting inhibits and HFD-feeding 
induces it, and the deletion of DBC1 protects mice from HFD-induced hepatic steatosis (Escande et 
al. 2010). Furthermore, lys-specific demethylase 1 (LSD1)-SIRT1 complex represses Notch target 
gene expression by deacetylating and demethylating specific histones H3K4, H4K16 and H3K26  
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(Mulligan et al. 2011), and the repression is reversed by activation of the Notch pathway (Mulligan 
et al. 2011).  
As mentioned above (see page 26), NAD+ is an important cofactor regulating sirtuin activation 
(Figure 4d). NAD+ levels increase in muscle, liver and WAT in response to energy/nutrient stresses 
such as fasting (Rodgers et al. 2005, Canto et al. 2010), calorie restriction (Chen et al. 2008) and 
exercise (Canto et al. 2010) and accordingly, SIRT1 activity is enhanced in all of these conditions. In 
contrast, NAD+ levels decrease during HFD feeding in mice (Kim et al. 2011a). Sirtuin activity is 
inhibited by NAD+-derived metabolites, nicotinamide (NAM) and NADH (Bitterman et al. 2002, Lin 
et al. 2004). NAD+ is synthesized de novo from tryptophan mainly in the liver and kidneys (for 
review see Houtkooper et al. 2010). However, NAD+ can also be synthesized from nicotinic acid 
(NA) through the Preiss-Handler pathway and from nicotinamide (NAM) through the salvage 
pathway (for review see Houtkooper et al. 2010). Both NA and NAM present in the human diet as 
niacin (vitamin B3). Nicotinamide riboside (NR), found in cow`s milk, is also a precursor of NAD+, 
which increases NAD+ levels through the salvage pathway (Bieganowski and Brenner 2004, 
Belenky et al. 2007). Recently, it has been demonstrated that treatment with NR activates SIRT1 
and SIRT3, enhances oxidative metabolism, and protects against HFD-induced metabolic 
abnormalities in mice (Canto et al. 2012). In addition, in the salvage pathway NAM is converted to 
nicotinamide mononucleotide (NMN) by nicotinamide phosphoribosyltransferase (NAMPT) and 
inhibition or down-regulation of NAMPT has been shown to lead to reduced sirtuin activity 
(Revollo et al. 2004). HFD and aging have been shown to reduce NAMPT-mediated NAD+-
biosynthesis contributing to the development of type 2 diabetes in mice, which is reversed by 
treatment with NMN, a product of the NAMPT reaction, partly through activation of SIRT1 
(Yoshino et al. 2011).  
NAD+ levels can also be regulated by manipulating the NAD+-consuming enzymes (Figure 4d). 
The major group of those enzymes is PARPs and the deletion of those enzymes activates SIRT1, 
increases the number of mitochondria, enhances energy expenditure and protects against diet-
induced obesity (Bai et al. 2011a, b). In addition, the deletion of CD38, another NAD+ consuming 
enzyme, activates SIRT1 and protects against diet-induced obesity (Barbosa et al. 2007).  
 
Mammalian sirtuins in calorie restriction 
Results from lower organism and the response of mammalian sirtuins to cellular energy and 
nutrient status indicator NAD+ suggest that mammalian sirtuins can be important molecular 
mediators of CR. The SIRT1 protein levels have been shown to elevate during CR in the brain, WAT, 
skeletal muscle, liver and kidneys (Cohen et al. 2004, Nisoli et al. 2005). However, cellular NAD+ 
levels and the NAD+/NADH ratio fluctuate depending on the tissue type suggesting that sirtuins 
have a tissue-specific response to CR (Chen et al. 2008). Currently, evidence is insufficient to 
categorize mammalian SIRT1 as a longevity gene as the overexpression of SIRT1 does not extend 
lifespan (Herranz et al. 2010), and only one report directly shows that SIRT1 is necessary for CR-
induced longevity (Boily et al. 2008). However, recent studies strongly suggest that SIRT1 mediates 
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adaptive responses to CR in mammals, and it has a crucial role in several metabolic- and aging-
associated diseases. One of these pieces of evidence is the observation that CR-induced elevation 
of physical activity is abolished in SIRT1-deficient mice (Chen et al. 2005a). Other studies have also 
shown that SIRT1 is required for normal response to CR (Boily et al. 2008, Cohen et al. 2009). 
Furthermore, SIRT1-overexpressing transgenic mice display phenotypes similar to mice under CR, 
including reduced body weight, improved glucose tolerance, reduced blood cholesterol, 
adipokines, insulin and fasted glucose levels, better performance in rotarod challenge, and a delay 
in reproduction (Bordone et al. 2007). Additionally, whole body SIRT1-overexpressing transgenic 
mice are protected from adverse effects of HFD- and aging-induced changes in metabolism, such 
as hepatic steatosis, insulin resistance, diabetes and cancers (Banks et al. 2008, Pfluger et al. 2008, 
Herranz et al. 2010). Moreover, several studies in mice have shown a protective role of SIRT1 
against cardiovascular (Alcendor et al. 2007, Zhang et al. 2008, Stein et al. 2010a, b) and 
neurodegenerative diseases (Kim et al. 2007a, Donmez 2010).  
In addition to SIRT1, mitochondrial SIRT3 associates with CR. SIRT3 expression is induced by CR 
in the liver and skeletal muscle as well as in WAT and brown adipose tissue (BAT) (Shi et al. 2005, 
Palacios et al. 2009, Schwer et al. 2009). Interestingly, SIRT3 is the only sirtuin with a reported 
association with the human lifespan (Rose et al. 2003, Bellizzi et al. 2005). Data from mouse 
models studies have shown that SIRT3 prevents several pathological conditions that are mediated 
by cellular oxidative damage, including stress induced tumor progression (Kim et al. 2010), and 
age-related cardiac hypertrophy and hearing loss (Sundaresan et al. 2009, Hafner et al. 2010, 
Someya et al. 2010).     
 
SIRT1 and metabolic regulation 
SIRT1 regulates whole-body metabolism by deacetylating several targets important in a variety 
of metabolic processes, including in hepatic gluconeogenesis and lipid metabolism, fat cell 
accumulation and maturation, pancreatic insulin secretion and central nutrient sensing (for review 
see Li and Kazgan 2011, Chalkiadaki and Guarente 2012) (Figure 5).  
During reduced calorie intake, the liver converts lipid and glycogen stores into available energy 
by increasing fatty acid oxidation and gluconeogenesis, and decreasing glycolysis (van den Berghe 
1991). SIRT1 deacetylates and activates peroxisome proliferator-activated receptor-γ coactivator 
1α (PGC-1α), which leads to activation of gluconeogenetic genes and inhibition of glycolytic genes 
(Rodgers et al. 2005). SIRT1 also induces gluconeogenesis by deacetylating FOXO1 (Daitoku et al. 
2004, Frescas et al. 2005) and signal transducer and activator of transcription 3 (STAT3) (Nie et al. 
2009). On the other hand, SIRT1 has been shown to suppress hepatic glucose production in the 
late phase of fasting by deacetylating CREB regulated transcription coactivator 2 (CRTC2, also 
known as TORC2) leading to CRTC2 degradation and reduction in transcription of gluconeogenic 
genes (Liu et al. 2008). Even though results in mice overexpressing SIRT1 suggest that SIRT1 may 
function as insulin sensitizer (see above on this page), studies with mice lacking SIRT1 specifically  
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Figure 5. Metabolic roles of SIRT1 in peripheral tissues and central nervous system. CRTC2; CREB regulated 
transcription coactivator 2, FOXO1; forkhead box protein O1, FXR; farnesoid X receptor, LXRα, nuclear receptors liver X 
receptor α, PGC-1α; PPAR-γ coactivator 1α, PPAR-α/γ; peroxisome proliferator activated receptor-α/γ, PTB1B; protein 
tyrosine phosphatase 1B, SREBP; sterol regulatory element-binding protein, STAT3; signal transducer and activator of 
transcription 3, UCP-2; mitochondrial uncoupling protein 2.  (Adapted from Nogueiras et al. 2012).   
 
in the liver demonstrate conflicting results regarding the role of SIRT1 in gluconeogenesis and 
insulin sensitivity. Acute adenovirus-mediated SIRT1 knockdown in the liver induced mild 
hypoglycemia (Rodgers and Puigserver 2007). By contrast, a complete absence of SIRT1 in the liver 
caused chronic hyperglycemia and insulin resistance (Wang et al. 2011c), whereas in two other 
studies it showed normal glucose homeostasis (Chen et al. 2008, Purushotham et al. 2009).    
SIRT1 promotes hepatic fatty acid oxidation through activating peroxisome proliferator-
activated receptor α (PPARα) and PGC-1α (Purushotham et al. 2009). Liver-specific deletion of the 
hepatic SIRT1 has been shown to lead to reduced expression of fatty acid oxidation genes (Rodgers 
and Puigserver 2007, Purushotham et al. 2009). Impaired fatty acid oxidation in hepatic SIRT1-
deficient mice results in the development of liver steatosis under normal and high-fat diets 
(Purushotham et al. 2009, Wang et al. 2010). By contrast, adenovirus-mediated overexpression of 
hepatic SIRT1 attenuates hepatic steatosis and systemic insulin resistance in diet-induced and 
genetically obese mice (Li et al. 2011a). In one study, however, liver-specific SIRT1-deficient mice 
were protected against hepatic steatosis but the reason for these conflicting results is unclear 
(Chen et al. 2008).   
SIRT1 also regulates hepatic cholesterol and bile acid homeostasis by deacetylating nuclear 
receptors liver X receptor α (LXRα) and farnesoid X receptor (FXR) (Li et al. 2007, Kemper et al. 
2009). Deletion of SIRT1 in mice leads to decreased LXRα and FXR activity and deleterious 
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metabolic outcomes, such as decreased HDL cholesterol, liver steatosis and decreased bile output 
(Li et al. 2007, Kemper et al. 2009). Another way by which SIRT1 regulates hepatic lipid 
metabolism is through deacetylation of the sterol regulatory element binding protein (SREBP) 
family of transcription factors (Ponugoti et al. 2010, Walker et al. 2010) that regulate lipid 
metabolism by promoting expression of lipogenic and cholesterolgenic genes involved in lipid 
storage (Osborne and Espenshade 2009). 
Skeletal muscle fatty acid oxidation is also important in preserving glycogen stores and blood 
glucose levels during reduced calorie intake. In skeletal muscle, SIRT1 promotes mitochondrial 
biogenesis and fatty acid oxidation by deacetylating PGC-1α (Gerhart-Hines et al. 2007, Amat et al. 
2009, Canto et al. 2010). In myotube cells, SIRT1 inhibits the transcription of protein tyrosine 
phosphatase 1B (PTP1B), the negative regulator of insulin signaling, suggesting that SIRT1 may 
have role in skeletal muscle insulin sensitivity (Sun et al. 2007).       
During reduced calorie intake, energy stored in the WAT is mobilized to be utilized by other 
tissues. SIRT1 inhibits adipogenesis and improves lipolysis by repressing the nuclear receptor 
PPAR-γ through promoting the assembly of co-repressors NCoR1 and SMRT on the promoters of 
PPARγ (Picard et al. 2004) (see page 28). In addition, SIRT1 regulates the production and/or the 
secretion of insulin-sensitizing factors adiponectin and fibroblast growth factor 21 (FGF21) through 
the regulation of FOXO1 and PPARγ (Qiao and Shao 2006, Qiang et al. 2007, Banks et al. 2008, 
Wang et al. 2008). The results, however, are contradictory and further work is needed to 
understand the role of SIRT1 in adipose tissue insulin sensitivity.  
In pancreatic β-cells, SIRT1 enhances glucose-stimulated insulin secretion and improves glucose 
tolerance which is thought to occur by repressing the expression of uncoupling protein 2 (UCP-2), 
an inner mitochondrial membrane protein (Moynihan et al. 2005, Bordone et al. 2006). Pancreatic 
β-cell-specific SIRT1-overexpressing (BESTO) transgenic mice maintain glucose tolerances under 
the long-term HFD feeding (Ramsey et al. 2008). SIRT1 has been shown to protect β-cells against 
cellular injuries through deacetylating FOXO1 and NF-kB signaling pathways (Kitamura et al. 2005, 
Lee et al. 2009). 
In the hypothalamus, the anorexigenic POMC expressing neurons produce satiety peptides and  
thereby inhibit food intake after feeding, and the orexigenic agouti-related protein (AgRP) 
expressing neurons promotes feeding in response to fasting and CR (Morton et al. 2006). During 
CR and fasting, hypothalamic SIRT1 expression and activity are increased (Cakir et al. 2009, Satoh 
et al. 2010). Inhibition of hypothalamic SIRT1 has been shown to decrease food intake and body 
weight gain by increasing POMC and decreasing AgRP expression through FOXO1 and S6K signaling 
dependent manners (Cakir et al. 2009). This SIRT1 hypothalamic activity is in contrast to its anti-
obesity function in the peripheral tissues, and it appears to be neuron-specific. AgRP neurons-
specific deletion of SIRT1 decreases AgRP neuronal activity and alleviates the inhibitory tone on 
the POMC neurons resulting in decreased food intake and body weight (Dietrich et al. 2010). In 
contrast, specific deletion of SIRT1 in POMC neurons impairs leptin signaling and reduces energy 
expenditure leading to a higher risk of obesity (Ramadori et al. 2010). Furthermore, deletion of 
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SIRT1 in POMC neurons contributes to the development of obesity by reducing sympathetic nerve 
activity and BAT-like remodeling of perigonadal WAT under HFD (Ramadori et al. 2010). 
 
Mitochondrial sirtuins and metabolic regulation 
CR improves mitochondrial function by increasing mitochondrial biogenesis and decreasing ROS 
production (for review see Guarente 2008). CR strongly changes the acetylation of mitochondrial 
proteins (Kim et al. 2006, Schwer et al. 2009), and the acetylation/deacetylation of proteins within 
mitochondria is considered to be one mechanisms by which changes in mitochondrial function is 
mediated in response to CR. Mitochondrial sirtuins SIRT3, SIRT4 and SIRT5 are assumed to function 
as a metabolic sensors that modulate the activity of metabolic enzymes via protein deacetylation 
or mono-ADP-ribosylation (for review see Huang et al. 2010, He et al. 2012) (Figure 6).   
Among the mitochondrial sirtuins, SIRT3 function has been the most widely studied. SIRT3 has 
been shown to be responsible for acetylations of several proteins in mitochondria, because the 
loss of SIRT3, but not SIRT4 or SIRT5, leads to hyperacetylation of mitochondrial proteins (Lombard 
et al. 2007). The first SIRT3 substrate identified was the mitochondrial enzyme acetyl-CoA 
synthase 2 (AceCS2) (Hallows et al. 2006, Schwer et al. 2006) which produces acetyl-CoA for the 
tricarboxylic acid (TCA) cycle to produce ATP and CO2. SIRT3 also plays an important role in hepatic 
fatty acid oxidation by activating long-chain acyl-CoA dehydrogenase (LCAD) (Hirschey et al. 2010) 
and in hepatic ketone bodies production by activating 3-hydroxy-3-methylglutaryl-CoA synthase 2 
(HMGCS2) (Shimazu et al. 2010). SIRT3 also deacetylates ROS-scavenging enzymes isocitrate 
dehydrogenase 2 (IDH2) (Someya et al. 2010), superoxide dismutase 2 (SOD2) (Qiu et al. 2010),  
SIRT3 SIRT5
CPS1 ↑
MITOCHONDRIA:
↑ Urea cycle
HMGCS2 ↑   MnSOD2 ↑
IDH2 ↑      NDUFA9 ↑
LCAD ↑      SOD2 ↑
LIVER:
↑ Fatty acid oxidation
↓ Triglyseride content
↑ Ketone body formation
↑ ROS protection
SKELETAL MUSCLE:
↑ Mitochondrial 
biogenesis
↑ ROS protection
SIRT4
GDH ↓
PANCREAS:
↑ Amino acid 
catabolism
↓ Insulin secretion 
BAT:
↑ Thermogenesis
PGC-1α ↑
UCP-1 ↑ 
PGC-1α ↑ 
 
Figure 6. Metabolic roles of mitochondrial sirtuins SIRT3, SIRT4 and SIRT5 in peripheral tissues. CPS1; carbamoyl 
phosphate synthetase 1, GDH; glutamate dehydrogenase, HMGCS2; 3-hydroxy-3-methylglutaryl-CoA synthase 2, IDH2; 
isocitrate dehydrogenase 2, LCAD; long-chain acyl-CoA dehydrogenase, MnSOD2; manganese superoxide dismutase, 
NDUFA9; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 9, PGC-1α; peroxisome proliferator-activated 
receptor-gamma coactivator 1α,  SOD2; superoxide dismutase 2, UCP-1; mitochondrial uncoupling protein 1. (Adapted 
from Nogueiras et al. 2012).     
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and manganese superoxide dismutase (MnSOD) (Tao et al. 2010). Moreover, SIRT3 facilitates 
mitochondrial oxidative phosphorylation by deacetylating mitochondrial complex I component 
NDUFA9 (Ahn et al. 2008, Bao et al. 2010, Kim et al. 2010), as well as other electron transfer 
components, including complex II (Cimen et al. 2010), III (Kendrick et al. 2011 , Kim et al. 2010), IV 
(Kendrick et al. 2011), and V (Bao et al. 2010).  SIRT3 also affects extra-mitochondrial processes 
and SIRT3 is required for normal PGC-1α expression in BAT and skeletal muscle (Shi et al. 2005, 
Palacios et al. 2009).  SIRT3 promotes PGC-1α expression by stimulating phosphorylation and PGC-
1α activating factors, including CREB and AMPK (Shi et al. 2005, Palacios et al. 2009, Pillai et al. 
2010). Constitutive expression of SIRT3 in BAT increases the expression of PGC-1α and UCP-1, 
leading to higher thermogenesis and oxygen consumption (Shi et al. 2005). In muscle cells, SIRT3 is 
also required for PGC-1α-dependent induction of genes involved in mitochondrial biogenesis and 
ROS-detoxifying (Kong et al. 2010). Recent studies have revealed that hyperacetylation of 
mitochondrial proteins in SIRT3-deficient mice leads to metabolic disturbances, including reduced 
ATP production, decreased rates of fatty acid oxidation and ketone body production, and a 
propensity to develop fatty liver and metabolic syndrome (Ahn et al. 2008, Hirschey et al. 2010, 
Shimazu et al. 2010, Hirschey et al. 2011, Kendrick et al. 2011). 
The less studied mitochondrial sirtuins are SIRT4 and SIRT5. The only known substrate of SIRT4 
is the glutamate dehydrogenase (GHD) enzyme that converts glutamate to α-ketoglutarate and 
allows it to enter TCA cycle (Haigis et al. 2006). SIRT4 ADP-ribosylates and inactivates GDH leading 
to repression of amino acid-stimulated insulin secretion in pancreatic β-cells (Haigis et al. 2006). In 
the liver, SIRT4 expression has been shown to decline during CR (Haigis et al. 2006), whereas in 
genetic models of diabetes increased SIRT4 protein expression is seen (Nasrin et al. 2010). SIRT4 
also plays a role in the regulation of fatty acid oxidation and mitochondrial gene expression in the 
liver and muscle cells, but the mechanism underlying those effects is still unclear (Nasrin et al. 
2010). During CR, amino acid catabolism is activated and up-regulation of urea cycle is a necessity 
to remove excess amounts of ammonia. SIRT5 deacetylates and activates carbamoyl phosphate 
synthetase 1 (CPS1), an enzyme catalyzing the first step of the urea cycle (Nakagawa et al. 2009).  
 
2.2.3.2 AMPK pathway 
 
The adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a crucial cellular energy 
sensor with the ability to regulate the whole body metabolism. It is sensitive to cellular changes in 
AMP/ATP and ADP/ATP ratios, which reflect the energy status of the cell. AMPK is activated in 
responses to metabolic stresses that deplete cellular ATP supplies (e.g. hypoxia, ischemia, low 
nutrient intake), or stimulate ATP consumption (e.g. exercise, fasting) (for review see Hardie et al. 
2012a). The ability of AMPK to sense energy stresses and regulate metabolism, suggest that AMPK 
might also be important in mediating the effects of CR.  
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AMPK structure and regulation 
AMPK is an evolutionarily conserved heterotrimeric serine/threonine protein kinase that is 
composed of a catalytic α-subunit and regulatory β- and γ-subunits. There are two different forms 
of α (α1 and α2) and β (β1 and β2) subunits, and three different γ isoforms (γ1, γ2 and γ3). α subunits 
contains the Thr172 residue, whose phosphorylation is required for AMPK enzymatic activity. The 
β subunit contains a carbohydrate-binding domain, which allows association with glycogen 
particles. The γ-subunits contain four tandem repeats known as cystathione β-synthase (CBS) 
motifs that bind AMP, ADP or ATP in a mutually exclusive way. (For review see Hardie 2007). 
In basal conditions, the binding of ATP keeps the enzymatic activity low. Binding of AMP, which 
is a signal of low cellular energy status, activates AMPK in two different ways; through allosteric 
activation and by promoting the phosphorylation of Thr172 (for review see Hardie et al. 2012a). 
Upstream kinases phosphorylate Thr172 and in mammals, two major upstream kinases are the 
LKB1-STRAD-MO25 complex (Hawley et al. 2003, Woods et al. 2003, Shaw et al. 2004) and the 
Ca2+/calmodulin-activated protein kinase kinases, especially CaMKKβ (Hawley et al. 2005, Hurley 
et al. 2005, Woods et al. 2005). The LKB1-STRAD-MO25 complex has high basal activity and it 
continuously phosphorylates Thr172 that is modulated by the binding of AMP to the AMPK γ-
subunit, which promotes phosphorylation and inhibits dephosphorylation (Hawley et al. 1995, 
Davies et al. 1995, Xiao et al. 2011). Although AMP can only allosterically activate AMPK, the 
effects on phosphorylation and dephosphorylation can also be produced by ADP (Xiao et al. 2011). 
Since ADP usually presents in cells at a higher concentration than AMP, it has been assumed that 
ADP regulates Thr172 phosphorylation during moderate energy stress and allosteric activation by 
AMP occurs during a more severe stress (for review see Hardie et al. 2012a). CaMKKβ serves as 
alternative pathway through which AMPK activity is regulated. CaMKKβ activates AMPK in 
response to increases in cellular Ca2+ without necessarily requiring any changes in AMP or ADP 
levels (Hawley et al. 2005, Hurley et al. 2005, Woods et al. 2005).  
As mentioned above, AMPK is activated in response to changes in AMP, ADP and Ca2+ levels. 
Several cytokines, including leptin, adiponectin, ghrelin and interleukin-6, activate AMPK activity 
(for review see Hardie et al. 2012a). In addition, several drugs, in particular the anti-diabetic drugs 
metformin and thiazolidinediones (Fryer et al. 2002) and natural plant products (e.g. resveratrol) 
stimulate AMPK activation (see section 2.2.4.1). Furthermore, AMPK has been shown to be 
activated by ROS- and DNA-damaging agents without changes in AMP, ADP and Ca2+ levels, but the 
mechanism for that is unclear (for review see Hardie et al. 2012a).    
 
AMPK function  
In general, AMPK activation switches on ATP-producing catabolic pathways, such as the uptake 
and metabolism of glucose and fatty acids, and switches off ATP-consuming anabolic pathways, 
such as the synthesis of fatty acids, cholesterol, glycogen and proteins (for review see Hardie et al. 
2012a) (Figure 7). This happens through a direct phosphorylation of metabolic enzymes or through 
a phosphorylation of coactivators and transcription factors that regulate gene expression. 
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Figure 7. AMPK activation switches on ATP-producing catabolic pathways (a) and switches off ATP-consuming 
anabolic pathways (b). ACC1/2; acetyl-CoA carboxylase 1/2, ChREBP; carbohydrate response element binding protein, 
CRTC2; cyclic AMP response element binding protein (CREB)-regulated transcription coactivator-2, GPAT; glycerol 
phosphate acyl transferase, HDACs; histone deacetylases,  HMGR; 3-hydroxy-3-methylglutaryl CoA reductase, HSL; 
hormone-sensitive lipase, PFKFB2/3; 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2/3, PGC-1α; peroxisome 
proliferator-activated receptor gamma coactivator 1-α, SREBP-1c; sterol response element binding protein-1c, 
TBC1D1; TBC1 domain family member 1, TSC2; tuberous sclerosis complex protein 2, ULK1; unc-51-like kinase 1. 
(Adapted from Hardie et al. 2012b).     
 
Catabolic events mediated by AMPK include enhanced glucose uptake in muscle, which is 
mediated through increasing the translocation of the glucose transporter type 4 (GLUT4) to the 
plasma membrane (Kurth-Kraczek et al. 1999) (Figure 7a). AMPK phosphorylates TBC1 domain 
family member 1 (TBC1D1) which is one of the RabGAPs regulating translocation of glucose 
transporters from storage vehicles to plasma membranes (Frosig et al. 2010). AMPK also promotes 
glucose uptake into cells expressing only GLUT1 through activation of GLUT1 that already exist in 
plasma membrane (Barnes et al. 2002). In addition, AMPK promotes fatty acid uptake into cardiac 
myocytes via translocation of CD36 to the membrane (Habets et al. 2009). 
After the glucose and fatty acid enter into the cells, AMPK also promotes their catabolism by 
enhancing glycolysis and fatty acid β-oxidation. AMPK induces heart glycolysis by phosphorylating 
and activating PFKFB2 isoform of 6-phosphofructo-2-kinase (PFK-2), the enzyme responsible for 
the synthesis of fructose 2,6-bisphosphate, a potent stimulator of glycolysis (Marsin et al. 2000). 
AMPK also phosphorylates PFKFB3 isoform of 6-phosphofructo-2-kinase in monocytes and 
macrophages (Marsin et al. 2002). In muscle cells, AMPK promotes fatty acid oxidation by 
phosphorylating and inactivating the mitochondria-associated isoform of acetyl-CoA carboxylase 
(ACC2) (Merrill et al. 1997). ACC2 inactivation lowers malonyl-CoA, an inhibitor of fatty acid uptake 
into mitochondria via the carnitine:palmityl-CoA transferase system (Merril et al. 1997). Although 
AMPK broadly induces catabolism, it still inhibits catabolic pathway lipolysis in rodent and human 
adipocytes by phosphorylation of hormone-sensitive lipase (HSL) (Daval et al. 2005, Bourron et al. 
2010). This is suggested to be due to fact that the recycling of lipolysis-produced fatty acids back 
to triglycerides consumes large amounts of ATP (for review see Hardie et al. 2012b).  
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    AMPK promotes glucose and fatty acid oxidative catabolism through enhanced mitochondrial 
biogenesis. AMPKβ1/AMPKβ2 double knockout mice have markedly reduced muscle 
mitochondrial content (O`Neill et al. 2011). AMPK phosphorylates PGC-1α, a master regulator of 
mitochondrial biogenesis, both directly and indirectly through SIRT1 (Jäger et al. 2007, Canto et al. 
2010). Phosphorylation of PGC-1α by AMPK is suggested to make it more susceptible for 
deacetylation by SIRT1 (Canto et al. 2009). In addition, AMPK has been shown to increase NAD+ 
concentration, which leads to increased SIRT1 activity and thus promotes PGC-1α deacetylation 
(Canto et al. 2009, Canto et al. 2010). AMPK also triggers an autophagy cascade by 
phosphorylating UNC-51-like kinase (ULK1, also called Atg1) (Lee et al. 2010b, Egan et al. 2011, 
Kim et al. 2011b). In particular, AMPK improves mitochondria turnover via autophagy (mitophagy), 
suggesting that AMPK is required for the clearance of dysfunctional mitochondria (Egan et al. 
2011).            
AMPK conserves ATP for cells by switching off anabolic pathways, including the biosynthesis of 
lipids, carbohydrates and proteins (Figure 7b). AMPK inhibits fatty acid synthesis by 
phosphorylating and inactivating ACC1 (Davies et al. 1992), and triglyceride and phospholipid 
synthesis by inactivating glycerol phosphate acyl transferase (GPAT) (Muoio et al. 1999). AMPK 
also inhibits cholesterol synthesis through phosphorylating and inactivating 3-hydroxy-3-
methylglutaryl CoA reductase (HMGR) (Clarke and Hardie 1990). AMPK phosphorylates 
carbohydrate response element binding protein (ChREBP) and sterol response element binding 
protein-1c (SREBP-1c), and thus inhibits transcription of lipogenic genes (Kawaguchi et al. 2002, Li 
et al. 2011b). Furthermore, AMPK inhibits transcription of hepatic gluconeogenic genes by 
phosphorylating cyclic AMP response element binding protein (CREB)-regulated transcription 
coactivator-2 (CRTC2, also known as TORC2) (Koo et al. 2005) and class IIa histone deacetylases 
(HDAC-4, -5 and -7) (Mihaylova et al. 2011). In addition, AMPK inhibits glycogen synthesis by 
phosphorylating and inactivating glycogen synthase 1 and 2 in muscle and the liver, respectively 
(Jorgensen et al. 2004, Bultot et al. 2012). AMPK also reduces protein synthesis by phosphorylating 
tuberous sclerosis complex protein 2 (TSC2) (an upstream regulator of mTOR) and Raptor (a 
component of mTORC1 complex) leading to inactivation of mammalian target-of-rapamycin 
complex 1 (mTORC1) (Inoki et al. 2003, Gwinn et al. 2008).  
In addition to the effects of AMPK in peripherial tissues, AMPK also influences metabolism and 
energy balance on the whole body level through its action in the hypothalamus. An injection of 
pharmacological activators of AMPK or DNA encoding activated mutants into the hypothalamus 
promotes feeding (Andersson et al. 2004, Minokoshi et al. 2004). In addition, hormones that 
inhibit feeding, such as leptin, inhibit AMPK activation and in contrast, hormones that promote 
feeding, such as ghrelin, activate AMPK (Andersson et al. 2004, Minokoshi et al. 2004). Ghrelin, 
which is released from the stomach during fasting, has been shown to activate AMPK through 
growth hormone secretagogue receptor 1 (GHSR) triggering a Ca2+ release and thereby lead to the 
action of AMPK by the CaMKKβ pathway (Andrews 2011). 
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AMPK also has a role in several processes beyond metabolism, including cell cycle and 
membrane excitability. AMPK regulates the cell cycle through cyclin-dependent kinase inhibitors 
p21WAF1 and p27KIP1 (Imamura et al. 2001, Jones et al. 2005, Liang et al. 2007). AMPK also 
phosphorylates the voltage-gated, delayed rectifier K+ channel, Kv2.1 and reduces membrane 
excitability and limits the rate of firing of action potentials in neurons (Ikematsu et al. 2011). 
Because firing of action potentials in the brain is the major consumer of energy, this may protect 
neurons during energy stress. 
 
AMPK in calorie restriction 
As a cellular energy sensor and metabolic regulator, AMPK is believed to act as a mediator of CR 
induced lifespan extension and health benefits. Enhanced AMPK activity has been shown to 
extend lifespan in worms and flies (Apfeld et al. 2004, Funakoshi et al. 2011). The role, however, of 
yeast AMPK ortholog Snf1 in longevity is very complex, as both deletion of Snf1 and forced 
overexpression of Snf1 reduce lifespan (Ashrafi et al. 2000). In worms, reduced glucose intake has 
been shown to extend lifespan via AMPK ortholog aak-2-dependent manner which is due to 
increased mitochondrial respiration, suggesting that AMPK is also important for CR-induced 
lifespan extension (Schulz et al. 2007). However, whether the AMPK activity is involved in the 
lifespan effect of CR in other species is unclear.  
The effect of CR on mammalian AMPK activity is very conflicting. In mice, CR has no effects on 
AMPK activity in the heart, liver or skeletal muscle (Gonzalez et al. 2004). However, Palacios and 
colleagues (2009) have shown that CR increases AMPK activity in mice skeletal muscle. Results 
from studies carried out in rats are even more controversial. One study has shown that CR reduces 
the AMPK activity in the liver (To et al. 2007), while other studies have shown that AMPK activity is 
increased in the heart and liver (Shinmura et al. 2005, Jiang et al. 2008, Finckenberg et al. 2012).    
Even though evidence that CR activates mammalian AMPK is scarce, AMPK activation still 
mediates several benefits in glucose and lipid metabolism (Figure 7). As stated above, some of the 
effects of the anti-diabetic drugs metformin and thiazolidinediones are mediated through AMPK, 
indicating that AMPK has insulin-sensitizing effects. AMPK has also been shown to be activated by 
CR-mimetic compound resveratrol (see section 2.2.4.1). In addition, AMPK regulates other known 
CR mediators. In particular, AMPK and SIRT1 activities are positively linked to each other (see page 
37). AMPK enhances SIRT1 activity by increasing NAD+ levels, which leads to enhanced 
mitochondrial biogenesis through PGC-1α, which is one of the important effects of CR (Canto et al. 
2009, Canto et al. 2010). In contrast, SIRT1 has been shown to activate AMPK by deacetylating and 
activating LKB1 (Hou et al. 2008, Lan et al. 2008), showing that there is a positive feedback loop 
between AMPK and SIRT1. Furthermore, AMPK induces autophagy and inhibits mTOR pathway 
(see page 37), the other important mediators of CR. AMPK can also impact on autophagy indirectly 
through SIRT1, which has been shown to form a complex with several components of autophagy 
machinery, including Atg5, Atg7 and Atg8 (Lee et al. 2008). The results indicate that AMPK is an 
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important energy sensor that can mimic several metabolic effects of CR directly or indirectly 
through other nutrient sensing pathways.  
 
2.2.3.3 mTOR pathway 
 
The target of rapamycin (TOR) is a highly conserved atypical serine/threonine protein kinase that 
belongs to the phosphoinositide-3-kinase (PI3K)-related kinase family. The TOR pathway controls 
cell growth and metabolism in response to growth factors (e.g. insulin, IGF-1), nutrients (e.g. 
amino acids), cellular energy (AMP/ATP ratio) and stress. The name of the kinases refers to the 
feature that kinases activity is inhibited by immunosuppressant drug rapamycin. The mammalian 
TOR protein is called mTOR, and it interacts with several proteins to form two distinct complexes 
termed mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).  
 
mTOR structure and regulation 
mTORC1 is a complex of six proteins and mTORC2 complex of seven proteins. They share catalytic 
mTOR subunits, and three other subunits called mLST8 (mammalian lethal with sec-13 protein 8), 
DEPTOR (DEP domain containing mTOR-interacting protein) and Tti1/Tel2 complex. Otherwise, the 
structure differs and for that reason complexes have different biological responses and different 
sensitivities to intracellular and extracellular signals and rapamycin. As compared to mTORC1, 
much less is known about the mTORC2 pathway, and therefore only mTORC1 regulation and 
function is described below. (For review see Laplante and Sabatini 2012). 
The heterodimer consisting of tuberous sclerosis 1 (TSC1) and TSC2 is a key upstream regulator 
of mTORC1. TSC1/2 complex is a GTPase-activating protein (GAP) for the Ras homolog enriched in 
the brain (Rheb) GTPase (for review see Huang and Manning 2008). The GTP-bound form of Rheb 
interacts with mTORC1 and stimulates its kinase activity. TSC1/2 complex induces the conversion 
of Rheb-GTP into Rheb-GDP, and thereby negatively regulates mTORC1 activity (Tee et al. 2003).  
TSC1/2 complex transmits many of the upstream signals that impact of mTORC1 activity. 
Nutrient, growth factors, energy and stress are the major regulators of the mTOR pathway. Insulin 
and insulin-like growth factor 1 (IGF-1) stimulates mTORC1 through the phosphoinositide-3-kinase 
(PI3K)/Akt and the Ras–ERK (extracellular signal regulated kinase) pathways, which phosphorylate 
a tyrosine on TSC2 leading to its inactivation (for review see Manning and Cantley 2007, Ma and 
Blenis 2009). In addition, proinflammatory cytokines, such as TNF-α, activates mTORC1 through 
IкB kinase β (IKKβ), which phosphorylates TSC1 and causes TSC1/2 inhibition (Lee et al. 2007). 
Furthermore, several stresses, including low energy and oxygen levels and DNA damage, activate 
mTORC1. AMPK responds to low energy levels and inactivates mTORC1 by phosphorylating TSC2 
and Raptor (Inoki et al. 2003, Gwinn et al. 2008) (see in section 2.2.3.2). Amino acids, in 
particularly leucine and arginine, activate mTORC1 independently of TSC1/2 complex. The 
molecular mechanism of how amino acids stimulate mTORC1 is still unclear, but it has been 
suggested to be dependent on the Rag GTPases (Kim et al. 2008b, Sancak et al. 2008).  
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mTOR function 
The best-characterized substrates of the mTOR pathway are translation initiation factor 4E (eIF4E)-
binding protein 1 (4E-BP1) and S6 kinase 1 (S6K1), whose phosphorylation by mTORC-1 promotes 
protein synthesis (for review see Ma and Blenis 2009) (Figure 8). mTORC1 also promotes protein 
synthesis by activating the element tripartite motif-containing protein 24 (TIF-1A), which enhances 
its interaction with RNA polymerase I (Pol I) and the expression of ribosomal RNA (rRNA) (Mayer et 
al. 2004). In addition, mTORC1 phosphorylates and inhibits Maf1, a Pol III repressor, and thereby 
induces 5S rRNA and transfer RNA (tRNA) transcription (Kantidakis et al. 2010, Shor et al. 2010).  
mTORC1 also promotes lipid synthesis that is required for proliferating cells to generate cell 
membranes (for review see Laplante and Sabatini 2009). Inhibition of mTORC1 represses the 
expression of SREBP1 and 2 transcription factors that control the expression of numerous genes 
involved in fatty acid and cholesterol metabolism (Porstman et al. 2008, Duvel et al. 2010, Li et al. 
2010, Wang et al. 2011a). mTORC1 regulates SREBP function by several different mechanisms, 
including through S6K1 (Duvel et al. 2010, Li et al. 2010, Wang et al. 2011a) and lipin-1 (Peterson 
et al. 2011). mTORC1 also influences lipid metabolism by promoting the expression and activity of 
PPAR-γ, a master regulator of adipogenesis (Kim and Chen 2004, Zhang et al. 2009).  
     mTORC1 regulates cellular metabolism and ATP production. mTORC1 activates HIF-1α, which 
positively regulates several glycolytic genes (Hudson et al. 2002, Brugarolas et al. 2003, Duvel et al. 
2010). mTORC1 also promotes mitochondrial biogenesis and oxidative metabolism by mediating 
the nuclear association between PGC-1α and the transcription factor Ying-Yang 1 (YY1) 
(Cunningham et al. 2007).  
 
                           
Figure 8. The key outputs of mTORC1 pathway. 4E-BP1; eukaryotic translation initiation factor 4E (eIF4E)-binding 
protein 1, HIF-1α; hypoxia inducible factor 1α, PGC-1α; PPAR-γ coactivator 1α, PPAR-γ; peroxisome proliferator-
activated receptor γ, S6K1; S6 kinase 1, SREBP1/2; sterol regulatory element-binding protein 1/2, ULK1/Atg13/FIP200; 
unc-51 –like kinase 1/mammalian autophagy-related gene 13/focal adhesion kinase family-interacting protein of 200 
kDA, YY1; ying-yang 1. (Adapted from Laplante and Sabatini 2012).        
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 mTORC1 is also a major negative regulator of autophagy. mTORC1 directly phosphorylates and 
suppresses ULK1/Atg13/FIP200 (unc-51 –like kinase 1/mammalian autophagy-related gene 
13/focal adhesion kinase family-interacting protein of 200 kDA), a kinase complex important in the 
initiation of autophagy (Ganley et al. 2009, Hosokawa et al. 2009, Jung et al. 2009). In addition, 
mTORC1 regulates autophagy also through other mechanisms, including through death-associated 
protein 1 (DAP1), a negative autophagy regulator (Koren et al. 2010), and through mTOR-
dependent phosphoproteome WIPI2 (Atg18 orthologue) (Hsu et al. 2011).      
 
mTOR in calorie restriction  
TOR signaling controls several cellular processes in response to nutrient availability, suggesting 
that the TOR pathway might have a role in mediating the effects of CR on health and lifespan. 
Results from lower organisms support this, and the inhibition of the TOR pathway extends lifespan 
in yeast (Kaeberlein et al. 2005b, Medvedik et al. 2007), worms (Vellai et al. 2003) and flies (Kapahi 
et al. 2004, Bjedov et al. 2010). In yeast, CR does not further extend lifespan in the absence of 
TOR1 gene, which is one of the two TOR genes in yeast (Kaeberlein et al. 2005b). In addition, 
similar results have been seen in worms, where inhibition of the TOR gene does not extend 
lifespan in eat-2 mutant worms which have impaired feeding behavior, and represents the genetic 
model of CR (Hansen et al. 2008), indicating that the TOR pathway is crucial in CR mediated 
lifespan extension.  
In mice, deletion of S6K1 leads to increased lifespan and reduced incidence of age-related 
pathologies (Selman et al. 2009). In addition, inhibition of mTOR with rapamycin extends lifespan 
in mice (Harrison et al. 2009, Miller et al. 2011). This is in contrast to other studies, which have 
unexpectedly shown that inhibition of mTOR with rapamycin causes diabetes-like syndrome by 
reducing β-cells mass and disrupting glucose and lipid metabolism (Cunningham et al. 2007, 
Fraenkel et al. 2008, Houde et al. 2010). Therefore, it has been suggested that too intensive mTOR 
inhibition has detrimental effects and the dose of rapamycin should be more carefully adjusted to 
get beneficial effects on metabolism and longevity (for review see Laplante and Sabatini 2012).    
In mammals, mTOR pathway activity is highly responsive to cellular nutritional status and 
inhibition of the mTOR pathway mimics several metabolic effects of CR. Obesity, high-fat feeding 
and insulin resistance increase (Um et al. 2004, Khamzina et al. 2005, Tremblay et al. 2007) and CR 
decreases mTOR activity in animals (Jiang et al. 2008, Moore et al. 2008, Estep et al. 2009). Mice 
with adipose-specific loss of mTORC1 have markedly less adipose tissue and they are resistant to 
HFD-induced obesity and hypercholesterolemia, and they have improved insulin sensitivity (Polak 
et al. 2008). In skeletal muscle, impaired mTORC1 is associated with reduced muscle mass and 
oxidative capacity and increased glycogen stores (Ohanna et al. 2005, Aguilar et al. 2007, 
Bentzinger et al. 2008, Risson et al. 2009). In the liver, inhibition of mTORC1 is required for PPAR-α 
activation, which induces the production of ketone bodies in response to fasting (Sengupta et al. 
2010). Liver-specific deletion of mTORC1 also reduces SREBP1 activity and protects mice against 
HFD-induced hepatic steatosis and hypercholesterolemia (Peterson et al. 2011).  
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In all the above mentioned metabolic tissues, mTORC1 has been shown to promote insulin 
resistance through S6K1-mediated inhibition of insulin substrate 1 (IRS-1) (Um et al. 2004, 
Khamzina et al. 2005, Tremblay et al. 2007). The impairment of insulin signaling increases 
lipotoxicity and ectopic fat accumulation by increasing fatty acid release from adipocytes, and 
increases hyperglycemia and hyperinsulinemia by increasing gluconeogenesis in the liver and 
decreasing glucose uptake in muscles (Um et al. 2004, Khamzina et al. 2005, Tremblay et al. 2007). 
All together, these changes contribute to systemic insulin resistance. However, in pancreatic β-
cells, mice with the loss of S6K1 have a reduced number and size of β-cells, reduced insulin 
secretion, and they are glucose intolerant and hypoinsulinemic (Pende et al. 2000, Ruvinsky et al. 
2005). This is in contrast to other tissues, where mTORC1 induces insulin resistance. It has been 
shown, however, that constitutive activation of mTORC1/S6K1 disturbs the insulin signaling 
pathway through S6K1-mediated inhibition of IRS-1, which leads to β-cells apoptosis and impaired 
insulin sensitivity (Shigeyama et al. 2008, Elghazi et al. 2010).  
In addition to peripheral tissues, leptin and leucine induced activation of hypothalamic mTORC1 
reduces food intake (Cota et al. 2006). High-fat feeding is known to induce leptin resistance, which 
blocks the ability of leptin to activate hypothalamic mTORC1 contributing to increased food intake 
(for review see Cota 2009). These results indicate that the mTOR pathway has an important role in 
the whole body metabolism, and in the development of a number of pathological conditions that 
are due to excess calorie intake, including diet-induced obesity, diabetes and NAFLD. Therefore, 
CR induced suppression of the mTOR pathway can be important in CR mediated effects on health 
and lifespan.    
 
2.2.3.4 Insulin/IGF-1 pathway 
 
As previously shown, insulin/insulin like growth factor-1 (IGF-1) signaling is associated with the 
mTOR pathway, and the reduction in insulin/IGF-1 signaling during CR has been linked to health 
and lifespan enhancing effects of CR. This proposition is based on the several studies, which have 
demonstrated that suppression of insulin/IGF-1 signaling improves health and extends lifespan in a 
variety of animals. In worms (C. elegans) and fruit flies (D. melanogaster), several genes 
homologue to the mammalian insulin/IGF-1 signaling have been identified, and the loss of 
function mutations of those genes lead to increased longevity (Kenyon et al. 1993, Kimura et al. 
1997, Clancy et al. 2001, Tatar et al. 2001, Giannakou et al. 2004). In mice, mutations in the PROP-
1 (Ames dwarf mice) and PIT-1 (Snell dwarf mice) genes, which encodes transcription factors for 
controlling pituitary development, lead to dwarfism and reduced levels of IGF-1 and insulin 
(Flurkey et al. 2001. Liang et al. 2003). Both Ames and Snell mice strains are remarkably long-lived, 
indicating that insulin/IGF-1 signaling regulates lifespan also in mammals. In addition, mice with 
reduced function in IGF-1 and growth hormone (GH) receptors, as well as defects in downstream 
molecules of IGF-1 signaling (such as p66shc, klotho, IRS-1 molecules) are associated with longevity 
(for review see Barbieri et al. 2003,  Berryman et al. 2008), further improving the role of 
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insulin/IGF-1 axis in mammals lifespan. Animals with repression of insulin/IGF-1 share several 
similar phenotypic characteristics as animals under CR, including reduced body weight and body 
temperature, improved insulin sensitivity and stress resistance, and lower incidences of cancer (for 
review see Berryman et al. 2008). Interestingly, CR has been shown to be able to further extend 
lifespan in Ames mice (Bartke et al. 2001), but not in GH receptor knockout mice (Bonkowski et al. 
2006), indicating that GH signaling appears to be important for the lifespan enhancing effect of CR.  
In humans, polymorphisms in the IGF-1 receptor and P13KCB (phosphoinositide-3-kinase), and 
genotype combination of polymorphisms, which are associated with reduced plasma IGF-1 levels, 
are more frequent in long-lived people (Bonafe et al. 2003), suggesting that insulin/IGF-1 signaling 
can be important in human lifespan as well.  However, long-term severe CR has not been shown to 
reduce serum IGF-1 concentration in humans (Fontana et al. 2008). 
 
2.2.3.5 Autophagy 
 
All previously described nutrient sensing pathways regulate autophagy, suggesting that autophagy 
may function as mechanistic links to how these pathways mediate beneficial effects on health and 
lifespan. Autophagy is an evolutionarily conserved lysosomal degradation pathway that is essential 
for cell survival, differentiation, development and energy homeostasis. It is a cellular self-digestion 
process, which exists in at least three different forms; chaperone-mediated autophagy, 
microautophagy and macroautophagy (Mizushima et al. 2008). The most prominent and best-
studied form of autophagy is macroautophagy (hereinafter referred to as autophagy) in which 
portions of cytoplasm, including excess or damaged organelles and misfolded and aggregated 
proteins, is sequestered into double-membrane vesicle called autophagosomes for degradation 
and recycling in lysosomes. The autophagy pathway is stimulated by multiple forms of cellular 
stress, and one potent known physiological inducer of autophagy is nutrient deprivation (Kroemer 
et al. 2010). Under nutrient stress, autophagy is rapidly induced to generate nutrients and 
substrates for energy production. Impairment of the autophagy process is associated with many 
human diseases, including cancer, neurodenegerative and cardiac diseases (Levine and Kroemer 
2008). 
One common feature of all aging-related changes at the tissue level is the accumulation of 
damaged and harmful modifications of macromolecules and organelles (Terman and Brunk 2006).  
It has been repeatedly reported that aging decreases autophagy activity contributing to 
accumulation of intracellular waste products and, in particular, the degradation of defective 
mitochondria is impaired in senescence cells (Salminen and Kaarniranta 2009, Rubisztein et al. 
2011). CR, which is linked to longevity and healthy aging, promotes autophagy and prevents the 
age-dependent decline of autophagy (Cavallini et al. 2001, Donati et al. 2001, Bergamini et al. 
2004, Bergamini et al. 2007). In C. elegans, there is clear evidence that autophagy is linked to 
longevity (Melendez et al. 2003, Hars et al. 2007), suggesting that autophagy might also be 
important in mediating the anti-aging effects of CR.  
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Besides aging, autophagy is also linked to obesity and metabolic diseases. Both genetic and 
HFD-induced obesity, as well as insulin resistance and hyperinsulinemia, have been shown to 
decrease hepatic autophagy activity (Liu et al. 2009, Yang et al. 2010). Defective autophagy in 
obese mice leads to elevated endoplasmic reticulum (ER) stress and insulin resistance (Yang et al. 
2010). Autophagy also regulates lipid metabolism, and inhibition of autophagy in hepatocytes and 
mouse liver has been shown to be associated with increased triglyceride content in lipid droplets 
(Singh et al. 2009). The role of autophagy in lipid metabolism, insulin sensitivity and cellular injury, 
which are all contributors to hepatic steatosis, suggest that autophagy may be important in the 
development of NAFLD and NASH (for review see Amir and Czaja 2011). Taken into account that 
CR is the best way to activate autophagy in vivo, the recent results suggest that autophagy can be 
an important mechanism for CR induced health effects. 
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2.2.4 SIRT1 activators as calorie restriction mimetics 
 
Even though CR is known to induce several health benefits, it is unlikely that many would be 
willing or able to maintain a CR lifestyle. Therefore, there has been intense interest in finding 
compounds that could affect pathways that mediate CR effects, and thus could act as CR-
mimetics. Several plant polyphenols compounds; butein, fisetin, piceatannol, quercetin and 
resveratrol, have been shown to activate SIRT1, and of them, resveratrol was identified to be the 
most potent SIRT1 activator (Howitz et al. 2003) (Figure 9). After the findings that resveratrol was 
able to protect against metabolic stress (see below), there has been a strong effort to find sirtuin 
activating compounds (STACS) with improved bioavailability and specificity for sirtuin activation. 
Several synthetic compounds that are structurally unrelated to resveratrol and have more potent 
SIRT1- activating power in vitro have been developed and of the compounds SRT1720 is the most 
potent SIRT1 activator (Milne et al. 2007) (Figure 9). Currently, multiple clinical trials have been 
initiated with three selective SIRT1 activators; SRT2104, SRT2379 and SRT3025 to find out their 
potential in the treatment of inflammatory, metabolic and cardiovascular diseases (for review see 
Baur et al. 2012).  
 
 
                    
 
Figure 9. Structure of putative SIRT1 activators resveratrol and SRT1720. 
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2.2.4.1 Resveratrol 
 
Resveratrol (3,5,4`-trihydroxystilbene) is a polyphenol that belongs to the stilbene family of 
phytoalexins, which are antibiotic compounds produced by plants in response to infection and 
stress. Resveratrol has been detected at least in 72 different plant species, and the richest dietary 
sources of resveratrol are grapes, grape juice, red wine and peanuts (Jang et al. 1997, Burns et al. 
2002). Originally, resveratrol was believed to account for the `French paradox`, the observation 
that moderate red wine consumption protects against coronary heart diseases despite the 
consumption of a diet high in saturated fat (for review see Catalgol et al. 2012). Since that, the 
connection between resveratrol and cardiovascular health was intensively studied, and resveratrol 
was shown to have several cardiovascular protective properties, including anti-oxidant, anti-
inflammatory, anti-proliferative and anti-angiogenic effects (Catalgol et al. 2012). The finding that 
resveratrol can increase the activity of SIRT1 (Howitz et al. 2003) leads to the assumption that 
resveratrol could act as a CR-mimetic. After that finding, numerous studies have investigated the 
potential of resveratrol to mimic CR-induced benefits (Baur 2010a).  
Resveratrol has been shown to extend lifespan by 18-56% in yeast (Howitz et al. 2003), worms 
(Wood et al. 2004) and flies (Bauer et al. 2004), and it functions in a Sir2-dependent manner. Some 
studies, however, have failed to observe lifespan extension effect in yeast and flies (Kaeberlein et 
al. 2005a, Bass et al 2007). A study in mammals has shown that resveratrol delays aging-related 
deterioration and induces similar gene expression to CR in the heart, liver, adipose tissue, skeletal 
muscle and brain (Barger et al. 2008, Pearson et al. 2008). Resveratrol also increases survival in 
obese mice such that their lifespans are equivalent to those of lean, untreated mice (Baur et al. 
2006). However, resveratrol does not increase survival in lean and healthy mice (Pearson et al. 
2008, Miller et al. 2011). Therefore, it has been suggested that metabolic stress is important for 
the lifespan-extending effect of resveratrol.  
Numerous studies have demonstrated the ability of resveratrol to reverse many of the obesity-
induced pathologies (for review see Szkudelska and Szkudelska 2010). In HFD fed mice, resveratrol 
has been shown to increase motor function and change the expression of several genes towards 
the expression found in mice on a standard diet (Baur et al. 2006, Lagouge et al. 2006). Resveratrol 
also protects against obesity by reducing the total body fat content, fat pad depots and body 
weight gain in mice (Lagouge et al. 2006) and rats (Aubin et al. 2008, Rivera et al. 2009) fed a HFD. 
However, it is remarkable that in some studies, resveratrol has failed to prevent body weight gain 
(Baur et al. 2006, Rocha et al. 2009). In obese Zucker rats, resveratrol reduced plasma 
triglycerides, FFAs and total cholesterol levels, and hepatic lipid content (Rivera et al. 2009).  
In addition to reduced adiposity and body weight, resveratrol attenuates several obesity-
associated disorders. Resveratrol has been shown to improve NAFLD in HFD fed Wistar rats (Shang 
et al. 2008) and obese Zucker rats (Gòmez-Zorita et al. 2012). Attenuated NAFLD by resveratrol is 
suggested to be due to reduced fatty acid availability and oxidative stress in the liver (Gòmez-
Zorita et al. 2012). Resveratol also improves glucose tolerance in rats with type 2 diabetes, and 
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increases glucose transport in skeletal muscle (Su et al. 2006, Chi et al. 2007, Park et al. 2007, 
Deng et al. 2008). In obese Zucker rats, resveratrol has been shown to reduce blood pressure and 
have anti-inflammatory effects in adipose tissue (Rivera et al. 2009). Preliminary data from clinical 
trials support the metabolic effects of resveratrol that have been seen in animal studies (Brasnyo 
et al. 2011, Timmers et al. 2011, Crandall et al. 2012). In general, those trials have shown that 
resveratrol improves insulin sensitivity and metabolic profile, even though very different subject 
groups (obese healthy, type 2 diabetics and older adults) were used in trials. 
 The hypothesis that resveratrol mimics CR effects is based on the finding that resveratrol can 
activate SIRT1. This is further supported by the findings that many of the effects observed in 
resveratrol-treated animals are based on the deacetylation of SIRT1 target genes, in particularly 
PGC-1α (Baur et al. 2006, Lagouge et al. 2006). It has been argued, however, that resveratrol is not 
a direct activator of SIRT1. The in vitro Fluor-de-Lys assay that was used in the identification of 
SIRT1 activators requires the presence of fluorescent substrates and when a similar assay is 
performed using a non-fluorescent substrate, activation of SIRT1 by resveratrol was not observed 
(Kaeberlein et al. 2005a, Pacholec et al. 2010). Besides SIRT1, resveratrol also has several other 
targets proteins (for review see Baur 2010b). In fact, many of the metabolic effects of resveratrol 
are believed to be based on AMPK activation (Canto et al. 2010, Um et al. 2010). Taken into 
account that AMPK positively regulates NAD+ levels and SIRT1 activity (see in section 2.2.3.2), it 
suggests that resveratrol can also activate SIRT1 indirectly through AMPK. However, the 
therapeutic potential of resveratrol would be strengthened by further studies to clarify the role of 
SIRT1 and other target proteins on resveratrol metabolic benefits.  
              
2.2.4.2 SRT1720 
 
SRT1720 is structurally unrelated to resveratrol, but it was identified to be a 1000-fold more 
potent activator of SIRT1 (Milne et al. 2007). However, SRT1720, like resveratrol, exhibits a 
substrate-specific effect on SIRT1 activity in vitro (Pacholec et al. 2010) (see above), which arouses 
the suspicion of its mechanism of action. Unlike resveratrol, SRT1720 does not acutely activate 
AMPK (Feige et al. 2008), indicating a more specific activity. 
Similar to resveratrol, SRT1720 mitigates various negative effects of obesity in both mice and 
rats. SRT1720 has been shown to improve whole-body glucose homeostasis and insulin sensitivity 
in diet-induced obese mice and Zucker rats (Milne et al. 2007). Furthermore, SRT1720 has been 
shown to increase endurance performance and protect against diet-induced obesity and insulin 
resistance by enhancing oxidative metabolism in skeletal muscle, liver and BAT (Feige et al. 2008). 
The improved oxidative metabolism in mice was shown to occur through deacetylation of SIRT1 
targets genes PGC-1α, FOXO-1 and p53. The gene expression profile study in mice showed that 
SRT1720 regulates genes involved in mitochondrial biogenesis, metabolic signaling and 
inflammation (Smith et al. 2009), which further supports a strong metabolic effect of SRT1720. In 
addition, SRT1720 has been shown to reduce hepatic steatosis in genetic and monosodium 
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glutamate-induced obese mice due to the reduced expression of genes involved in lipogenesis, in 
particular SREBPs and its target genes (Yamazaki et al. 2009, Walker et al. 2010). Recently, 
SRT1720 was reported to improve survival in obese mice and this lifespan extension is 
accompanied by several health benefits including reduction in liver steatosis, improved insulin 
sensitivity, suppression of inflammation and apoptosis, and normalization of hepatic gene 
expression profile (Minor et al. 2011). These results strongly indicate that SRT1720 has protective 
effects against obesity similar to resveratrol.       
 
 
To summarize, studies with model organisms have shown that CR has several beneficial 
effects on health and lifespan. Preliminary data from humans have shown that CR 
reduces the risk of cardiovascular diseases and diabetes, and mediates similar adaptive 
responses that occur in lower organisms. The mechanisms underlying the effects of CR 
are unknown, and recent studies with model systems have shown an important role for 
highly conserved nutrient sensing pathways; sirtuin, AMPK and mTOR pathways, in 
mediating the effects. It is also well-established that the insulin/IGF-1 pathway and 
autophagy are involved in mediating the effects of CR. Compliance to long-term CR is 
low, and there has been strong effort to find compounds capable of mimicking CR. 
Accumulating evidence indicates that the SIRT1-activating compounds resveratrol and 
SRT1720 mimic several effects of CR and attenuate many of the obesity-induced 
pathologies.            
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2.3  Dairy products and calcium in obesity 
 
Nutrition has also an important role in the prevention and treatment of obesity. Dairy products 
are a fundamental part of a healthy diet and an important source of calcium and proteins. 
Epidemiological studies, clinical trials and animal studies have been shown that a diet high in dairy 
products supports weight management and facilitates weight loss during CR. Dairy calcium and 
proteins have been suggested to account for the anti-obesity effects of dairy products.   
 
2.3.1 Potential dairy components affecting obesity 
 
Bovine milk contains approximately 3.5% proteins. Lowering the pH of milk to 4.6 leads to 
separation of casein and whey protein fractions; casein is coagulated and whey proteins remain 
soluble (Farrell et al. 2004). The casein to whey ratio ranges during lactation and it varies largely 
between species. The whey to casein ratio in cow`s milk is on average 20:80.  
 
Caseins 
Caseins are the major protein component in bovine milk. Caseins are further divided to four types 
of molecules, the αs1-, αs2-, β-, and κ-caseins in the approximate relative amounts of 4:1:3.5:1.5, 
respectively. In milk, caseins exist as large aggregates that are called casein micelles. Many of the 
physical and chemical properties (e.g. white colour, stability in heat) of milk are due to properties 
of casein micelles (Fox and Brodkorb 2008). Caseins and casein-derived peptides are suggested to 
have several health properties, including immunomodulatory, anti-oxidative, anti-microbial and 
osteoprotective properties (for review see Möller et al. 2008). In addition, the anti-hypertensive 
effects of casein-derived tripeptides isoleucine-proline-proline (IPP) and valine-proline-proline 
(VPP) have been demonstrated both in animals and humans (for review see Jäkälä and Vapaatalo 
2010).     
 
Whey proteins 
Whey is the natural by-product of cheese-making process. It is the liquid that remain after 
removing caseins. Besides whey proteins, that liquid contains minerals, vitamins, lactose and 
traces of fat. Whey contains five major proteins; β-lactoglobulin, α-lactalbumin, serum albumin, 
immunoglobulin and proteose-peptone fractions (Farrell et al. 2004). β-lactoglobulin accounts for 
approximately 50% and α-lactalbumin approximately 25% of the total whey protein in bovine milk. 
In addition, whey also contains serum albumin, immunoglobulins and protease-peptose fractions 
(Farrell et al. 2004), and minor amounts of lactoferrin, lactoperoxidase, IGF, γ-globulins and 
several other small proteins (Yalcin 2006). Whey proteins have a diverse array of functional 
properties that affect different biological processes and organ systems, including anti-
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inflammatory, immunoregulatory, anti-oxidative and anti-cancer effects (Krissansen 2007). In 
addition, anti-hypertensive peptides have been derived from whey protein, but the possible 
clinical benefits of the whey-derived peptides are unclear (for review see Jäkälä and Vapaatalo 
2010).  
  
Calcium 
Bovine milk contains approximately 1.2 g/l of calcium, and dairy products are the most important 
dietary source of calcium in the Finnish diet (Paturi et al. 2008). In bovine milk, calcium is mainly 
bound to casein micelles, about one-third of calcium is in the aqueous phase of milk and a small 
proportion of calcium is also bound to α-lactalbumin (Gaucheron et al. 2005). Calcium is important 
for the health of bones and teeth. It may help prevent hypertension, decrease colon and breast 
cancer incidences, and lower the risk of kidney stones (for review see Haug et al. 2007). In 
addition, the potential of calcium to improve weight control has been studied since the 1980s (see 
section 2.4.1.1).        
 
2.3.2 Dairy products and obesity 
 
Epidemiological studies 
Several cross-sectional epidemiological studies in adults and children confirm the inverse 
association between dairy intake and obesity (for review see Dougkas et al. 2011). The largest of 
those studies was based on the Portuguese Health Interview Survey (n=37 513 adults) which 
showed significant inverse relationship between BMI and milk consumption (Marques- Vidal et al. 
2006). Similar results have been shown in Iranian adults (Mirmiran et al. 2005, Azadbakht and 
Esmailzadeh 2008) and Italian postmenopausal women (Varenna et al. 2007). However, all studies 
do not support these findings, and no significant association between dairy intake and obesity was 
seen in Japanese women (Murakami et al. 2006), US adults (Brooks et al. 2006) or Dutch women 
(Snijder et al. 2007).  
Even though cross-sectional studies mainly support the association between dairy intake and 
obesity, the results from prospective cohort studies are more controversial. One systematic review 
of 19 prospective cohort studies has been published recently (Louie et al 2011). Ten of the studies 
were conducted with children and adolescents, and nine with adults. Together eight studies, three 
with children (Carruth and Skinner 2001, Moore et al. 2006, Johnson et al. 2007) and five with 
adults (Pereira et al. 2002, Rosel et al. 2006, Sanchez-Villegas et al. 2006, Halkjaer et al. 2009, 
Poddar et al. 2009) showed a protective association of dairy intake against weight gain. One study 
reported significant protective association only in men who were initially overweight (Vergnaud et 
al. 2008), whereas seven studies reported no effect (Philips et al. 2003, Newby et al. 2004, 
Striegel-Moore et al. 2006, Tam et al. 2006, Snijder et al. 2008, Fiorito et al. 2009, Huh et al. 2010), 
and one reported an increased risk (among children) (Berkey et al. 2005). Two studies reported 
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both increased and decreased risk depending on the type of dairy intake (Drapeau et al. 2004, 
Rajpathak et al. 2006).    
Although the evidence from epidemiological studies is inconclusive, the growing body of 
evidence suggests that dairy consumption has beneficial effects on the metabolic syndrome 
(Crichton et al. 2011). Several cross-sectional (Mennen et al. 2000, Yoo et al. 2004, Azadbakht et 
al. 2005, Liu et al. 2005, Elwood et al. 2007, Ruidavets et al. 2007) and prospective cohort studies 
(Pereira et al. 2002, Lutsey et al. 2008) have shown that dairy consumption is inversely associated 
with the prevalence or incidence of the metabolic syndrome. However, some studies failed to see 
an association between dairy consumption and metabolic syndrome (Snijder et al. 2007, Snijder et 
al. 2008, Shin et al. 2009), and two studies showed a higher prevalence of metabolic syndrome in 
subjects with higher dairy intakes (Lawlor et al. 2005, Beydoun et al. 2008).  
The type of dairy product used in epidemiological studies has been shown to affect outcomes, 
and interestingly some studies have shown an inverse association between BMI and high-fat, but 
not low-fat, dairy intake (Rajpathak et al. 2006, Rosell et al. 2006, Snijder et al. 2007). In some 
studies higher cheese consumption is associated with higher BMI (Snijder et al. 2007, Beydoun et 
al. 2008), while milk and yoghurt intake were negatively related to adiposity (Beydoun et al. 2008). 
In the Bogalusa Heart Study, dairy intake from foods such as pizza, lasagna and cheeseburgers was 
also included in the analysis (Brooks et al. 2006). This indicates that the type of dairy products 
strongly varies between cross-sectional studies or it has not been reported at all, which 
complicates the comparison of the epidemiological studies and can explain why some studies 
failed to show an inverse association between dairy intake and obesity. In addition, in studies 
examining the effects of dairy product intake on metabolic syndrome, the differences in metabolic 
syndrome diagnostic criteria can explain, at least in part, the inconclusive nature of the results.           
 
 
Clinical trials 
The randomized clinical trials have investigated the effect of dairy intake on body weight gain and 
weight loss. One meta-analysis concerning the effect of dairy consumption on weight and body 
composition has been published (Abargouei et al. 2012). Overall, the meta-analysis consisting of 
14 randomized controlled clinical trials showed that high dairy intake resulted in -0.61 kg (95% 
confidence interval (CI): -1.29, 0.07, P=0.08) greater reduction in body weight, 0.72 kg (95% CI: -
1.29, -0.14. P=0.01) greater reduction in fat mass, 0.58 kg (95% CI: 0.18, 0.99, P˂0.01) gain in LBM 
and 2.19 cm (95% CI: -3.42, -0.96, P˂0.001) further reduction in waist circumference (WC) than in 
the control group. However, there was a significant heterogeneity between studies and therefore 
studies were categorized into two major groups; those that assessed the effects of high-dairy diets 
on weight loss (with CR, 500 kcal/day less than the estimated energy requirement) both in 
intervention and control groups, and those that assessed the effects of high-dairy diets on weight 
gain (without CR). Ten studies with CR showed that high-dairy intake (additional calcium intake of 
550-1000 mg/day via dairy products in intervention group vs. calcium intake of 290-800 mg/day in 
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control group) resulted in 1.29 kg (95% CI: -1.98, -0.6, P˂0.001) greater weight loss, 1.11 kg (95% 
CI: -1.75, -0.47. P=0.001) greater reduction in body fat mass, 0.72 kg (95% CI: 0.12, 1.32, P=0.02) 
gain in LBM and 2.43 cm (95% CI: -3.42, -1.44, P˂0.001) further reduction in WC compared to 
controls. However, five studies without CR did not show any significant differences in weight, body 
fat mass, LBM or WC between subjects with high dairy intake (additional calcium intake of 400-
850 mg/day via dairy products) and with low dairy intake (maintained at habitual diet). The meta-
analysis demonstrated that increased dairy intake enhances weight and fat loss during CR, but it 
has no beneficial effects on weight and body composition in situations without CR.    
 
2.4 Dairy components and obesity 
2.4.1.1 Dietary calcium and obesity 
 
Epidemiological studies  
McCarron and his group (1984) were the first to show that calcium intake was inversely related to 
body weight. After that, numerous cross-sectional and prospective cohort studies have been 
published, and several of those studies support the inverse association between calcium intake 
and body weight both in adults and children (for review see Dougkas et al. 2011). Since dairy is the 
major dietary source of calcium, studies also subsequently evaluated the role of dairy. Dougkas et 
al. (2011) conducted a mixed-model regression analysis of the 18 epidemiological studies and 
created a linear regression equation showing the association between calcium intake and 
predicted BMI. According to that equation low dietary calcium intake with a 400 mg/d dose 
predicted a BMI of 25.6 kg/m2, and high dietary calcium with a 1200 mg/d dose predicted a BMI of 
24.7 kg/m2. In other words, this means that an increase in calcium intake of 800 mg/day is 
associated with a decrease in BMI of 1.1 kg/m2. In addition to BMI, epidemiological studies have 
also shown that higher calcium intake is associated with lower blood pressure, fasting glucose, 
insulin and cholesterol levels, insulin resistance (McCarron et al. 1984, Jacqmain et al. 2003, 
Drouillet et al. 2007, Kruger et al. 2007, dos Santos et al. 2008), and the reduced risk of stroke (Iso 
et al. 1999, Abbott et al. 1996, Umesawa et al. 2008).   
  
Clinical trials 
Even though most of the epidemiological studies show an inverse correlation between calcium 
intake and BMI, results from clinical trials are more controversial. The meta-analysis including 13 
randomized controlled trials showed that high-calcium intake from calcium a supplement source 
(mean difference -1.79 kg, 95% CI -3.04, -0.55, P=0.05) or dairy product source (mean difference 
0.85 kg, 95% CI -4.39, 6.08, P=0.75) did not have significant effect on body weight (Trowman et al. 
2006). However, only one of those trials was directed at studying the effects of calcium treatment 
on body weight (Zemel et al. 2004), while the other studies were investigating bone mass during 
calcium treatment. Furthermore, one systematic review using 49 randomized trials, of which 38 
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trials investigated the effect of calcium and/or dairy supplementation on weight gain (without CR) 
and 11 trials on weight loss (with CR) (Lanou and Barnand 2008). As many as 41 trials had no effect 
on body weight during weight gain or weight loss. Of the weight gain trials, only one trial showed a 
lower rate of weight gain (Caan et al. 2008), two trials showed weight gain (Barr et al. 2000, Lau et 
al. 2001) and one trial showed weight loss (Recker et al. 1996). In contrast, only four trials showed 
that calcium/dairy supplementation induces weight loss during CR (Zemel et al. 2004, Zemel et al. 
2005a, Zemel et al. 2005b). 
In most of the clinical trials that showed an effect on body weight, the source of calcium was 
dairy supplementation (Zemel et al. 2004, Zemel et al. 2005a, Zemel et al. 2005b), which suggests 
that the source of Ca can affect results. Zemel et al. (2004) reported more effective weight and fat 
loss during CR in obese subjects who received calcium as dairy products compared to calcium 
supplements. This is further supported by the other study showing greater fat loss in high-dairy 
diet compared to calcium supplementation (Zemel et al. 2009). However, the study did not 
observe significant differences in weight loss. Similarly, in postmenopausal women, high-dairy 
intake resulted in greater loss of leg fat and a lower increase in the sum of skinfold thickness 
compared to the high supplemental calcium, even though BMI and weight were unchanged in the 
study (Manios et al. 2009). In addition, dietary calcium has been shown to be more effective in the 
prevention of weight re-gain than calcium supplements (Ochner and Lowe 2007).  
 
Animal studies 
The anti-obesity effects of dietary calcium has been widely studied in transgenic aP2-agouti mice, 
which are lean when fed normal chow diets, but are very susceptible to adult-onset diet-induced 
obesity. aP2-agouti mice gain weight when they are fed a low-calcium diet, and a high-calcium diet 
suppresses fat accretion and weight gain in animals maintained at identical caloric intakes (Zemel 
et al. 2000, Sun and Zemel 2006). In addition, high-calcium diets accelerate weight and fat loss 
during CR more than low-calcium diets (Shi et al. 2001). After CR, aP2-agouti mice fed with high-
calcium diets exhibited a 50-85% reduction in weight and fat re-gain (Sun and Zemel 2004a). 
Only one study reports a lack of effect of calcium intake on body weight and body fat in rats 
and mice (Zhang and Tordoff 2004). However, studies in many other animal models, including 
spontaneously hypertensive rats, Wistar rats and HFD fed C57Bl/6J mice, confirm the observation 
that increased calcium intake lowers body weight and fat gain (Metz et al. 1988, Papakonstantinou 
et al. 2003, Parra et al. 2008).       
In addition to the effects on body weight and fat content, a high-calcium diet has been shown 
to decrease adipose tissue intracellular ROS production, and the expression of pro-inflammatory 
cytokines TNF-α and IL-16 in adipose tissue in aP2-agouti mice (Sun and Zemel 2006, Sun and 
Zemel 2007a, Zemel and Sun 2008a, Bruckbauer and Zemel 2009). The results indicate that a high-
calcium diet suppresses both ROS and inflammatory stress, and both are important contributors to 
many obesity-associated disorders.     
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2.4.1.2 Dairy proteins and obesity 
 
Dietary calcium has been estimated to be responsible for approximately 50% of the anti-obesity 
bioactivity of dairy products, which suggest that dairy products contain also other bioactive 
components (for review see Zemel 2009). Dairy products are also an important dietary source of 
high-quality proteins, and accumulating evidence indicates that the intake of proteins may be 
important during weight loss and weight maintenance (Clifton et al. 2008, Clifton et al. 2009, 
Westerterp-Plantenga 2009). However, it is unknown whether the type of dietary protein has 
impact on weight management.  
Dairy proteins contain bioactive compounds that may have anti-obesity effects (for review see 
Krissansen 2007, Möller et al. 2008). Among those bioactive compounds are casein- and whey-
derived peptides having angiotensin-converting enzyme (ACE) inhibitor activity (for review see 
Jäkälä and Vapaatalo 2011). In addition to blood pressure regulation, ACE inhibitor activity is 
suggested to be associated with weight regulation. The adipose tissue local renin-angiotensin-
aldosterone system (RAAS) is linked to the development of obesity and metabolic syndrome 
(Engeli et al. 2003). Furthermore, angiotensin II is known to up-regulate fatty acid synthase (FAS) 
expression in adipocytes, and ACE inhibition has been shown to mildly attenuate obesity in 
hypertensive mice and humans (for review see Zemel et al. 2009). 
Accumulating evidence suggests that whey proteins in particular enhance the anti-obesity 
effects of dairy products. Studies with Wistar rats have shown that whey protein prevents body 
weight gain more that red meat (Belobrajdic et al. 2004) or casein (Royle et al. 2008). In C57BL/6J 
mice, a high-calcium whey protein diet inhibited body weight and fat gain, accelerated weight and 
fat loss during CR and prevented weight and fat re-gain after CR more than a high-calcium casein 
diet (Pilvi et al. 2007, Pilvi et al. 2009). In addition, comparison between different high-calcium 
whey protein fraction diets (whey protein isolate, α-lactalbumin, β-lactoglobulin and lactoferrin) 
showed that α-lactalbumin was the most effective in inducing weight loss and preventing weight 
re-gain as compared to other whey protein fractions (Pilvi et al. 2009). In addition, a high-calcium 
whey protein diet has been shown to decrease blood glucose and serum insulin levels more than a 
casein-based diet during CR (Pilvi et al. 2008a). A high-calcium whey protein diet also beneficially 
modulates hepatic lipid profile (Pilvi et al. 2008a) and adipose tissue gene expression profile 
during CR (Pilvi et al. 2008b). Similar beneficial effects have been seen in humans as well and 
during CR, a whey protein supplement has been shown to enhance weight loss and spare the 
muscle mass (Frestedt et al. 2008). Clinical trials have also shown that whey protein has blood 
glucose and/or insulin lowering effects and it may increase muscle protein synthesis (for review 
see Graf et al. 2011).    
The anti-obesity effects of whey protein are suggested to be due to its amino acid composition. 
Whey contains a high concentration of branched chain amino acids (BCAAs, ~26%) (leucine, 
isoleucine and valine) (Ha and Zemel 2003). Of the BCAAs, leucine is of particular interest, because 
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it has a distinct role in protein metabolism and it is important in the stimulation of muscle protein 
synthesis (Ha and Zemel 2003). Furthermore, leucine appears to be an important factor in lipid 
metabolism and energy partitioning between adipocytes and skeletal muscle cells (Sun and Zemel 
2007b).  
   
2.4.2 Mechanisms explaining the anti-obesity effects of dairy products 
 
The potential mechanism underlying the effect of high-dairy intake on body weight and body fat is 
still quite unclear. Currently, the most highly plausible mechanisms refer to dietary calcium and its 
effects on intracellular calcium and subsequent impact on adipocyte lipid metabolism and fatty 
acid absorption from the gastrointestinal tract. In addition, whey proteins have been suggested to 
have satiety and insulinotropic effects, which can enhance the anti-obesity effects of dairy 
products. 
 
Calcium and adipocyte lipid metabolism 
Zemel and his group were the first who showed the association between low-calcium intake and 
fat accumulation (Xue et al. 1998, Zemel et al. 2000). Intracellular calcium has been shown to 
promote fat storage, which is due to the stimulation of de novo lipogenesis through the regulation 
of fatty acid synthase (FAS), and the inhibition of lipolysis through the activation of 
phosphodiesterase 3B (PDE3B) (Zemel 2002). The concentration of intracellular calcium in human 
adipocytes is regulated by calcium-regulating hormones parathyroid hormone (PTH) and 1,25 
dihydroxy-vitamin D3 (1,25(OH)2D3). High-calcium intake decreases the concentration of 
calcitrophic hormones (PTH and 1,25(OH)2D3) and thereby decreases the concentration of 
intracellular calcium, which inhibits lipogenesis and stimulates lipolysis leading to decreased lipid 
storage (Zemel 2003).  
In addition, decreased 1,25(OH)2D3 during high-calcium intake has several lipid storage 
decreasing functions. At first, decreased 1,25(OH)2D3 increases the expression of UCP-2 via the 
nuclear vitamin D receptor in WAT which leads to improved thermogenesis (Shi et al. 2002). 
Thereby, high-calcium intake attenuates the decline in thermogenesis which usually occurs during 
CR. Secondly, the regulation of UCP-2 and intracellular calcium by 1,25(OH)2D3 appears to 
modulate adipocyte apoptotic death (Sun and Zemel 2004b, Zemel and Sun 2008b). The third 
possible explanation is that decreased 1,25(OH)2D3 down-regulates 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD) expression and decreases the concentration of glucocorticoid 
which in turn decreases the size of the fat deposit (Morris and Zemel 2005). Finally, decreased 
1,25(OH)2D3 has an impact on human adipocyte differentiation and proliferation via the regulation 
of ROS and inflammatory cytokines (Sun et al. 2008, Sun and Zemel 2008). Even though evidence 
from cell-culture and animals studies shows the role of high-calcium intake in adipocyte fat 
metabolism, recent results from human studies failed to support it (Boon et al. 2005, Boon et al. 
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2007, Bortoletti et al. 2008) indicating that further studies are required to explore the effect of 
high-calcium on lipid metabolism in humans.        
 
Calcium and fat oxidation 
The effect of high-calcium intake on whole body fatty acid oxidation has been examined in 
randomized clinical trials, and the results from those studies are controversial. Melanson and his 
group (2005) showed that high-calcium diet during CR increased 24 h whole-body fat oxidation by 
28% as compared to a low-calcium diet during CR. Similar results have been seen in other studies 
(Gunther et al. 2005, Cummings et al. 2006, Teegarden et al. 2008, Zemel et al. 2008), while 
several studies also fail to support the role of high-calcium consumption in fat oxidation (Boon et 
al. 2005, Jacobsen et al. 2005, Bortolotti et al. 2008). Although dietary calcium is known to 
regulate expression of the fat oxidation gene UCP-2 (Shi et al. 2002), the clear mechanism of how 
dietary calcium regulates fat oxidation is unknown. 
 
Calcium and fatty acid absorption     
Another possible mechanism that has been suggested as responsible for the effect of calcium on 
body adiposity is reduced fat absorption from the gastrointestinal tract. Calcium has been shown 
to increase faecal excretion of fat via the formation of insoluble fatty acid soaps or by the binding 
of bile acids which weakens the formation of micelles (Denke et al. 1993, Welberg et al. 1994, 
Shahkhailili et al. 2001, Jacobsen et al. 2005, Bendsen et al. 2008). Recently, meta-analysis of 
randomized controlled trials examining the impact of both dairy and supplemental calcium on 
faecal fat excretion has been published (Christensen et al. 2009). It showed that both dairy and 
supplemental calcium increased faecal fat excretion approximately 2.2 g/day (95% CI 0.63, 1.34, 
P˂0.0001), but there was some heterogeneity (I2=49.5%) among studies indicating some 
inconsistency in trial outcomes. When only studies using dairy-derived calcium were analyzed, 
results showed homogeneous outcomes and it was estimated that increasing dairy calcium intake 
by 1241 mg/day resulted in an increase in faecal fat of 5.2 g/day (95% CI: 1.6, 8.8). Authors also 
estimated that 5.2 g/day faecal fat excretion is equivalent to 4.7 kcal/day or 1.9 kg body fat or 2.2 
kg body weight loss over in one year. In addition to fatty acid absorption, high-calcium intake has 
been shown to decrease postprandial lipidemia as compared to low-calcium intake, and calcium 
from dairy products was more effective than supplementary calcium (Lorenzen et al. 2007).  
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Dairy proteins and satiety 
Among the other dairy components, the proteins have the greatest role in appetite control. It is 
well documented that dietary proteins suppress food intake more than carbohydrates and fats 
(Anderson and Moore 2004), and diets high in protein content are more satiating than low protein 
diets (Skov et al. 1999, Weigle et al. 2005). Currently, there is little evidence showing whether the 
satiety effect of proteins is dependent on the source of protein. Since dairy products are an 
important source of protein, there has been great interest in investigating the potential of dairy 
proteins providing satiety signals. 
Whey proteins have been shown to be more satiating than casein, soy proteins, turkey or egg 
proteins (Hall et al. 2003, Anderson et al. 2004, Veldhorst et al. 2009, Pal and Ellis 2010). Some 
studies, however, have not seen a difference in the satiating effect between whey and casein 
(Bowen et al. 2006). Whey and casein have different physical properties that contribute to their 
functionality in food systems. The digestion of whey into peptides and amino acids and then 
absorption is faster than that of casein and therefore casein and whey proteins are classified as 
`slow` and `fast` proteins, respectively (for review see Luhovyy et al. 2007). It is assumed that 
whey and casein have a synenergistic effect; whey reduces food intake at 90 min and casein at 150 
min after meal consumption. The more satiating effect whey protein is mediated by its effect on 
the release of satiety hormones. Whey protein ingestion resulted in higher plasma concentration 
of cholecystokinins (CCKs) and glucagon-like peptide-1 (GLP-1) than casein (Hall et al. 2003). Also, 
the high concentration of leucine in whey protein is proposed to explain the satiating effect of 
whey. Leucine enters the brain from blood faster than other amino acids and 
intracerebroventricular administration of leucine has been shown to reduce food intake which is 
thought to be due to activation of mTOR in hypothalamus (for review see Potier et al. 2009) (see 
section 2.2.3.3). Noteworthy is that most of the above mentioned effects of whey are based on 
high whey protein diets and it is unknown whether similar effects are obtained with normal 
serving sizes of dairy products which were used in the experimental studies and clinical trials 
studying the effect of dairy products on body weight. 
 
Dairy proteins and insulinotropic properties          
High dairy intake has beneficial effects on metabolic syndrome (Crichton et al. 2011) and, in 
particular, high dairy intake is linked to a lower risk of type 2 diabetes (for review see Tremblay 
and Gilbert 2009). Several studies have shown that whey proteins enhance postprandial glycemic 
response (Nilsson et al. 2004, Frid et al. 2005, Ma et al. 2009, Akhavan et al. 2010). As mentioned 
above, whey is a rapidly digested protein that promotes a higher concentration of amino acids in 
plasma after a meal, which can stimulate insulin secretion. The mixture of leucine, isoleucine, 
valine, lysine and threonine has been shown to induce similar glycemic and insulinemic responses 
as whey in healthy subjects (Nilsson et al. 2007), suggesting that BCAAs of whey proteins are 
important for whey protein mediated glycemic response.       
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In addition, whey protein has been suggested to mediate the insulinotrophic properties 
through incretin hormones. Incretin hormones, such as insulinotropic polypeptide (GIP) and GLP-1 
are gut-derived peptides that potentiate insulin secretion from the islet β-cell in a glucose-
dependent manner (Drucker 2006a). Incretin hormones are released after food consumption and 
they are rapidly degraded by dipeptidyl peptidase IV (DPP-IV). In mice, whey protein has been 
shown to inhibit DPP-IV and raise GLP-1 concentration resulting in an increased and prolonged 
insulin response (Gunnarsson et al. 2006). The mechanism for that is unknown, but it has been 
suggested that dipeptides and tripeptides formed during whey digestion may serve as an 
endogenous inhibitors of DPP-IV activity in the proximal gut (for review see Drucker 2006b).  
 
Taken together, the growing body of evidence from epidemiological studies has shown 
that a diet high in dairy products is inversely associated with BMI and it is related to a 
lower risk of type 2 diabetes and metabolic syndrome. According to clinical trials high-
dairy product intake enhances weight and fat loss during CR. Dairy calcium has been 
suggested to account for part of the anti-obesity effects of dairy products via increased 
fat excretion and 1,25(OH)2D3-mediated changes in adipocyte lipid metabolism. 
Importantly, dairy-derived calcium has been shown to be more effective than calcium 
supplementation, indicating that dairy products also contain other anti-obesity 
components. Dairy proteins, especially whey proteins, have been shown to prevent 
weight gain and enhance weight loss during CR. The mechanisms underlying the anti-
obesity effects of whey proteins are still unclear, but it has been suggested to be due to 
their higher satiety and insulinotropic effects.  
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3. Aims of study 
 
Weight loss is the primary treatment for obesity and obesity associated diseases. Calorie 
restriction (CR) with adequate nutrition is the effective method to induce weight loss, but 
compliance to CR lifestyle is often very low. Better understanding of the mechanism how CR 
mediates its effects could reveal new targets for anti-obesity drug development. The main aim of 
the present study was to investigate the molecular and signaling pathways mediating the effects 
of CR with special emphasis on the sirtuin, AMPK and mTOR pathways. Milk-derived whey proteins 
have been shown to augment the weight loss effect of CR via a still unknown mechanism. 
Therefore, the study also aimed to clarify the anti-obesity whey proteins and their mechanism of 
action.    
 
The specific objectives were the following: 
 
1. To investigate the effects of CR on diet-induced obesity, fatty liver formation, and adipose 
tissue inflammation. The influences of CR on calorimetry, metabolic performance, and on 
nutrient sensing pathways in metabolically important tissues were also examined. Finally, the 
potential of SIRT1 activating compound resveratrol to mimic the beneficial effects of CR was 
also studied.  
 
2. To compare the adipose tissue cytokine and angiogenesis protein profiles from obese and lean 
mice and to investigate the influence of CR. 
 
3. To investigate the potential of whey proteins and calcium to modify skeletal muscle gene 
expression profile during CR. 
 
4. To evaluate the potential of a novel whey protein isolate, rich in lactoperoxidase, lactoferrin, 
growth factors and immunoglobulins, in the prevention and treatment of diet-induced obesity 
and fatty liver formation. 
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4. Materials and methods 
4.1 Materials 
4.1.1 Experimental animals and animal welfare 
 
All studies were conducted with C57Bl/6J mouse strain, which is a widely used inbred mouse strain 
for nutritionally-induced obesity. This mouse strain develops obesity and metabolic compliances 
such as insulin resistance and fatty liver when fed a HFD, and thus serves as a human-like 
experimental model in obesity research.   
6-9 week-old male C57Bl/6J mice were purchased from Charles River Europe (Sulzfeld, 
Germany) (studies I,II,IV) or from Harlan (Horst, the Netherlands) (study III). The mice were 
housed 3-5 per cage in a standard experimental animal laboratory (illuminated from 07.00 a.m to 
19.00 p.m (06.30-18.30 in study III), temperature 22 ± 1 °C).  
The protocols were approved by the Animal Experimentation Committee of the University of 
Helsinki, Finland, and the principles of laboratory animal care (NIH publication no. 85-23, revised 
1985) were followed. Mice had free access to feed and tap water during the experiments. Before 
the experiments all mice were kept on 1-week acclimatization period when mice were fed with 
Harlan chow diet (Harlan Tekland 2018; Harlan Holding, Inc., Wilmington, DE, USA).  
 
4.1.2 Study design and dietary interventions 
 
Obesity for mice was induced by feeding the mice with normal-calcium (0.8%, D12492M, Research 
diet Inc., USA) (studies I, II, IV) or low-calcium high-fat diet (HFD) (0.4%, D05031101M, Research 
diet Inc.) (study III). 30% calorie restriction (energy intake 70% of ad libitum intake) was used in 
the studies.   
The study designs and dietary interventions are shown in Table 3. In study I mice were fed with 
high-fat and low-fat diets for 15 weeks (=105 days) and resveratrol (Orchid Chemicals & 
Pharmaceuticals Ltd., India) was mixed into the HFD with two different doses (2g/food kg and 4g/ 
food kg). The resveratrol dosages were based on the previous study by Lagouge and coworkers 
(2006). 
Studies II-IV consisted of different phases; weight gain phase and calorie restriction (CR) 
phase, and in study IV a weight re-gain phase was used. During weight gain phase mice were fed 
with HFD ad libitum for 100 days. After that, body-weight matched mice were divided into study 
groups and they were moved into the CR phase for 50 days. In studies III and IV, the protein 
source varied between study groups during the CR phase, the casein in diets was replaced with 
different combinations of whey proteins (Table 3).  Study IV included a weight re-gain phase and 
after the CR phase mice were fed with same diets ad libitum for 50 days. All diets used in studies 
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were purchased from Research diet Inc. (New Brunswick, NJ, USA) except for the Harlan chow diet 
(Harlan Tekland 2018; Harlan Holding, Inc.). The whey protein isolates (WPI) in studies III and IV 
were different in composition; a novel WPI in the study IV was rich in lactoperoxidase, lactoferrin, 
immunoglobulins and growth factors, and it has a special amino acid composition.     
 
Table 3. Study groups and dietary interventions used in the thesis. 
Study  Group N Diet characteristics 
(Fat, protein, Ca
2+
)
*
 
Dietary protein Feeding Total duration of 
study (days)
#
 
I HFD  
HFD + R2 
HFD + R4 
CR 
LFD 
18 
19 
19 
18 
18 
60%, 18%, 0.8% 
60%, 18%, 0.8% 
60%, 18%, 0.8% 
60%, 18%, 0.8% 
10%, 18%, 0.8% 
casein 
casein 
casein 
casein 
casein 
AdL 
AdL 
AdL 
30% CR 
AdL 
105 
II Obese 
Obese CR 
Lean 
Lean CR 
7 
6 
6 
6 
60%, 18%, 0.8% 
60%, 18%, 0.8% 
18%, 24%, 1.0% 
18%, 24%, 1.0% 
casein 
casein 
cannot be separated 
cannot be separated 
AdL 
30% CR 
AdL 
30% CR 
150 
III Obese 
Lean 
CR casein 
CR WPI + Ca 
CR α-lact. + Ca 
10 
10 
10 
10 
10 
60%, 18%, 0.4% 
18%, 24%, 1.0% 
60%, 18%, 0.4% 
60%, 18%, 1.8% 
60%, 18%, 1.8% 
casein 
cannot be separated 
casein 
whey 
α-lactalbumin 
AdL 
AdL 
30% CR 
30% CR 
30% CR 
150 
IV Obese Control 
Casein Control 
WPI 5% 
WPI 50% 
WPI 100% 
14 
14 
14 
15 
13 
60%, 18%, 0.8% 
60%, 18%, 0.8% 
60%, 18%, 0.8% 
60%, 18%, 0.8% 
60%, 18%, 0.8% 
casein 
casein  
whey 5%/casein 95% 
whey 50%/casein 50% 
whey 100%/casein 0% 
AdL 
30% CR 
30% CR 
30% CR 
30% CR 
200 
AdL, ad libitum; CR, calorie restriction; HFD, high-fat diet; LFD, low-fat diet; R2, resveratrol dose 2 g/food kg; R4, 
resveratrol dose 4g/food kg, WPI, whey protein isolate, * show the amount of energy from fat and proteins and the 
Ca2+ content of diets, # studies II-IV consisted of different phases; 100 day weight gain phase (HFD AdL) and 50 day 
calorie restriction (CR) phase, and in study IV a 50 day weight re-gain phase was used.  
 
4.2 Methods 
 
4.2.1 Body weight, body fat percentage and LBM measurements 
 
In study I, the body weight was monitored three times per week by using a standard table scale 
(Mettler-Toledo, Columbus, USA) and the body fat percentage was analyzed from anesthetized 
mice magnetic resonance imaging (MRI; Oxford Instrument, Oxford, UK) (Siiskonen et al. 2007). 
In other studies (studies II-IV), the body weight was monitored once per week using a standard 
table scale (Ohaus Scout TM Pro; SP4001, Nänikon, Switzerland), and the body fat percentage and 
lean body mass (LBM) were analyzed by dual-energy X-ray (DEXA; Lunar PIXImus, GE Healthcare, 
Chalfont St. Giles, UK) before and after CR and also after weight re-gain (study IV). 
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4.2.2 Faecal fat excretion (studies II and IV) 
 
At the end of CR (studies II and IV) and weight re-gain phases (study IV) mice were housed in 
metabolic cages for 24 h. The faecal samples were collected and the faecal fat content was 
determined by Schmid-Bondzynski-Ratzlaff method (International standard 1986). The apparent 
fat digestibility (%) was determined from fat intake and faecal fat content as described previously 
(Papakonstantinou et al. 2003), using the formula: the apparent fat digestibility (%) = 100 x [(fat 
intake – faecal fat content)/fat intake]. 
 
4.2.3 Oral glucose tolerance test (studies II and IV) 
 
Glucose (glucose dosage 1/kg, given as 20% glucose solution) was given by cavage after 6 h fasting. 
Blood glucose was determined by a glucometer (Super GlucocardTM II, GT-1630, Arkray Factory 
Inc., Shiga, Japan) on blood samples taken from the tail vein at time points 0, 15, 30, 60 and 90 
min after the gavage. The areas under the curve (AUC) (blood glucose x time) were calculated.  
 
4.2.4 Calorimetry and metabolic performance (study I) 
 
The effects of CR and resveratrol on metabolic performance, physical activity, drinking and feeding 
behavior were analyzed by housing a group of mice (n=6/group) in a home cage-based monitoring 
system for laboratory animals (Labmaster TSE System, Bad Homburg, Germany). After a one-week 
acclimatization period, mice were housed in one-mouse cages during study weeks 12-15. The 
measuring time was 100 hours (52 h in light phase and 48 h in dark phase). The system consisted 
of high-precision feeding and drinking sensors, an indirect calorimetry system that allows for 
determination of O2 consumption, CO2 production, respiratory exchange rate and heat production, 
and infrared light-beams that detected the animals’ physical activity comprising ambulatory, fine 
and rearing movements. 
 
4.2.5 Tissue sample preparation 
 
Mice were decapitated at the end of the treatment periods. In studies II-IV mice were rendered 
unconscious with CO2/O2 (95:5% v/v; AGA, Riihimäki, Finland) before decapitation. The blood 
samples were placed into plastic tubes and the serum was separated by centrifugation at 960 x g 
at 4°C for 20 min. The subcutaneous, epidymal, abdominal and perirenal fat pads, liver and 
skeletal muscle (musculus quadriceps femoris) were removed, washed with saline, blotted dry and 
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weighed. Samples were snap-frozen in liquid nitrogen and stored at -80 °C until assayed. The right 
tibia length (study IV) was measured by micrometer and it was used for relative organ weight 
measurements.  Liver samples for histology (studies I and IV) and perirenal samples for adipocyte 
cross sectional area (studies II and IV) measurements were fixed in 10% formaline and embedded 
in paraffin with routine techniques.        
 
4.2.6 Liver histology (studies I and IV) 
 
Liver sections (4 µm) from the paraffin-embedded liver samples were cut with a microtome. Liver 
sections were stained with a hematoxylin and eosin (H&E) stain and examined under conventional 
light microscopy in a “blinded” fashion. The samples were subjected to a semiquantitative 
histological analysis using the nonalcoholic steatohepatitis (NASH) Clinical Research Network 
scoring system for NAFLD with slight modifications for mice samples (Kleiner et al. 2005, Tiniakos 
et al. 2010, Pilvi et al. 2008a). 
  
4.2.7 Adipocyte cross sectional area (studies II and IV) 
 
The fat pads were fixed in 10% formaline and embedded in paraffin with routine techniques. 
Sections (4 µm) of paraffin embedded fat samples were cut with microtome and they were 
mounted on charged glass slides, deparaffinized in xylene and stained. Four (study II, n=6-
7/group) or eight (study IV, n=5/group) images were taken from each sample with a microscope 
camera. The adipocyte cross-sectional area was determined from each images using Leica QWin 
Standard- software (Leica Microsystems Imaging Solutions Ltd, Cambridge, UK). 
 
4.2.8 Cytokine and angiogenesis arrays (study II) 
 
Proteins from abdominal fats (n=3/group) were isolated by homogenizing the samples with a 
Bertin Precellys 24 homogenizer (Bertin Technologies, Aix en Provence, France) and ceramic beads 
(Precellys CK14, Bertin Technologies). Protein analysis was performed using a mouse cytokine 
array panel A (represents 40 mouse cytokine proteins) and mouse angiogenesis array kits 
(represents 53 mouse angiogenesis-related proteins) (Proteome Profiler™ antibody arrays, R&D 
Systems, Inc., MN, USA) according to the protocol of the manufacturer. 750 µg of the total protein 
from three pooled samples was used for one membrane in which each of the antibodies was 
spotted in duplicates. Chemiluminescence solution (ECLplus; Amersham Biosciences, GE 
Healthcare, Little Chalfont, UK) was used for protein detection. The protein expression in the 
membranes was visualized by FLA-9000 fluorescent image analyzer (Fujifilm, Tokyo, Japan) and the 
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relative protein expression between study groups was determined by analyzing the pixel densities 
of spots in each of the arrays.  
 
4.2.9 Microarray procedure (study III) 
 
The total RNA from skeletal muscle samples (n=5/group) was isolated by TRIzol® Reagent 
(Invitrogen, Carlsbad, CA, USA) and purified with the RNeasy mini kit (Qiagen, Valencia, CA, USA) 
according to the manufacturer’s instructions. The concentration and integrity of total RNA were 
analyzed with a spectrophotometer and 2100 Bionanalyzer (Agilent Technologies, Santa Clara CA, 
USA). The purified RNA (1 µg) was reverse transcribed to cDNA and tagged with biotin with one-
cycle target labelling and control reagents (Affymetrix, Santa Clara, CA, USA). The labelled cDNAs 
were hybridized to Affymetrix GeneChip® Mouse Genome 430 2.0 Arrays, representing over 
30,000 mouse transcripts. The arrays were scanned with Affymetrix GeneChip Scanner 3 000.  
 
4.2.10 Microarray data processing (study III) 
 
The microarray data were normalized with the RMA reprocessing algorithm and then normalized 
to the median per chip. The differences between the gene expression in groups were analyzed by 
Welch type test and Benjamini-Hochberg`s false discovery rate and were used as an adjustment 
for multiple comparisons. The genes passing the statistical comparison with the corrected p-value 
0.05 and exceeding the ± 1.2-fold change limit between the compared group and the obese group 
were then classified as up-regulated and down-regulated in the respective groups. The list of 
genes with differences in expression between obese vs. lean, and the list with differences in 
expression between the CR group vs. obese were compared by logical comparison statements to 
create lists of genes regulated uniquely in the groups. The functional annotation describing the 
categorical data for gene ontology (GO) and pathway information for the lists of genes were 
performed with The Database for Annotation, Visualization and Integrated Discovery (DAVID) 2008  
(Dennis et al. 2003).  
To detect the putative differences between the CR groups, the expression of the genes on three 
CR groups was analyzed by using hierarchical clustering. Noise-reduction was applied prior to the 
clustering by restricting the dataset to contain only the genes which were significantly regulated in 
at least one comparison between the CR groups vs. obese group. This data for over 3 000 genes 
were clustered into a hierarchical tree from which the clusters A to R were selected. The KEGG 
pathways associated with the genes belonging to these created clusters were inspected with 
DAVID (Dennis et al. 2003). 
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4.2.11 Quantitative RT-PCR (studies I, III and IV) 
 
Total RNA from perirenal fat (studies I, IV), liver (study I) and skeletal muscle (study III) samples 
was isolated by TRIzol® Reagent (Invitrogen, Carlsbad, CA, USA), treated with DNAse 1 
(Deoxyribonuclease 1, Sigma Chemicals Co., St Louis, MO, USA) and 1 µg of RNA was reverse 
transcribed to cDNA with the reverse transcription enzyme (Im-Prom-II reverse transcription 
system, Promega, Madison, WI, USA). cDNA samples were amplified using FastStart DNA Master 
SYBR Green 1 (Roche diagnostics) in the presence of 0.5 µM primers (Table 4). The mRNA 
expression analysis was performed using Light-Cycler quantitative RT-PCR instrument (Roche 
Diagnostics, Neuilly-Sur-Seine, France) for detection of adiponectin, aldehyde dehydrogenase 
family 1 subfamily A7 (Aldh1a7), Cd68, fatty acid synthase (Fasn), leptin, monocyte 
chemoattractant protein 1 (MCP-1), nuclear respiratory factor 1 (Nrf1), nuclear receptor subfamily 
4 group A member 3 (Nr4a3), plasminogen activator-1 (PAI-1), peroxisome proliferator-activated 
receptor-γ coactivator 1α (PGC-1α), stearoyl-coenzyme A desaturase 1 (Scd1), transcription factor 
A mitochondrial (Tfam), visfatin and 18S. The quantities of the PCR products were quantified with 
an external standard curve amplified from the purified PCR product. The quantities of the PCR 
products were quantified with an external standard curve amplified from the purified PCR 
product. All the values were normalized to 18S mRNA levels. 
 
Table 4. The sequences of qRT-PCR primers used in the thesis. 
Gene symbol Forward primer (5`→3`) Reverse primer (5`→3`) 
Adiponectin GTATCGCTCAGCGTTC GTCGTTGACGTTATCTGC 
Aldh1a7 GTGTGGAGCGGGCTAAGA TGTTCCCCCAGCGACC 
Cd68 CCCGAGTACAGTCTACC GTTGATTGTCGTCTGCG 
Fasn AATCCGCACCGGCTAC ATTACCACGCCCGCAG 
Leptin AGACCGGGCAAGAGTG GCCATAGTGCAAGGTT 
MCP-1 CGGAACCAAATGAGATCAG TCACAGTCCGAGTCAC 
Nrf1 GCACCGTGTCGCTCAT GCTTGCGTCGTCTGGAT 
Nr4a3 CGCCACCCAATAGGAGC ATCGGTTTCGGCGTCT 
PAI-1 ACAGCCTTTGTCATCTCAGCC CCGAACCACAAAGAGAAAGGA 
PGC-1α GGTCCCCAGGCAGTAG CTCCATCATCCCGCAG 
Scd1 CCTCCCCCAGTATCCG CTCCGACACACACCGAG 
Tfam GGATGCCCGGACCTCT CCCAACACCTCCCCCGAT 
Visfatin AGAGTGCTACTGGCTTACC CTTTCCCCCACGCTGT 
18S ACATCCAAGGAAGGCAGCAG TTTTCGTCACTACCTCCCCG 
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4.2.12 Western blotting (studies I, III and IV) 
 
Proteins from perirenal fat samples were isolated with a cell extraction buffer (Invitrogen, 
Carlsbad, CA, USA) and complete protease inhibitors (Roche Diagnostics, Neuilly-Sur-Seine, France) 
(study I). Proteins from the liver (studies I and IV) and muscle samples (studies I and III) were 
isolated with a lysis buffer (NaCl 136 mM, Na2HPO4 8 mM, KCl 2.7 mM, KH2PO4 1.46 mM, Tween 
20 0.001% and complete protease inhibitors (Roche Diagnostics)). In immunoblotting 20 µg of the 
total proteins were used and protein were separated by 8% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis. The proteins were transferred to a polyvinyldifluoride 
membrane (Immobilon-FL, Millipore, Bedford, Massachusetts, USA) and blocked for 2 h with 5% 
non-fat milk-Tris-buffered saline-0.05% Tween-20 buffer. The membranes were probed with anti-
SIR2α (Upstate, Lake Placid, N.Y., USA) at dilution 1:1500, anti-SIRT3 (Abcam, Cambridge, UK) at 
dilution 1:500, anti-SIRT4 (Abcam) at dilution 1:1000, AMP-activated protein kinase α (AMPKα) 
(Cell Signaling, Beverly, MA, USA) at dilution 1:1000, phospho-AMPKα (Thr172) (Cell Signaling) at 
dilution 1:1000, S6 (Cell Signaling) at dilution 1:2000, phospho-S6 (Ser240/244) (Cell Signaling) at 
dilution 1:2000 and LC3B (Cell Signaling) at dilution 1:500 in a blocking buffer. Alpha-tubulin 
(Abcam) at dilution 1:2000 was used as a loading control. Horse-radish peroxidise-conjugated 
antirabbit secondary antibody (Chemicon, Temecula, CA, USA) was used at dilution 1:5000. The 
localization of horse-radish peroxidise was detected with Amersham ECL Plus (GE Healthcare, 
Little Chalfont, UK) according to the instructions of manufacturer and visualized by a FLA-9000 
fluorescent image analyzer (FUJIFILM Corp, Tokyo, Japan). 
 
4.2.13  Statistical analysis 
 
Data are presented as mean ± SEM. GraphPad Prism, version 4.02 (GraphPad Software, Inc., San 
Diego, CA, USA) was used for the statistical analyses. Statistically significant differences in mean 
values were tested by ANOVA followed by the Newman-Keuls multiple comparison test (studies I-
III) or the Dunnett`s test (study IV). Analyses in a function of time were done by two-way ANOVA 
followed by the Bonferroni test (study I). P-values below 0.05 were considered statistically 
significant.  
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5. Results 
5.1 Body composition and energy intake 
5.1.1 Body weight  
 
CR effectively prevented body weight gain (study I, p˂0.05 CR vs. HFD) and induced weight loss 
both in obese (studies II, III, p˂0.05 Obese CR/CR casein vs. Obese) and lean mice (study II, p˂0.05 
Lean CR vs. Lean) compared to the ad libitum fed counterparts (Figure 10). Resveratrol both with 
low- and high-doses was unable to prevent body weight gain compared to HFD group (study I) 
(Figure 10).  
High-calcium whey protein diets induced weight loss more than the casein-based diet (study III, 
p˂0.05 WPI + Ca and α-lactalbumin + Ca vs. CR casein) (Figure 10). A novel whey protein isolate 
(WPI) induced weight loss (study IV, p˂0.05 WPI 5%, 50% and 100% vs. Casein Control) and 
prevented body weight gain compared to the casein-based diet (study IV, p˂0.05 WPI 100% vs. 
Casein control) (Figure 10).  
                                 
Figure 10. Difference in mean body weight after weight gain (study I), calorie restriction (CR) (studies II-IV) and 
weight re-gain phases (study IV). Differences and comparison between study groups in body weight are calculated 
using endpoint body weight values from original publications. * p˂0.05 vs. HFD/Obese, # p˂0.05 vs. CR casein, ¤ 
p˂0.05 vs. Lean (statistical significant differences based on ANOVA Newman-Keuls multiple comparison test (studies I-
III)), § p˂0.05 vs. Casein Control (statistical significant differences based on ANOVA Dunnett`s test (study IV)). 
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5.1.2 Body fat percentage (all studies) 
 
CR prevented fat accumulation (study I, p˂0.05 CR vs. HFD) and decreased body fat content both 
in obese (study II, Obese CR vs. Obese) and lean mice (study II, Lean CR vs. Lean) compared to the 
ad libitum fed counterparts (Figure 11). Resveratrol treatment with low- and high-doses did not 
prevent body fat accumulation compared to HFD group (study I) (Figure 11).  
The high-calcium whey and α-lactalbumin diets decreased the body fat content more than the 
casein-based diet during weight loss (study III, p˂0.05 WPI + Ca and α-lactalbumin + Ca vs. CR 
casein) (Figure 11). Compared to the casein-based diet, a novel WPI dose-dependently reduced 
body fat content during weight loss (study IV, p˂0.05 WPI 5%, 50% and 100% vs. Casein Control) 
and prevented body fat accumulation during the weight re-gain period (study IV, p˂0.05 WPI50% 
and WPI100% vs. Casein Control) (Figure 11).  
 
 
                          
Figure 11. Difference in mean body fat loss (%) after weight gain (study I), calorie restriction (CR) (studies II-IV) and 
after weight re-gain phases (study IV). Differences and comparison between study groups in body fat are calculated 
using endpoint body fat values from original publications. * p˂0.05 vs. HFD/Obese, # p˂0.05 vs. CR casein, ¤ p˂0.05 vs. 
Lean (statistical significant differences based on ANOVA Newman-Keuls multiple comparison test (studies I,-III)), § 
p˂0.05 vs. Casein Control (statistical significant differences based on ANOVA Dunnett`s test (study IV)). 
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5.1.3 LBM maintenance (studies II-IV) 
 
The impact of CR, whey proteins and calcium on LBM maintenance was studied by comparing the 
amount of LBM before and after the CR phase. CR in obese (study II, p˂0.05 Obese CR vs. Obese) 
induced an approximately 6%, and in lean mice (study II, p˂0.05 Lean CR vs. Lean) an 
approximately 9%, reduction in LBM maintenance compared to the ad libitum fed obese and lean 
counterparts (Figure 12). High-calcium whey and α-lactalbumin diets (study III) as well as a novel 
WPI with different doses (study IV) did not affect LBM maintenance more than casein-based diet 
(Figure 12).  
                        
Figure 12. Lean body mass maintenance (LBM) (%) after CR phase. Values are calculated by comparing the amount of 
LBM before and after the CR phase. * p˂0.05 vs. Obese, ¤ p˂0.05 vs. Lean (statistical significant differences based on 
ANOVA Newman-Keuls multiple comparison test).   
 
5.1.4 Energy intake (all studies) 
 
In all studies the energy intake of calorie restricted mice was approximately 70% of the ad libitum 
intake. As compared to HFD group, resveratrol had no significant effect on mice energy intake 
(59.3 ± 4.0 kcal/mouse/day in the HFD, 57.7 ± 2.6 kJ/mouse/day in the HFD+R2, 56.7 ± 2.0 
kJ/mouse/day in the HFD+R4, ANOVA p=0.827) (study I).  
In study III, the energy intake during the last two study weeks of the weight gain phase was 
55.3 ± 1.3 kJ/mouse/day. This value was used for the calculation of 30% CR, and the energy intake 
of CR groups on casein, WPI + Ca and α-lactalbumin + Ca diets was approximately 38.7 
kJ/mouse/day and no differences were seen between treatment groups. 
As compared to the casein-based diet, a novel WPI did not affect energy intake when measured 
during CR (42.6 ± 0.4 kJ/mouse/day in the casein control, 42.1 ± 0.4 kJ/mouse/day in WPI 5%, 41.8 
± 0.1 kJ/mouse/day in WPI 50%, 43.2 ± 0.5 kJ/mouse/day in WPI 100%, ANOVA p=0.10) or the 
weight re-gain phase (62.3 ± 3.5 kJ/mouse/day in casein control, 77.7 ± 17.3 kJ/mouse/day in WPI 
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5%, 65.8 ± 3.6 kJ/mouse/day in WPI 50%, 71.6 ± 5.7 kJ/mouse/day in WPI 100%, ANOVA p=0.69) 
(study IV).  
 
5.2 Apparent fat digestibility (studies II and IV) 
 
The effect of CR (study II) and a novel WPI (study IV) on apparent fat digestibility was determined 
from fat intake and faecal fat content. 
The apparent fat digestibility of obese mice under CR did not differ from the obese ad libitum 
fed mice (p˃0.05 93.8 ± 2.1% in obese CR vs. 90.7 ± 5.5% in the obese). In lean mice CR 
significantly increased the apparent fat digestibility compared to the ad libitum fed lean mice 
(p˂0.05 76.5 ± 3.2% in lean CR vs. 65.1 ± 2.5% in lean).  
A novel WPI did not influence apparent fat digestibility both in the CR phase (93.8 ± 2.1% in 
casein, 90.9 ± 1.9% in WPI 5%, 89.7 ± 1.7% in WPI 50% and 90.3 ± 3.4% in WPI 100%, ANOVA p-
value 0.61) and in the weight re-gain phase (92.5 ± 1.5% in casein, 93.4 ± 2.3% in WPI 5%, 95.0 ± 
1.7% in WPI 50% and 94.6 ± 0.4% in WPI 100%, ANOVA p-value 0.71).  
 
5.3 Oral glucose tolerance test (studies II and IV) 
 
The effects of CR on blood glucose tolerance were tested (study II). The oral glucose tolerance test 
(OGTT) showed that CR had no effect on blood glucose AUC (blood glucose level x time) in obese 
(p˃0.05 1074.7 ± 22.9 mmol/l x min in obese CR vs. 1259.2 ± 147.9 mmol/l x min in obese) or lean 
mice (p˃0.05 608.8 ± 28.0 mmol/l x min in lean CR vs. 722.7 ± 29.3 mmol/l x min in lean).     
The effects of novel WPI on glucose tolerance were also studied (study IV). There was no 
statistical significant difference in blood glucose among the treatment groups after the CR phase 
(7.7 ± 0.5 mmol/l in casein, 9.2 ± 1.0 mmol/l in WPI 5%, 8.4 ± 0.6 mmol/l in WPI 50%, 6.6 ± 0.5 
mmol/l in WPI 100%, ANOVA p-value 0.115). After the re-gain phase, blood glucose was lower in 
the WPI 5% and WPI 100% groups compared to the casein control (p˂0.05 7.5 ± 0.6 mmol/l in WPI 
5%, 6.6 ± 0.2 mmol/l in WPI 100% vs. 10.2 ± 1.1 mmol/l in casein). OGTT showed that blood 
glucose AUC did not show any significant differences among treatment groups after the CR phase 
(1074.7 ± 22.9 mmol/l x min in casein, 1094.0 ± 132.5 mmol/l x min in WPI 5%, 922.6 ± 68.3 
mmol/l x min in WPI 50%, 1032.6 ± 91.1 mmol/l x min in WPI 100%, ANOVA p-value 0.075) or after 
the weight re-gain phase (1551.3 ± 114.3 mmol/l x min in casein, 1273.3 ± 129.8 mmol/l x min in 
WPI 5%, 1067.5 ± 134.8 mmol/l x min in WPI 50%, 1139.5 ± 141.1 mmol/l x min in WPI 100%, 
ANOVA p-value 0.0913). However, when the AUCs of the same treatment group measured after 
the CR phase and the re-gain phase were compared, blood glucose AUC in the casein group was 
increased (p˂0.05 casein CR phase vs. casein re-gain phase), whereas in the WPI 100% group the 
blood glucose AUC were unaltered.     
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5.4 Metabolic performance and physical activity (study I) 
 
The effects of CR and resveratrol on drinking and feeding behavior, metabolic performance, and 
physical activity were studied by housing a group of mice in a home cage-based monitoring system 
for laboratory animals (study I).   
The food intake in the CR group was approximately 70% of HFD group (p˂0.05 2.2 ± 0.1 g/day in 
CR vs. 3.0 ± 0.2 g/day in HFD) as stated in the study plan. Resveratrol had no effect on food intake 
as compared to the HFD group (3.0 ± 0.2 g/day in HFD, 2.9 ± 0.1 g/day in HFD+R2 and 2.9 ± 0.1 
g/day in HFD+R4, p˃0.05). CR had no effect on water intake, but both low- and high-dose 
resveratrol treatment decreased water intake (2.2 ± 0.1 ml/day in HFD, 2.3 ± 0.1 ml/day in CR, 1.9 
± 0.1 ml/day in HFD+R2, 1.8 ± 0.1 ml/day in HFD+R4, p˂0.05 HFD+R2/HFD+R4 vs. CR) 
Metabolic performance measured as respiratory exchange ratio (RER), CO2, O2 or heat 
productions were unchanged by CR and resveratrol as compared to the HFD group. CR increased 
ambulatory movement, total (p˂0.05 CR vs. other study groups) and rearing activity (p˂0.05 CR vs. 
HFD+R2/HFD+R4), whereas cumulative fine movement was unchanged by CR. Resveratrol had no 
significant effect on physical activity. 
 
5.5 Liver histology (studies I and IV) 
 
In study I, mice fed with HFD for 15 weeks showed prominent steatosis. In addition, hepatocyte 
ballooning indicating the activity of hepatocyte degeneration was also found in mice fed with HFD. 
Complete absence of steatosis and hepatocyte ballooning was seen in mice under CR. A higher 
dose of resveratrol tended to ameliorate steatosis and hepatocyte ballooning. 
In study IV, obese mice fed with HFD for 150 days showed prominent steatosis, but merely 
minimal foci of inflammatory cells and a complete absence of fibrosis was seen. 50 days CR on a 
novel WPI with different doses (WPI 5%, WPI 50% and WPI 100%) did not show clear improvement 
in liver morphology. However, after weight re-gain, whey protein fraction with 50% and 100% 
doses improved liver morphology, and a complete absence of steatosis was seen in the WPI 100% 
group.   
 
5.6 Adipocyte cross sectional area (studies II and IV) 
 
The effects of CR and a novel WPI on adipocyte size (arbitrary units) were measured as a cross-
sectional area. The adipocyte size of obese mice under CR was significantly decreased compared 
to the ad libitum fed mice (p˂0.05 4303.3 ± 138.1 in obese CR vs. 5207.6 ± 403.0 in obese). The 
adipocyte size of lean mice under CR was moderately, but not significantly, decreased compared 
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to the ad libitum fed lean mice (p˃0.05 922.3 ± 91.3 in lean CR vs. 1567.3 ± 184.4 in lean) (study 
II).   
 A novel WPI decreased adipocyte size more than the casein-based diet both during the CR 
phase (p˂0.05 3029.3 ± 476.8 in WPI 5%, 2683.2 ± 289.4 in WPI 50% and 2605.1 ± 175.1 in WPI 
100% vs. 4947.6 ± 337.5 in casein) and during the weight re-gain phase (p˂0.05 3502.9 ± 473.8 in 
WPI 5%, 4013.4 ± 503.5 in WPI 50% and 2619.8 ± 674.3 in WPI 100% vs. 6616.3 ± 151.4 in casein) 
(study IV).  
 
5.7 mRNA expression of adipose tissue inflammatory markers and hepatic 
visfatin (studies I and IV) 
 
The effects of CR and resveratrol on adipose tissue inflammation were determined by measuring 
mRNA expression of adiponectin, Cd68, leptin, MCP-1 and PAI-1 (study I). CR increased the mRNA 
expression of anti-inflammatory gene adiponectin (2.8 ± 0.5 in CR vs. 1.0 ± 0.2 in HFD), and 
decreased mRNA expression of pro-inflammatory genes Cd68 (0.2 ± 0.1 in CR vs. 1.0 ± 0.2 in HFD), 
leptin (0.4 ± 0.1 in CR vs. 1.0 ± 0.2 in HFD), MCP-1 (0.2 ± 0.1 in CR vs. 1.0 ± 0.2 in HFD) and PAI-1 
(0.5 ± 0.1 in CR vs. 1.0 ± 0.2 in HFD) compared to the HFD group (in all p˂0.05). Resveratrol with 
high- and low-doses did not influence the mRNA expression of adiponectin, Cd68, leptin, MCP-1 
and PAI-1 in adipose tissue compared to the HFD fed mice. The effects of CR and resveratrol on 
hepatic visfatin mRNA expression were also studied (study I). CR markedly increased hepatic 
visfatin mRNA expression (p˂0.05 1.8 ± 0.1 in CR vs. 1.0 ± 0.1 in HFD), whereas resveratrol had no 
effect on visfatin mRNA expression.    
In study IV, the effects of novel WPI on adipose tissue leptin, MCP-1 and PAI-1 mRNA 
expression were determined. CR per se decreased the mRNA expression of leptin (1.0 ± 0.2 in 
obese, 0.6 ± 0.3 in casein, 0.4 ± 0.1 in WPI 5%, 0.5 ± 0.2 in WPI 50%, 0.4 ± 0.1 in WPI 100%, p˂0.05 
WPI 100% vs. Obese) and MCP-1 (p˂0.05 0.4 ± 0.2 in casein, 0.4 ± 0.1 in WPI 5%, 0.4 ± 0.2 in WPI 
50% and 0.4 ± 0.1 WPI 100% vs. 1.0 ± 0.2 in obese) as compared to obese mice fed ad libitum. 
However, comparison between casein and a novel WPI diet showed no differences between 
treatment groups. After the weight re-gain phase, there was not any significant difference 
between study groups.    
 
5.8 Adipose tissue cytokine and angiogenesis protein profiles (study II) 
 
The effects of obesity and CR on adipose tissue cytokine and angiogenesis-related protein profiles 
were analyzed using sensitive high-throughput antibody arrays (study II).  
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Cytokine protein expression 
Of the 40 analyzed cytokines, the expression of 27 cytokines were more highly expressed in obese 
than in lean mice. The highly expressed proteins included interleukins IL-1ra, IL-2 and IL-16, 
chemokines MCP-1, MIG and RANTES, complement component C5a, adhesion molecule sICAM-1 
and matrix metallopeptidase inhibitor TIMP-1 (Table 5). 
The comparison between calorie restricted and ad libitum fed counterparts revealed that CR in the 
obese decreased 22 protein and increased 5 protein expressions. In contrast, in lean mice CR 
increased the expression of 26 proteins. CR both in obese and lean mice increased sICAM-1 and 
TIMP-1 protein expression (Table 5). Overall, CR showed opposite effect on cytokine profile 
between obese and lean mice, and several protein expressions including IL-2, MCP-1 and C5a were 
decreased by CR in obese and increased in lean mice (Table 5). 
 
Table 5. Adipose tissue cytokine protein expressions in ad libitum and calorie restricted (CR) obese and lean mice. 
 Classification Obese vs. 
Lean 
Obese CR vs. Obese Lean CR vs. Lean 
IL-1ra Interleukin ↑ ↓ ↔ 
IL-2 Interleukin ↑ ↓ ↑ 
IL-16 Interleukin ↑ ↑ ↔ 
MCP-1 Chemokine ↑ ↓ ↑ 
MIG Chemokine ↑ ↔ ↑ 
RANTES Chemokine ↑ ↑ ↔ 
C5a Complement component ↑ ↓ ↑ 
sICAM-1 Adhesion molecule ↑ ↑ ↑ 
TIMP-1 MMP inhibitor ↑ ↑ ↑ 
↓ indicates that protein expression is significantly (p˂0.05) decreased, ↑ indicates that protein expression is 
significantly (p˂0.05) increased, ↔ indicates that no significant (p˃0.05) difference is seen. Comparisons between 
study groups have been done with ANOVA followed by Newman-Keuls comparison test using the data from original 
publication. C5a; complement component 5a, IL-1ra; interleukin-1 receptor antagonist protein, IL-2; interleukin 2, IL-
16; interleukin 16, MCP-1; monocyte chemotactic protein-1, MIG; chemokine (C-X-C motif) ligand 9, RANTES; 
chemokine (C-C motif) ligand 5, sICAM;  soluble intercellular adhesion molecule 1, TIMP-1; tissue inhibitor of 
metalloproteinase 1.      
 
Angiogenesis-related protein expression 
53 pro- and anti-angiogenesis proteins were analyzed, and of them 17 proteins were expressed at 
higher levels and 6 proteins at lower levels in obese mice than in lean mice. The protein 
expressions of cell growth regulators angiogenin, endoglin, endostatin and endothelin-1 as well as 
angiogenic growth factors IGFBP-3 and leptin were increased in obese mice compared to lean mice 
(Table 6).  In addition, obesity increased the protease MMP-3 and the protease inhibitors PAI-1 
and TIMP4 protein expressions in adipose tissue (Table 6). Furthermore, chemokines CXCL16 and 
platelet factor 4, adhesion molecule DPPIV and coagulation factor III were more highly expressed 
in obese mice than in lean mice (Table 6). 
CR in obese mice decreased 14 protein expressions and increased 6 protein expressions. In lean 
mice, CR induced major changes in angiogenesis protein profile; 32 protein expressions were 
increased and 9 protein expressions were decreased. CR increased endoglin, endostatin and 
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platelet factor 4 expressions, and decreased IGFBP-3, NOV, MMP-9, CXCL16 and osteopontin 
expressions both in obese and lean mice (Table 6). However, several changes were distinct 
between obese and lean mice; leptin and TIMP4 expressions were decreased in obese mice and 
increased in lean mice (Table 6). In addition, CR uniquely in obese mice decreased MMP-3 and PAI-
1 expressions, whereas uniquely in lean mice decreased FGF acidic, FGF basic and coagulation 
factor III and increased angiogenin and DPPIV expressions (Table 6).          
 
Table 6. Adipose tissue cytokine protein expressions in ad libitum and calorie restricted (CR) obese and lean mice. 
↓ indicates that protein expression is significantly (p˂0.05) decreased, ↑ indicates that protein expression is 
significantly (p˂0.05) increased, ↔ indicates that no significant (p˃0.05) difference is seen. Comparisons between 
study groups have been done with ANOVA followed by Newman-Keuls comparison test using the data in original 
publication. CXCL16; chemokine (C-X-C motif) ligand 16, DPPIV; dipeptidyl peptidase-IV, FGF; fibroblast growth factor, 
IGFBP-3; insulin-like growth factor-binding protein 3, NOV; nephroblastoma overexpressed, MMP-3/9; matrix 
metallopeptidase 3/9, PAI-1; plasminogen activator inhibitor-1, TIMP-4; metalloproteinase inhibitor 4.          
 
5.9 Skeletal muscle gene expression (study III) 
 
The potential of whey proteins and calcium to modify skeletal muscle gene expression during CR 
was investigated using Affymetrix Mouse genome 430 2.0 array representing over 30,000 mouse 
transcripts (study III). Hierarchical clustering containing over 3000 genes with differences between 
the CR groups vs. obese groups revealed that 208 and 287 genes were altered by WPI + Ca and α-
lactalbumin + Ca diets compared to the casein diet, respectively. 186 genes were common to both 
the WPI and α-lactalbumin diets, whereas 22 genes were regulated only by the WPI + Ca diet and 
101 genes were regulated only by the α-lactalbumin + Ca diet. Several genes from Wnt signaling 
 Classification Obese vs. Lean Obese CR vs. Obese Lean CR vs. Lean 
Angiogenin  Cell growth regulator ↑ ↔ ↑ 
Endoglin Cell growth regulator ↑ ↑ ↑ 
Endostatin/Collagen XVII Cell growth regulator ↑ ↑ ↑ 
Endothelin-1 Cell growth regulator ↑ ↔ ↔ 
FGF acidic Growth factor ↔ ↔ ↓ 
FGF basic Growth factor ↓ ↔ ↓ 
IGFBP-3 Growth factor ↑ ↓ ↓ 
Leptin Growth factor ↑ ↓ ↑ 
NOV Growth factor ↔ ↓ ↓ 
MMP-3 Metallopeptidase activity ↑ ↓ ↔ 
MMP-9 Metallopeptidase activity ↔ ↓ ↓ 
PAI-1 Protease inhibitor ↑ ↓ ↔ 
TIMP-4 Metallopeptidase activity ↑ ↓ ↑ 
CXCL16 Chemokine ↑ ↓ ↓ 
Platelet factor 4 Chemokine ↑ ↑ ↑ 
DPPIV Cell adhesion ↑ ↔ ↑ 
Osteopontin Cell adhesion ↓ ↓ ↓ 
Coagulation factor III Coagulation cascade ↑ ↔ ↓ 
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were regulated by high-calcium whey protein diets, in particularly by the α-lactalbumin + Ca diet. 
Wnt signaling is associated with muscle cell differentiation, and modest changes in muscle 
hypertrophy/atrophy were seen. The expression of atrophy signaling genes Acvr2b and Fbxo32 
(also called atrogin-1) were slightly, but ˃1.2-fold up-regulated by high-calcium whey proteins 
diets. Correspondingly, the expression hypertrophy signaling genes Eif4ebp1 and Rps6 were ˃1.2-
fold up-regulated during CR irrespective of dietary protein source. 
The potential of high-calcium and whey protein to reverse the obesity induced changes were 
also examined. Of the 2693 genes expressed differently between obese and lean, CR on casein diet 
reversed partially or completely the expression of 46% (n= 1191), CR on WPI + Ca of 47% (n=1229) 
and CR on α-lactalbumin + Ca of 51% (n=1322) of the genes. Fatty acid and lipid metabolism was 
the most enriched gene ontology (GO) term among genes ˃2-fold up-regulated between obese 
and lean mice. Quantitative RT-PCR analysis revealed that the mRNA expression of Aldh1a7, Fasn, 
leptin, Nr4a3 and Scd1 were expressed lower in the WPI + Ca and α-lactalbumin + Ca diet groups 
than in the casein diet group (in all p˂0.05 WPI + Ca and α-lactalbumin + Ca vs. casein), indicating 
dietary protein source-dependent alterations in muscle lipid and fatty acid metabolism. 
 
5.10 Nutrient sensing pathways (studies I, III, IV and some unpublished data) 
5.10.1 Sirtuin pathway 
 
The effects of CR and resveratrol (study I) as well as whey proteins and calcium (studies III-IV) on 
the sirtuin pathway were studied by analyzing the SIRT1, SIRT3 and SIRT4 in the liver, skeletal 
muscle and adipose tissue.  
 
                
Figure 13. Effects of CR and resveratrol on SIRT1 protein level in the liver and skeletal muscle (a), and SIRT4 protein 
level in the skeletal muscle (b). * p˂0.05 vs. HFD groups (statistical significant differences based on ANOVA Newman-
Keuls multiple comparison test). 
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Compared to HFD group, CR increased the SIRT1 protein expression in the liver and skeletal 
muscle (Figure 13a) and the SIRT4 expression in the skeletal muscle (Figure 13b). CR also increased 
the SIRT3 protein expression in the liver, skeletal muscle and adipose tissue (Figure 14a).  
Resveratrol in a high-dose increased the SIRT1 and SIRT4 protein expressions in skeletal muscle 
as compared to the HFD group (Figure 13a, b). Resveratrol did not influence the SIRT3 protein 
expression in any studied tissues (Figure 14a). 
High-calcium whey protein diets and (WPI + Ca and α-lactalbumin + Ca) and a novel WPI 
(WPI5%, WPI50% and WPI100%) did not affect the SIRT1 protein expression in skeletal muscle and 
the liver, respectively. The SIRT3 protein expression in skeletal muscle was significantly increased 
by the α-lactalbumin + Ca diet compared to the obese group (Figure 14b). A novel WPI with 50% 
and 100% dosages increased the SIRT3 protein expression in the liver compared to the casein diet 
(Figure 14c).   
    
                   
Figure 14. Effects of CR and resveratrol on SIRT3 in the liver, skeletal muscle and adipose tissue (a) as well as effects 
of whey proteins and calcium on SIRT3 in the liver (b) and skeletal muscle (c). * p˂0.05 vs. HFD/Obese (statistical 
significant differences based on ANOVA Newman-Keuls comparison test), § p˂0.05 vs. casein control (statistical 
significant differences based on ANOVA Dunnett`s test). 
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5.10.2 Autophagy, AMPK and mTOR pathways 
 
The effect of CR on the hepatic LC3B protein expression, an indicator of autophagy, was analyzed 
in obese and lean mice (study II, unpublished data). The LC3B ratio (14kDA/16 kDA) was higher in 
obese mice than in lean mice (Figure 15a). CR in obese decreased the LC3B ratio, but in lean mice 
the ratio was unchanged as compared to the ad libitum fed counterparts (Figure 15a).  
The effects of resveratrol (study I, unpublished data), CR (study II, unpublished data) and novel 
WPI (study IV) on phosphorylation level of AMPK were studied. There were no significant 
differences between study groups in the phosphorylation level of AMPK. 
 CR per se did not affect the hepatic phosphorylation level of S6 (study II, unpublished data).  
However, novel WPI with all concentrations (5%, 50% and 100%) decreased the phosphorylation 
of the S6 ribosomal protein in the liver compared to the casein diet, suggesting inhibition of the 
mTOR pathway (study IV) (Figure 15b). 
 
                       
Figure 15. Effects of CR on LC3B protein (14kDa/16kDA) expression in the liver (a) and a novel whey protein on 
phosphorylation level of S6 in the liver (b). * p˂0.05 vs. Obese (statistical significant differences based on ANOVA 
Newman-Keuls comparison test), § p˂0.05 vs. casein control (statistical significant differences based on ANOVA 
Dunnett`s test). 
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6. Discussion 
 
Obesity and obesity-associated health problems are ameliorated by weight loss and the most 
effective method to induce weight loss is through CR. However, the precise molecular mechanisms 
by which CR induces health benefits is not yet clear, even though accumulating evidence suggests 
an important role for nutrient sensing pathways; sirtuins, AMPK and mTOR, as cellular mediators 
of CR. Epidemiological studies have shown that a diet high in dairy products is inversely associated 
with BMI, risk of metabolic syndrome and type 2 diabetes. Dairy calcium and proteins, in particular 
whey proteins, have been suggested to account for the anti-obesity effects of dairy products by 
promoting weight loss during CR via an unknown mechanism. The study investigated the potential 
molecular mechanism explaining the effects of CR with special emphasis in the above mentioned 
nutrient sensing pathways. The study also clarified the anti-obesity effects of whey proteins and 
their mechanism of action.    
 
6.1 Methodology aspects 
 
Animal model 
All studies were conducted with C57BL/6J mice, which is the most widely used diet-induced 
obesity rodent model (Kanasaki and Koya 2011). These mice are lean and physiologically normal 
when fed a normal rodent diet, but they develop obesity and hyperinsulinemia, insulin resistance, 
hypertension and fatty liver when allowed ad libitum access to HFD (Collins et al. 2004). Therefore, 
HFD fed C57Bl/6J obese mice serve as a very human-like model of obesity and metabolic 
syndrome as compared to other widely used obese mouse models, such as leptin-deficient ob/ob 
and leptin-resistant db/db mice.   
Several problems linked to obesity research in clinical trials can be avoided by using the HFD fed 
C57BL/6J mice as an experimental model of obesity. In humans, obesity and obesity-related 
metabolic disorders develop in the long term. In contrast, C57BL/6J mice develop obesity relatively 
fast, the increase in body weight can already be noticed after only 2 weeks of HFD feeding, and it 
becomes apparent after 4 weeks (Wang and Liao 2012). After 16-20 weeks of HFD feeding, mice 
have usually exhibit a 20-30% increase in body weight when compared to normal diet fed mice. 
Hyperglycemia develops after 4 weeks of HFD feeding (Collins et al. 2004, Wang and Liao 2012). In 
addition, the non-compliance to long-term low-calorie diets in clinical trials can be avoided by 
using the HFD fed C57BL/6J mice as an experimental model for obesity. However, obesity is a 
multifactorial disease, and the results obtained from animal experiment are only directional and 
cannot be directly extrapolated to humans.   
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Dietary modifications 
CR is a dietary intervention where calorie intake is reduced below usual ad libitum intake while 
adequate intakes of proteins and micronutrients are maintained at sufficient levels to avoid 
malnutrition. Restricting calories 20-60% of ad libitum intake has several beneficial effects on the 
health of animals (for review see Speakman and Mitchell 2011). In the present study, 30% calorie 
restriction (CR) was used, which was widely used in previous animal studies and has been shown 
to be safe and relevant way to induce weight loss.   
The anti-obesity effects of different dosages of a novel WPI were investigated. The novel WPI is 
manufactured from pasteurized whey proteins using ion exchange technology. Its composition 
differs from normal WPI that has been used in previous studies. The novel WPI is comprised of 
mainly lactoperoxidase (~50% vs. 0.5% in normal WPI) and lactoferrin (15% vs. ~1% in normal 
WPI) (Krissansen 2007), and it is rich in immunoglobulins and growth factors. A comparison 
between casein and normal WPI reveals its high branched chain amino acids (BCAAs) content, 
whereas the major difference between the novel WPI and casein is related to the levels of 
cysteine, glutamic acids, methionine and proline.              
 
Protein and gene expression analysis 
Mouse cytokine and angiogenesis antibody array kits (Proteome Profiler™ antibody arrays) were 
used to analyze the adipose tissue cytokine and angiogenesis protein profiles of visceral fat. These 
arrays are sensitive high-throughput tools for simultaneously profiling the relative levels of 
multiple proteins between samples. Mouse cytokine and angiogenesis array kits allowed for the 
analysis of the protein expressions of 40 cytokines and chemokines, and 52 angiogenesis-related 
proteins, respectively. We pooled proteins from three samples together, and used this protein 
mixture for membranes where each antibody was spotted in duplicates. In the present study, we 
did not confirm the results in protein or RNA levels by other methods, even though that would be 
advisable to avoid wrong interpretations. 
Microarray genechips were used to analyze skeletal muscle gene expression profiles. 
Microarray is a fast and quite simple method to generate large amounts of data. The gene 
expression profiles were analyzed by Mouse Genome 430 2.0 Arrays, which allowed the analysis of 
30,000 transcripts simultaneously. The biggest challenge with the microarray, however, is the data 
analysis. There is no single right method to analyze the data, which exacerbates the comparison of 
data between different experiments (Cordero et al. 2007). Furthermore, the huge amounts of data 
complicate the findings of the significant and biologically relevant results. Therefore, important 
findings must always be confirmed by other methods, and in the present study the significant 
results were verified with qRT-PCR.   
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6.2 Calorie restriction in experimental obesity 
 
The present study showed that CR protected against obesity and induced body weight and fat loss. 
CR also protected against fatty liver formation and ameliorated adipose tissue inflammation. The 
study also demonstrated that CR was superior in protection against diet-induced obesity and fatty 
liver formation as compared to oral resveratrol supplementation. The polyphenolic compound 
resveratrol is a widely used CR-mimetic compound, which effects are believed to be mediated in a 
SIRT1-dependent manner. In some previous studies, resveratrol has been shown to reduce body 
weight and adiposity in HFD fed mice (Lagouge et al. 2006) and rats (Aubin et al. 2008, Rivera et al. 
2009). In the present study, resveratrol dosages, route of administration, and the treatment 
period were based on the study by Lagouge and co-workers (2006), but any statistically significant 
differences in body weight or adiposity were not seen. Only a modest trend toward reduced body 
weight was seen both with low- and high-doses of resveratrol, suggesting that in this case higher 
dosages and longer treatment period might be needed for prevention of body weight gain. 
However, resveratrol was not completely ineffective because with a higher-dose it partially 
attenuated fatty liver by reducing hepatic steatosis and hepatocyte ballooning. Similar beneficial 
effects of resveratrol on NAFLD have been seen in previous studies as well, and it has been 
suggested that it is due to reduced hepatic fatty acid availability and oxidative stress in resveratrol 
treated animals (Shang et al. 2008, Gòmez-Zorita et al. 2012). However, several other studies have 
also been unable to confirm the beneficial effects of resveratrol on body weight and adiposity 
(Baur et al. 2006, Rivera et al. 2009, Rocha et al. 2009). These findings and the statement that 
resveratrol is not a direct activator of SIRT1 (Kaeberlein et al. 2005a, Pacholec et al. 2010) suggest 
that more specific sirtuin activating compounds are needed to mimic the effects of CR on body 
composition. 
 
6.3 Molecular and signaling pathways mediating the effects of CR 
 
Effects of CR on adipose tissue cytokine and angiogenesis profiles 
Adipose tissue expansion during obesity is characterized by adipocyte hypertrophy (an increase in 
adipocyte volume), which causes adipocyte dysfunction and leads to changes in adipocyte 
metabolic and secretion activity (Guilherme et al. 2008, Hajer et al. 2008, Spalding et al. 2008). The 
present study supported the previous findings, and larger adipocyte size in obese groups 
associated with higher cytokine protein expression. The most highly up-regulated cytokines were 
IL-1ra, IL-2, IL-16, MCP-1, MIG, RANTES, C5a and sICAM-1. CR, when performed for obese mice, 
reduced obesity-induced adipocyte hypertrophy and attenuated adipose tissue cytokine protein 
expression. Interestingly, in lean mice CR had no effect on adipocyte size, but a much higher 
cytokine protein expression was seen, indicating that CR might have detrimental effect on adipose 
81 
 
tissue remodeling in lean mice. The distinct effect of CR on cytokine expression between obese 
and lean mice cannot be explained by different response of obese and lean mice to CR as both the 
body weight and body fat percentage were decreased by CR to similar extent in obese and lean 
mice. However, these findings are in line with previous studies showing that CR in lean mice 
increases serum cytokine levels (Fenton et al. 2009), and ameliorates adipose tissue inflammation 
in obese mice, in particularly when CR is carried out by restricting the intake of HFD (Wang et al. 
2011b).  
Adipose tissue is a highly vascularized organ, and therefore expansion of adipose tissue during 
development of obesity is dependent on the angiogenesis. Some of the anti-angiogenic agents, 
including TNP-470 and a broad-spectrum of endogenous protein inhibitors, angiostatin and 
endostatin have been shown to prevent genetically and diet-induced obesity in animals (Rupnick 
et al. 2002, Bråkenhielm et al. 2004). Therefore, a better understanding of the regulation of 
angiogenesis process may provide new drug targets for obesity and obesity-related disorders. The 
present study showed that obesity is associated with marked alteration in the protein expression 
of cell growth regulators, angiogenic growth factors and proteases, as well as their inhibitors. CR 
markedly modulated adipose tissue angiogenesis-related protein profiles and the effects of CR 
were largely distinct between obese and lean mice.  
Leptin, a food intake regulator and a potent angiogenic growth factor, was decreased by CR in 
obese and increased in lean mice. In addition, angiogenic growth factor endoglin and endogenous 
angiogenesis inhibitor endostatin were up-regulated by CR both in obese and lean mice. In 
addition to angiogenic growth factors, pericellular proteases have been shown to be important in 
regulating angiogenesis by participating in extracellular matrix (ECM) remodeling, generating pro- 
and anti-angiogenic factors from ECM proteins and processing growth factors and receptors (Van 
Hinsbergh et al. 2006). The proteolytic system consisting of two major component plasminogen 
activator-plasmin system (fibrinolytic system) and matrix metalloproteinases (MMPs) showed 
response to CR. MMP-9 expression was decreased by CR in both obese and lean mice, while MMP-
3 and PAI-1, an inhibitor of fibrinolytic system, were decreased by CR only in obese mice. MMPs 
are inhibited by endogenous tissue inhibitors (TIMPs). CR increased TIMP-1 expression both in 
obese and lean mice, whereas TIMP-4 expression was down-regulated by CR in obese mice and 
up-regulated in lean mice.   
The findings underscore the importance of angiogenesis-related protein and cytokines in 
adipose tissue remodeling during development of obesity and CR induced weight loss. The findings 
also support the notion that by modulation of adipose tissue cytokine and angiogenesis-related 
proteins, it might be possible to influence the development of obesity.    
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Effects of CR on nutrient sensing signaling pathways 
The effects of CR on the sirtuin pathway were analyzed. Recent studies strongly suggest that SIRT1 
mediates adaptive responses to CR in mammals (Bordone et al. 2007, Boily et al. 2008, Cohen et 
al. 2009). SIRT1 is suggested to be required for increased physical activity response of CR in mice, 
as SIRT1-deficient mice do not respond to CR with increased physical activity (Chen et al 2005a). In 
accordance with previous studies, the present study also demonstrated higher physical activity in 
CR mice, and showed increased SIRT1 expression in skeletal muscle and the liver in mice under CR.  
Relatively less is known about the other sirtuins role in CR, and in the present study, the effects 
of CR on mitochondrial sirtuins SIRT3 and SIRT4 expression were investigated. Interestingly, the 
SIRT4 expression was increased by CR in skeletal muscle. This is in contrast to other studies which 
have shown that CR decreases the expression of SIRT4 rather than increases it (Haigis et al. 2006). 
However, although in muscle cells SIRT4 depletion has been shown to improve mitochondrial 
function (Nasrin et al. 2010), its role in skeletal muscle metabolism is still quite unknown.  
The most important finding of the present study was that CR markedly increased SIRT3 protein 
expression in the liver, skeletal muscle and adipose tissue. SIRT3 has been shown to be responsible 
for acetylations of several proteins in mitochondria, as the loss of SIRT3, but not other 
mitochondrial sirtuins SIRT4 and SIRT5, leads to hyperacetylation of mitochondrial proteins 
(Lombard et al. 2007). Included in those hyperacetylated proteins are several proteins from energy 
metabolism as well as oxidative stress reducing enzymes and mitochondrial electron transfer 
components (for review see Huang et al. 2010, He et al. 2012). SIRT3-deficient mice have several 
metabolic abnormalities, including reduced ATP production, decreased rate of fatty acid oxidation 
and ketone body production, and fatty liver (Ahn et al. 2008, Hirschey et al. 2010, Shimazu et al. 
2010, Kendrick et al. 2011). These findings strongly suggest that the effects of CR are mediated, at 
least in part, via a SIRT3-dependent manner.     
Interestingly, CR increased the mRNA expression of hepatic visfatin (also called NAMPT). 
Visfatin is the enzyme that converts the NAM to nicotinamide mononucleotide (NMN), which is 
the first and rate-limiting step in NAD+ biosynthesis. Inhibition or down-regulation of visfatin has 
been shown to lead to reduced SIRT1 activation (Revollo et al. 2004). Recently, it has been 
demonstrated that HFD feeding and aging reduce visfatin-mediated enzymatic reactions leading to 
glucose intolerance, whereas treatment with NMN reverses the changes (Yoshino et al. 2011). 
Higher expressions of hepatic visfatin in calorie restricted mice can thus explain the higher SIRT1 
and SIRT3 protein expressions in the liver. Resveratrol, which failed to prevent obesity, induced 
SIRT1 and SIRT4 expressions in skeletal muscle.  However, resveratrol was unable to induce both 
visfatin and SIRT3 expressions in metabolically important tissues, which can, at least in part, 
explain its inability to mimic beneficial health effects of CR.  
The effects of CR on the AMPK, mTOR and autophagy signaling pathways were also studied. 
Both the AMPK and mTOR pathways are sensitive to cellular nutritional status (for review see 
Hardie et al. 2012a, Laplante and Sabatini 2012). However, our study did not support this as we 
did not notice any significant changes by CR in phosphorylation of AMPK or in phosphorylation of 
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S6, a main substrate of the mTOR pathway. Interestingly, we demonstrated increased hepatic 
expressions of autophagic effector protein LC3B-II (14 kDa) in obese mice and the expressions 
were decreased by CR. This is in contrast to other studies showing that hepatic autophagy is 
decreased by genetic and HFD-induced obesity (Liu et al. 2009, Yang et al. 2010) and CR is believed 
to activate autophagy in vivo (for review see Kroemer et al. 2010). However, autophagy is the 
complex process and over 30 autophagy-related genes (ATGs) have been found from yeast and 
many of the genes have orthologues in eukaryotes (Xie and Klionsky 2007). Therefore, it would be 
advisable to investigate how CR influences those other protein expressions to find out which 
direction CR induces autophagy.    
 
6.4 Whey proteins and calcium in experimental obesity 
 
In previous studies, it has been shown that high-calcium whey protein diets prevent weight gain, 
induce weight loss during CR and prevent weight re-gain after CR more than a casein-based diet 
(Pilvi et al. 2007, Pilvi et al. 2009). Of the different whey protein fractions, α-lactalbumin has been 
shown to have the most effective anti-obesity effects (Pilvi et al. 2009). It has also been shown 
that whey proteins and calcium enhance the blood glucose and insulin lowering effects of CR (Pilvi 
et al. 2008a), and they have beneficial effects on the liver metabolomic (Pilvi et al. 2008a) and 
adipose tissue gene expression profiles (Pilvi et al. 2008b). The present study, the novel WPI had 
unique protein and amino acid composition compared to previously studied whey proteins. The 
study further underlined the anti-obesity effects of whey proteins as the replacement for casein in 
the diet with a novel WPI dose-dependently enhanced weight and fat loss during CR and 
prevented weight and fat re-gain during ad libitum feeding after weight loss. The calcium content 
was the same in treatment groups and excluded the effects of a high-calcium diet that were used 
in previous studies. The study revealed that the novel WPI induced weight loss during CR was 
primarily due to changes in body fat content as the body fat percentage and adipocyte cross 
sectional area were decreased by a novel WPI, while LBM maintenance was unchanged by a novel 
WPI. The study also demonstrated that a novel WPI protected against development of fatty liver 
formation during ad libitum feeding after weight loss. A novel WPI did not influence energy intake 
or apparent fat digestibility, indicating that the beneficial effects of CR on body weight were not 
due to changes in satiety or increased faecal fat excretion. Taken into account the high 
lactoperoxidase, lactoferrin, immunoglobulins and growth factors content and the special amino 
acid composition of a novel WPI, it suggests that those components might have anti-obesity 
effects. This is further supported by the previous study showing that enteric-coated lactoferrin 
reduces visceral adiposity in obese patients (Ono et al. 2010).  
In addition to body composition changes, a novel WPI lowered blood glucose levels after the re-
gain phase, and when the AUCs from the oral glucose tolerance test after the CR and re-gain 
phases were analyzed, they showed a tendency towards improved insulin sensitivity. The 
84 
 
insulinotrophic effects of whey proteins are suggested to be due to its high-content of BCAAs 
(Nilsson et al. 2007) or it is regulated through incretin hormones that potentiate insulin secretion 
from the islet β-cell in a glucose-dependent manner (Gunnarsson et al. 2006). However, the major 
difference between casein and novel WPI amino acid compositions are not due to BCAAs, 
suggesting that insulinotrophic effects of a novel WPI are mediated through other components.     
   
6.5 Molecular and signaling pathways mediating the effects of whey proteins 
and calcium   
 
Effects of whey proteins and calcium on skeletal muscle gene expression profile 
The effects of high-calcium whey proteins diets on skeletal muscle gene expression profiles were 
investigated. Microarray results revealed that CR on different dietary regimens reversed 
approximately 50% of obesity-induced changes in a dietary protein and calcium dependent 
manner. The qRT-PCR analysis showed that five genes leptin, Scd1, Fasn, Nr4a3 and Aldh1a7 
related to skeletal muscle fatty acid and lipid metabolism were decreased by high-calcium whey 
protein diets as compared to a casein-based diet. Leptin has an important role in whole body 
energy homeostasis.  Leptin improves insulin sensitivity by stimulating fatty acid oxidation and 
decreasing muscle lipid content in skeletal muscle (Dyck 2009). Obesity is known to induce leptin 
resistance, which leads to the inability of leptin to suppress food intake and contributes to the 
development of obesity (Scarpace and Zhang 2009). In the present study, obesity-induced leptin 
expression was normalized by high-calcium whey protein diets, which can enhance its anti-obesity 
effects. Recent studies have shown that Scd1-deficient mice have several metabolic changes that 
protect mice from diet-induced obesity, insulin resistance and hepatic steatosis (for review see 
Flowers and Ntambi 2008). Interestingly, the lowest Scd-1 expression was seen in high-calcium α-
lactalbumin + Ca, which have been shown to be the most effective whey protein fraction in 
enhancing weight loss during CR.    
As compared to the casein diet, 208 and 287 genes were altered by high-calcium WPI and α-
lactalbumin diets, respectively. We noticed that high-calcium whey protein diets, in particular the 
α-lactalbumin diet, regulated several genes of the Wnt signaling pathway. In skeletal muscle, Wnt 
signaling improves insulin sensitivity by decreasing intramyocellular lipid depositions through 
down-regulation of SREBP-1c (sterol-regulatory element binding protein 1c) (Abiola et al. 2009). 
Both Scd-1 and Fasn are regulated by SREBP-1c (Eberlè et al. 2004), suggesting that Wnt signaling 
via regulation of SREBP-1c activity might function as a mechanistic link to how high-calcium whey 
proteins mediate changes in lipid and fatty acid metabolism.  
Intense CR can lead to unwanted depletion of skeletal muscle, which may down-regulate 
metabolic processes, such as protein turnover and basal metabolic rate, exacerbating the weight 
management after weight loss (Carbone et al. 2012). It has been proposed that whey protein has a 
role in preservation of muscle mass since it contains a high-proportion of BCAAs (leucine, 
85 
 
isoleucine and valine) important for muscle metabolism and protein synthesis (Ha and Zemel 
2003, Zemel 2009). The Wnt signaling pathway has been shown to interact with MyoD, which is 
important for muscle cell differentiation (Kim et al. 2008a). Therefore, the effects of high-calcium 
whey protein diets on hypertrophy/atrophy signaling were investigated. Two atrophy signaling 
genes Fbox32 (also called atrogin-1) and Acvr2b were slightly up-regulated by high-calcium whey 
protein diets, and two hypertrophy signaling genes Eif4ebp1 and Rsp6 were up-regulated by CR 
irrespective of dietary protein source. However, it is plausible that the findings were not clinically 
relevant as much higher Fbox32 expression has been seen in clinically relevant muscle atrophy 
(Bodine et al. 2001, Gomes et al. 2001), and any significant difference in LBM maintenance were 
not seen between the study groups.      
 
Effects of whey proteins and calcium on nutrient sensing signaling pathways 
Bieganowski and Brenner (2004) discovered nicotinamide riboside (NR), a NAD+ precursor, from 
whey protein fraction of cow`s milk, leading to the hypothesis that whey proteins might regulate 
the NAD+-dependent sirtuin pathway. Recently, NR has been shown to increase the NAD+ level in 
mammalian cells and mouse tissues and activate SIRT1 and SIRT3, resulting in enhanced oxidative 
metabolism and protection against HFD-induced metabolic abnormalities (Canto et al. 2012). In 
the present study, neither high-calcium whey protein diets (WPI and α-lactalbumin) nor a novel 
WPI with any dosages influenced the SIRT1 protein expression. The SIRT3 protein expression was 
increased in skeletal muscle by CR, especially with the high-calcium α-lactalbumin diet. After the 
CR phase, a novel WPI increased the hepatic SIRT3 protein expression more than the casein-based 
diet. However, during the re-gain phase a novel WPI did not influence the SIRT3 protein expression 
indicating that CR is a necessity for an increased SIRT3 expression by a novel WPI. These results 
strongly suggest that anti-obesity effects of whey proteins and calcium are, at least in part, 
mediated by the mitochondrial SIRT3 pathway. The effects of whey proteins and calcium on 
cellular energy status sensitive pathways AMPK and mTOR were also investigated. A novel WPI did 
not influence on AMPK phosphorylation. S6 phosphorylation was decreased by a novel WPI, 
indicating inhibition of the mTOR pathway. The high calcium WPI and α-lactalbumin diets did not 
affect S6 phosphorylation.      
 
6.6 Clinical relevance and future aspects 
 
The aim in the obesity treatment is to improve health, and to prevent and alleviate obesity 
associated co-morbidities which can be achieved by at least 5% permanent weight loss (Aikuisten 
lihavuus, Käypä hoito –suositus, 2011, Tsigos et al. 2008). In the present study, a 30% decrease in 
calorie intake below ad libitum intake induced weight and fat loss and the weight loss effects of CR 
were enhanced by whey proteins and calcium. Even thought results cannot be directly 
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extrapolated to humans, the study verifies the anti-obesity effects of whey proteins and suggests 
that increasing the amount of whey proteins in diets would be advisable during weight loss.      
However, the compliance to long-term low-calorie diet is very often poor in clinical trials and 
many fail in weight loss and weight management. Since SIRT1 is thought to mediate the effects of 
CR, several SIRT1 activating compounds have been developed (Howitz et al. 2003, Milne et al. 
2007). In this study the SIRT1 activator resveratrol was used and it did not protect against obesity 
or metabolic disorders. Currently, more potent SIRT1-activating compounds are developed. 
Multiple clinical studies have been initiated with three selective SIRT1 activators SRT2104, 
SRT2379 and SRT3025 to find out those compounds potential in inflammatory, metabolic and 
cardiovascular diseases (ClinicalTrials 2012). The present study also suggested that mitochondrial 
SIRT3 is an important mediator of CR, suggesting that it would be advisable to investigate the 
SIRT3 pathway potential in obesity treatment and prevention more closely. 
The adipose tissue cytokine and angiogenesis profiles showed great response to changes in 
body weight. Recent studies suggest that anti-angiogenic agents might have a role in the 
treatment of obesity and metabolic disorders (for review see Cao 2010). Early clinical studies with 
the anti-angiogenic drug bevacizumab have shown promising signs in the prevention of 
progression of diabetic retinopathy and diabetic maculopathy, both the complications related to 
type 2 diabetes (Steinbrook 2006). However, the safety of the anti-angiogenic drugs in treatment 
of obesity should be evaluated carefully as angiogenesis has several important physiological 
functions, including the healing of wounds. 
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7. Summary and conclusions 
 
The present study aimed to investigate the molecular mechanisms and signaling pathways 
mediating the beneficial effects of calorie restriction (CR) on experimental obesity.  The study also 
aimed to clarify the cellular mechanisms by which whey proteins enhance CR.  
 
The main findings and conclusions of the present study are as follows:  
 
1. CR protected against diet-induced obesity and fatty liver formation as well as ameliorated 
adipose tissue inflammation, and showed superior protection against diet-induced obesity as 
compared to the SIRT1 activating compound resveratrol. CR induced the sirtuin pathway and 
increased the SIRT3 protein expression in metabolically important tissues, suggesting an 
important role for sirtuins as mediators of CR.    
 
2. Obesity induced cytokine and angiogenesis protein expression in adipose tissue and these 
changes in protein profiles were largely ameliorated by CR. In contrast, in lean mice, CR 
increased the expression of several cytokines and angiogenesis-related proteins.  The results 
underscore the importance of adipose tissue cytokine and angiogenesis-related proteins in 
adipose tissue remodeling and the development of obesity. 
 
3. High-calcium WPI and α-lactalbumin diets enhanced the anti-obesity effects of CR compared to 
casein. Both WPI and α-lactalbumin modified skeletal muscle gene expression profile, in 
particular, the genes associated with the Wnt signaling pathway and skeletal muscle lipid and 
fatty acid metabolism. These findings can explain, at least in part, the greater anti-obesity 
effects of whey proteins and calcium compared to casein.   
 
4. A novel WPI, rich in lactoperoxidase, lactoferrin, growth factors and immunoglobulins, 
protected against fatty liver and exerted superior anti-obesity effects compared to casein. The 
beneficial effects of WPI were dose-dependent and mediated, at least in part, via activation of 
the sirtuin pathway. 
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